( (TITLE (S (NP-SBJ (NN PPAR) (NN gamma) (CD 2)) (VP (VBZ Prevents) (NP (NN Lipotoxicity)) (PP-MNR (IN by) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG Controlling) (NP (NP (NN Adipose) (NN Tissue) (NN Expandability)) (CC and) (NP (JJ Peripheral) (NN Lipid) (NN Metabolism))))))))) )
( (HEADING (NP (NN Abstract))) )
( (S (NP-SBJ (NP (NN Peroxisome) (NN proliferator) (VBN activated) (NN receptor) (NN gamma) (CD 2)) (-LRB- -LRB-) (NP (NN PPARg2))) (-RRB- -RRB-) (VP (VBZ is) (NP-PRD (NP (DT the) (ADJP (RB nutritionally) (VBN regulated)) (NN isoform)) (PP (IN of) (NP (NN PPARg))))) (. .)) )
( (S (NP-SBJ (NP (NN Ablation)) (PP (IN of) (NP (NN PPARg2)))) (PP-LOC (IN in) (NP (NP (NP (DT the) (NML (NN ob) (HYPH /) (NN ob)) (NN background)) (, ,) (NP (NML (NN PPARg2) (SYM −) (HYPH /) (SYM −)) (NML (NN Lepob) (HYPH /) (NN Lepob)))) (-LRB- -LRB-) (NP (NN POKO) (NN mouse)))) (-RRB- -RRB-) (, ,) (VP (VBD resulted) (PP (IN in) (NP (NP (VBN decreased) (NN fat) (NN mass)) (, ,) (NP (JJ severe) (NN insulin) (NN resistance)) (, ,) (NP (NML (NN β) (HYPH -) (NN cell)) (NN failure)) (, ,) (CC and) (NP (NN dyslipidaemia))))) (. .)) )
( (S (NP-SBJ (PRP$ Our) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ (DT the) (NN PPARg2) (NN isoform)) (VP (VBZ plays) (NP (DT an) (JJ important) (NN role)) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG mediating) (NP (NN adipose) (NN tissue) (NN expansion)) (PP (IN in) (NP (NP (NN response)) (PP (IN to) (NP (JJ positive) (NN energy) (NN balance))))))))))) (. .)) )
( (S (NP-SBJ (JJ Lipidomic) (NNS analyses)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NN PPARg2)) (VP (VBZ plays) (NP (DT an) (JJ important) (JJ antilipotoxic) (NN role)) (SBAR-TMP (WHADVP-2 (WRB when)) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBN induced) (NP-1 (-NONE- *)) (ADVP-MNR (RB ectopically)) (PP-LOC (IN in) (NP (NN liver) (CC and) (NN muscle))) (ADVP-TMP-2 (-NONE- *T*)) (PP-MNR (IN by) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VP (VBG facilitating) (NP (NP (NN deposition)) (PP (IN of) (NP (NN fat)))) (PP (IN as) (NP (ADJP (RB relatively) (JJ harmless)) (NN triacylglycerol) (NNS species)))) (CC and) (VP (ADVP (RB thus)) (VBG preventing) (NP (NP (NN accumulation)) (PP (IN of) (NP (JJ reactive) (NN lipid) (NNS species))))))))))))))) (. .)) )
( (S (NP-SBJ (PRP$ Our) (NNS data)) (ADVP (RB also)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ-1 (NN PPARg2)) (VP (MD may) (VP (VB be) (VP (VBN required) (NP-1 (-NONE- *)) (PP-PRP (IN for) (NP (NP (DT the) (NML (NN β) (HYPH -) (NN cell)) (JJ hypertrophic) (JJ adaptive) (NN response)) (PP (IN to) (NP (NN insulin) (NN resistance))))))))))) (. .)) )
( (S (PP (IN In) (NP (NN summary))) (, ,) (NP-SBJ (DT the) (NN PPARg2) (NN isoform)) (VP (VBZ prevents) (NP (NN lipotoxicity)) (PP-MNR (IN by) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VP (LST (-LRB- -LRB-) (LS a) (-RRB- -RRB-)) (VBG promoting) (NP (NN adipose) (NN tissue) (NN expansion))) (, ,) (VP (LST (-LRB- -LRB-) (LS b) (-RRB- -RRB-)) (VBG increasing) (NP (NP (DT the) (NML (NN lipid) (HYPH -) (VBG buffering)) (NN capacity)) (PP (IN of) (NP (JJ peripheral) (NNS organs))))) (, ,) (CC and) (VP (LST (-LRB- -LRB-) (LS c) (-RRB- -RRB-)) (VBG facilitating) (NP (NP (DT the) (JJ adaptive) (JJ proliferative) (NN response)) (PP (IN of) (NP (NN β) (HYPH -) (NNS cells))) (PP (IN to) (NP (NN insulin) (NN resistance))))))))) (. .)) )
( (HEADING (NP (NN Author) (NN Summary))) )
( (S (S (NP-SBJ-2 (NP (PRP It)) (SBAR-1 (-NONE- *EXP*))) (VP (VBZ is) (VP (VBN known) (NP-2 (-NONE- *)) (SBAR-1 (IN that) (S (NP-SBJ-3 (NN obesity)) (VP (VBZ is) (VP (VBN linked) (NP-3 (-NONE- *)) (PP (IN to) (NP (NML (NN type) (CD 2)) (NN diabetes)))))))))) (, ,) (S (ADVP (RB however)) (SBAR-NOM-SBJ (WHADVP-4 (WRB how)) (S (NP-SBJ (NN obesity)) (VP (VBZ causes) (NP (NP (NN insulin) (NN resistance)) (CC and) (NP (NN diabetes))) (ADVP-MNR-4 (-NONE- *T*))))) (VP (VBZ is) (RB not) (ADJP-PRD (RB well) (VBN understood)))) (. .)) )
( (S (NP-SBJ (DT Some) (ADJP (RB extremely) (JJ obese)) (NNS people)) (VP (VBP are) (RB not) (ADJP-PRD (JJ diabetic)) (, ,) (SBAR-ADV (IN while) (S (NP-SBJ (JJ other) (ADJP (RBR less) (JJ obese)) (NNS people)) (VP (VBP develop) (NP (JJ severe) (NML (NML (NN insulin) (NN resistance)) (CC and) (NML (NN diabetes)))))))) (. .)) )
( (S (NP-SBJ (PRP We)) (VP (VBP believe) (SBAR (-NONE- *0*) (S (NP-SBJ (NN diabetes)) (VP (VBZ occurs) (SBAR-TMP (WHADVP-1 (WRB when)) (S (S (S (NP-SBJ (NN adipose) (NN tissue)) (VP (VBZ becomes) (`` “) (ADJP-PRD (JJ full)))) (, ,) ('' ”) (CC and) (S (NP-SBJ (NN fat)) (VP (VBZ overflows) (PP (IN into) (NP (NP (JJ other) (NNS organs)) (PP (JJ such) (IN as) (NP (NN liver) (, ,) (NN pancreas) (, ,) (CC and) (NN muscle)))))))) (ADVP-TMP-1 (-NONE- *T*)))) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG causing) (NP (NP (NN insulin) (NN resistance)) (CC and) (NP (NN diabetes))))))))) (. .)) )
( (S (NP-SBJ (NP (NN Peroxisome) (NN proliferator) (VBN activated) (NN receptor) (NN gamma)) (-LRB- -LRB-) (NP (NN PPARg))) (-RRB- -RRB-) (VP (VBZ is) (ADJP-PRD (JJ essential)) (PP-PRP (IN for) (NP (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NN adipose) (NN tissue)))) (CC and) (NP (NP (NN control)) (PP (IN of) (NP (NN insulin) (NN sensitivity))))))) (. .)) )
( (S (NP-SBJ (NN PPARg2)) (VP (VBZ is) (NP-PRD (NP (NP (DT the) (NN isoform)) (PP (IN of) (NP (NN PPARg)))) (VP (VBN regulated) (NP (-NONE- *)) (PP-MNR (IN by) (NP (NN nutrition)))))) (. .)) )
( (S (ADVP (RB Here)) (NP-SBJ (PRP we)) (VP (VBP investigate) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NN PPARg2)))) (PP (IN under) (NP (NP (NNS conditions)) (PP (IN of) (NP (JJ excess) (NNS nutrients))))) (PP-MNR (IN by) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG removing) (NP (NP (DT the) (NN PPARg2) (NN isoform)) (PP (IN in) (NP (NP (ADJP (RB genetically) (JJ obese)) (NNS mice)) (, ,) (NP (DT the) (NN POKO) (NN mouse))))))))) (. .)) )
( (S (NP-SBJ (PRP We)) (VP (VBP report) (SBAR (IN that) (S (S-NOM-SBJ (NP-SBJ (-NONE- *PRO*)) (VP (VBG removing) (NP (NN PPARg2)))) (VP (VP (VP (VBZ decreases) (NP (NP (NN adipose) (NN tissue) (POS 's)) (NN capacity) (S (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB expand)))))) (CC and) (VP (VBZ prevents) (NP (DT the) (NN mouse)) (PP (IN from) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG making) (NP (NP (RB as) (JJ much) (NN fat)) (PP (IN as) (NP (DT a) (JJ normal) (JJ obese) (NN mouse))))))))) (, ,) (PP (IN despite) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG eating) (ADVP (RB similarly))))))))) (. .)) )
( (S (NP-SBJ (PRP$ Our) (NNS studies)) (VP (VBP suggest) (SBAR (IN that) (S (NP-SBJ (NN PPARg)) (VP (VBZ plays) (NP (DT an) (JJ important) (JJ antitoxic) (NN role)) (SBAR-TMP (WHADVP-2 (WRB when)) (S (NP-SBJ-1 (PRP it)) (VP (VBZ is) (VP (VBN induced) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NML (NN liver) (, ,) (NN muscle) (, ,) (CC and) (NN beta)) (NNS cells))) (PP-MNR (IN by) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VP (VBG facilitating) (NP (NP (NN deposition)) (PP (IN of) (NP (NN fat)))) (PP (IN as) (NP (ADJP (RB relatively) (JJ harmless)) (NNS lipids)))) (CC and) (VP (ADVP (RB thus)) (VBZ prevents) (NP (NP (NN accumulation)) (PP (IN of) (NP (JJ toxic) (NN lipid) (NNS species)))))))) (ADVP-TMP-2 (-NONE- *T*)))))))))) (. .)) )
( (S (NP-SBJ (PRP We)) (ADVP (RB also)) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ-1 (NN PPARg2)) (VP (MD may) (VP (VB be) (VP (VBN involved) (NP-1 (-NONE- *)) (PP (IN in) (NP (NP (DT the) (JJ adaptive) (NN response)) (PP (IN of) (NP (NN beta) (NNS cells))) (PP (IN to) (NP (NN insulin) (NN resistance))))))))))) (. .)) )
( (HEADING (NP (NN Introduction))) )
( (S (NP-SBJ (NP (DT An) (JJ adipocentric) (NN view)) (PP (IN of) (NP (NP (DT the) (JJ Metabolic) (NN Syndrome)) (-LRB- -LRB-) (NP (NN MS))))) (-RRB- -RRB-) (VP (VBZ considers) (S (NP-SBJ (NN obesity)) (PP-PRD (IN as) (NP (NP (DT the) (JJ major) (NN factor)) (VP (VBG leading) (PP (IN to) (NP (NP (NN insulin) (NN resistance)) (PP (IN in) (NP (JJ peripheral) (JJ metabolic) (NNS tissues)))))))))) (. .)) )
( (S (ADVP (RB However)) (, ,) (NP-SBJ (NP (DT the) (NN link)) (PP (IN between) (NP (NP (NN obesity)) (CC and) (NP (NN insulin) (NN resistance))))) (VP (VBZ is) (ADJP-PRD (JJ complex)) (, ,) (SBAR-ADV (IN as) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBN indicated) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (DT the) (NN fact) (SBAR (IN that) (S (NP-SBJ (DT some) (RB extremely) (JJ obese) (NNS people)) (VP (VBP are) (ADJP-PRD (NN glucose) (JJ tolerant)))))))))) (, ,) (SBAR-ADV (IN while) (S (NP-SBJ (NP (NNS others)) (PP (IN with) (NP (NP (DT a) (JJ mild) (NN degree)) (PP (IN of) (NP (NN obesity)))))) (VP (VBP develop) (NP (NP (JJ severe) (NN insulin) (NN resistance)) (CC and) (NP (NN diabetes))))))) (. .)) )
( (S (NP-SBJ (DT This)) (VP (VBZ suggests) (SBAR (IN that) (S (NP-SBJ (NP (NP (DT the) (JJ absolute) (NN amount)) (PP (IN of) (NP (NN fat)))) (VP (VBN stored) (NP (-NONE- *)))) (VP (MD may) (RB not) (VP (VB be) (NP-PRD (NP (DT the) (ADJP (RBS most) (JJ important)) (NN factor)) (VP (VBG determining) (NP (NP (DT the) (NN relationship)) (PP (IN between) (NP (NP (NN obesity)) (CC and) (NP (NN insulin) (NN resistance)))))))))))) (. .)) )
( (S (NP-SBJ (NP (JJ Recent) (NN work)) (VP (VBG showing) (NP (NP (DT the) (NN complexity)) (PP (IN of) (NP (NP (DT the) (JJ molecular) (NNS mechanisms)) (VP (VBG controlling) (NP (NN adipogenesis))))))) (PRN (-LRB- [) (NP (CD 1) (, ,) (CD 2)) (-RRB- ]))) (VP (VBZ suggests) (SBAR (IN that) (S (NP-SBJ (NN adipose) (NN tissue) (NN expandability)) (VP (MD may) (VP (VB be) (NP-PRD (NP (DT an) (JJ important) (NN factor)) (VP (VBG linking) (NP (NP (NN obesity)) (, ,) (NP (NN insulin) (NN resistance)) (, ,) (CC and) (NP (VBN associated) (NNS comorbidities)))))))))) (. .)) )
( (S (NP-SBJ (EX There)) (VP (VBP are) (NP-PRD (NP (CD two) (NNS mechanisms)) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBP have) (VP (VBN been) (VP (VBN proposed) (NP-1 (-NONE- *)))))))) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB explain) (SBAR-NOM (WHADVP-2 (WRB how)) (S (NP-SBJ (NP (NN expansion)) (PP (IN of) (NP (DT the) (NN adipose) (NN tissue) (NNS stores)))) (VP (VBZ affects) (NP (NN insulin) (NN sensitivity)) (ADVP-MNR-2 (-NONE- *T*))))))))) (. .)) )
( (S (NP-SBJ (CD One) (NN mechanism)) (VP (VBZ suggests) (SBAR (IN that) (S (NP-SBJ (VBN increased) (NN adiposity)) (VP (VBZ induces) (NP (NP (DT a) (JJ chronic) (JJ inflammatory) (NN state)) (VP (VBN characterized) (NP (-NONE- *)) (PP-MNR (IN by) (NP (NP (VBN increased) (NN cytokine) (NN production)) (PP (PP (IN by) (NP (NNS adipocytes))) (CONJP (CC and) (HYPH /) (CC or)) (PP (IN from) (NP (NP (NNS macrophages)) (VP (VBG infiltrating) (NP (NN adipose) (NN tissue)))))))))))))) (. .)) )
( (S (NP-SBJ (NP (NNS Cytokines)) (VP (VBN produced) (NP (-NONE- *)) (PP-MNR (IN by) (NP (NP (DT these) (NNS adipocytes)) (CC or) (NP (NNS macrophages)))))) (VP (MD may) (ADVP (RB directly)) (VP (VB antagonise) (NP (NN insulin) (NN signalling)) (PRN (-LRB- [) (NP (CD 3) (, ,) (CD 4)) (-RRB- ])))) (. .)) )
( (S (NP-SBJ (DT A) (JJ second) (JJ nonexclusive) (NN hypothesis)) (VP (VBZ is) (NP-PRD (NN lipotoxicity))) (. .)) )
( (S (NP-SBJ (DT The) (JJ lipotoxic) (NN hypothesis)) (VP (VBZ states) (SBAR (IN that) (S (SBAR-ADV (IN if) (S (NP-SBJ (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (NN fuel)))) (VP (VBG entering) (NP (DT a) (NN tissue)))) (VP (VBZ exceeds) (NP (PRP$ its) (NML (UCP (JJ oxidative) (CC or) (NN storage)) (NN capacity)))))) (, ,) (NP-SBJ-2 (NP (JJ toxic) (NNS metabolites)) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBP inhibit) (NP (NN insulin) (NN action)))))) (VP (VBP are) (VP (VBN formed) (NP-2 (-NONE- *)) (PRN (-LRB- [) (NP (NP (CD 5)) (PP (SYM –) (NP (CD 8)))) (-RRB- ]))))))) (. .)) )
( (S (PP (IN Of) (NP (NP (JJ particular) (NN relevance)) (PP (IN to) (NP (DT this) (NN article))))) (, ,) (NP-SBJ-1 (NP (NN lipid) (NNS metabolites)) (, ,) (PP (JJ such) (IN as) (NP (NP (NP (NNS ceramides)) (CC and) (NP (NP (NN diacylglycerol)) (-LRB- -LRB-) (NP (NN DAG)))) (-RRB- -RRB-) (CC or) (NP (NP (JJ reactive) (NN oxygen) (NNS species)) (VP (VBN generated) (NP (-NONE- *)) (PP (IN from) (NP (JJ hyperactive) (JJ oxidative) (NNS pathways)))))))) (, ,) (VP (VBP have) (VP (VBN been) (VP (VBN shown) (S (NP-SBJ-1 (-NONE- *)) (VP (VP (TO to) (VP (VB inhibit) (NP (NN insulin) (NN signalling)))) (CC and) (VP (TO to) (VP (VB induce) (NP (NN apoptosis)))))) (PRN (-LRB- [) (NP (NP (CD 9)) (PP (SYM –) (NP (CD 11)))) (-RRB- ]))))) (. .)) )
( (S (NP-SBJ-1 (DT The) (JJ nuclear) (NN receptor) (NML (NML (NN peroxisome) (NN proliferator) (VBN activated) (NN receptor) (NN gamma)) (-LRB- -LRB-) (NML (NN PPARg)))) (-RRB- -RRB-) (VP (VBZ is) (ADVP (RB critically)) (VP (VBN required) (NP-1 (-NONE- *)) (PP-PRP (IN for) (NP (NP (NN adipogenesis)) (CC and) (NP (NN insulin) (NN sensitivity)))) (PRN (-LRB- [) (NP (NP (CD 12)) (PP (SYM –) (NP (CD 15)))) (-RRB- ])))) (. .)) )
( (S (NP-SBJ (EX There)) (VP (VBP are) (NP-PRD (NP (CD two) (NN PPARg) (NNS isoforms)) (, ,) (NP (NN PPARg1) (CC and) (NN PPARg2)))) (. .)) )
( (S (NP-SBJ-1 (NN PPARg1)) (VP (VBZ is) (VP (VBN expressed) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NP (JJ many) (NML (NML (NNS tissues)) (CC and) (NML (NN cell) (NNS types)))) (, ,) (PP (VBG including) (NP (NP (ADJP (JJ white) (CC and) (JJ brown)) (NN adipose) (NN tissue)) (, ,) (NP (JJ skeletal) (NN muscle)) (, ,) (NP (NN liver)) (, ,) (NP (JJ pancreatic) (NML (NN β) (HYPH -) (NNS cells))) (, ,) (NP (NNS macrophages)) (, ,) (NP (NN colon)) (, ,) (NP (NN bone)) (, ,) (CC and) (NP (NN placenta)))))) (PRN (-LRB- [) (NP (CD 16)) (-RRB- ])))) (. .)) )
( (S (PP (IN Under) (NP (JJ physiological) (NNS conditions))) (, ,) (NP-SBJ-1 (NP (NN expression)) (PP (IN of) (NP (NP (NN PPARg2)) (, ,) (NP (DT the) (JJ other) (NN splice) (NN variant))))) (, ,) (VP (VBZ is) (VP (VBN restricted) (NP-1 (-NONE- *)) (PP (IN to) (NP (ADJP (JJ white) (CC and) (JJ brown)) (NN adipose) (NN tissue))) (PRN (-LRB- [) (NP (CD 16) (, ,) (CD 17)) (-RRB- ])))) (. .)) )
( (S (PP-LOC (IN In) (NP (NN adipose) (NN tissue))) (NP-SBJ (NN PPARg)) (VP (VBZ is) (NP-PRD (NP (DT the) (JJ key) (NN regulator)) (PP (IN of) (NP (NN adipogenesis))))) (. .)) )
( (S (S (NP-SBJ (NN PPARg2)) (VP (VBZ is) (NP-PRD (DT the) (ADJP (RBR more) (JJ adipogenic)) (NN PPARg) (NN isoform)) (ADVP (FW in) (FW vitro)))) (, ,) (S (NP-SBJ (PRP it)) (VP (VBZ is) (ADVP (RB also)) (NP-PRD (NP (DT the) (NN isoform)) (VP (VBN regulated) (NP (-NONE- *)) (ADVP (RB transcriptionally)) (PP (IN by) (NP-LGS (NN nutrition))))))) (PRN (-LRB- [) (NP (NP (CD 17)) (PP (SYM –) (NP (CD 20)))) (-RRB- ])) (. .)) )
( (S (SBAR-ADV (IN Although) (S (PP (IN under) (NP (JJ physiological) (NNS conditions))) (NP-SBJ-1 (NP (NN expression)) (PP (IN of) (NP (NN PPARg2)))) (VP (VBZ is) (VP (VBN limited) (NP-1 (-NONE- *)) (PP (IN to) (NP (NN adipose) (NNS tissues))))))) (, ,) (NP-SBJ (PRP we)) (VP (VBP have) (VP (VBN shown) (SBAR (IN that) (S (NP-SBJ-2 (NN PPARg2)) (VP (VBZ is) (ADVP (RB ectopically)) (VP (VBN induced) (NP-2 (-NONE- *)) (PP-LOC (IN in) (NP (NP (NN liver)) (CC and) (NP (JJ skeletal) (NN muscle)))) (PP (IN in) (NP (NP (NN response)) (PP (IN to) (NP (NP (NN overnutrition)) (CC or) (NP (JJ genetic) (NN obesity)))))))))) (PRN (-LRB- [) (NP (CD 2) (, ,) (CD 18)) (-RRB- ])))) (. .)) )
( (S (NP-SBJ (NP (ADJP (FW De) (FW novo)) (NN expression)) (PP (IN of) (NP (NN PPARg2)))) (PP-LOC (IN in) (NP (NN liver) (CC and) (NN muscle))) (PP (IN in) (NP (NN obesity))) (VP (VBZ suggests) (SBAR (IN that) (S (NP-SBJ (NN PPARg2)) (VP (MD may) (VP (VB have) (NP (DT a) (NN role)) (PP (IN in) (NP (NP (NP (NN insulin) (NN resistance)) (CC and) (NP (NN lipotoxicity))) (PP-LOC (IN in) (NP (DT these) (NNS tissues)))))))))) (. .)) )
( (S (NP-SBJ-1 (NP (JJ Little) (ADJP (FW in) (FW vivo)) (NN research)) (PP (IN into) (NP (NP (DT the) (JJ metabolic) (NNS roles)) (PP (IN for) (NP (NP (DT the) (JJ specific) (NNS isoforms)) (PP (IN of) (NP (NN PPARg)))))))) (VP (VBZ has) (VP (VBN been) (VP (VBN carried) (NP-1 (-NONE- *)) (PRT (RP out)) (, ,) (PP (IN with) (S-NOM (NP-SBJ (DT the) (NNS studies)) (ADVP (RB so) (RB far)) (VP (VBG focusing) (ADVP (RB almost) (RB exclusively)) (PP (IN on) (NP (NN adipose) (NN tissue)))))) (PRN (-LRB- [) (NP (CD 2) (, ,) (CD 13) (, ,) (CD 21) (, ,) (CD 22)) (-RRB- ]))))) (. .)) )
( (S (NP-SBJ-1 (NN PPARg) (PRN (-LRB- -LRB-) (NP (DT both) (NNS isoforms)) (-RRB- -RRB-)) (NNS deletions)) (VP (VBP have) (VP (VBN been) (VP (VBN generated) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (JJS most) (JJ major) (JJ metabolic) (NNS tissues)))))) (. .)) )
( (S (NP-SBJ (NP (NML (NN Liver) (HYPH -) (JJ specific)) (NN deletion)) (PP (IN of) (NP (DT both) (NN PPARg) (NNS isoforms)))) (VP (VBD caused) (NP (NP (DT an) (NN impairment)) (PP (IN in) (NP (NN insulin) (NN sensitivity)))) (, ,) (SBAR-ADV (ADVP (RB particularly)) (WHADVP-2 (WRB when)) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBN challenged) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (JJ different) (JJ genetic) (NNS backgrounds) (PRN (-LRB- -LRB-) (NP (UCP (JJ lipoatrophic) (CC or) (NN leptin)) (HYPH -) (NN deficiency)) (-RRB- -RRB-)))) (ADVP-TMP-2 (-NONE- *T*))))) (PRN (-LRB- [) (NP (CD 23) (, ,) (CD 24)) (-RRB- ]))) (. .)) )
( (S (NP-SBJ (NP (DT The) (NN effect)) (PP (IN of) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG ablating) (NP (CC both) (NN PPARg) (NNS isoforms)) (PP-LOC (IN in) (NP (NN muscle))))))) (VP (VBD produced) (NP (JJ controversial) (NNS results)) (, ,) (PP (IN with) (S-NOM (NP-SBJ (CD two) (NNS groups)) (VP (VBG reporting) (NP (JJ different) (NNS effects)) (PP (IN on) (NP (NN insulin) (NN sensitivity)))))) (PRN (-LRB- [) (NP (CD 25) (, ,) (CD 26)) (-RRB- ]))) (. .)) )
( (S (NP-SBJ (NP (DT The) (NN role)) (PP (IN of) (NP (NN PPARg))) (PP-LOC (IN in) (NP (JJ pancreatic) (NML (NN β) (HYPH -) (NNS cells))))) (VP (VBZ is) (ADJP-PRD (JJ unclear)) (, ,) (UCP-PRP (PP (ADVP (RB primarily)) (IN due) (IN to) (NP (NP (PRP$ its) (JJ low) (NN expression)) (PP (IN under) (NP (JJ physiological) (NNS conditions)))) (PRN (-LRB- [) (NP (NP (CD 27)) (PP (SYM –) (NP (CD 29)))) (-RRB- ]))) (CC and) (SBAR (ADVP (RB secondly)) (IN because) (S (NP-SBJ (NP (NN ablation)) (PP (IN of) (NP (NP (DT both) (NN PPARg) (NNS isoforms)) (PP-LOC (IN in) (NP (NN β) (HYPH -) (NNS cells)))))) (VP (VBD did) (RB not) (VP (VB result) (PP (IN in) (NP (DT a) (JJ metabolic) (NN phenotype))))))))) (. .)) )
( (S (ADVP (RB However)) (NP-SBJ (NN PPARg)) (VP (MD may) (VP (VB play) (NP (DT a) (NN role)) (PP (IN in) (NP (NML (NN β) (HYPH -) (NN cell)) (NN hyperplasia))) (PP (IN in) (NP (NP (NN response)) (PP (IN to) (NP (NN insulin) (NN resistance))))) (, ,) (NP-ADV (NP (DT an) (NN idea)) (VP (VBN supported) (NP (-NONE- *)) (PP (IN by) (NP-LGS (DT the) (NN fact) (SBAR (IN that) (S (NP-SBJ (NP (NNS mice)) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBP lack) (NP (NN PPARg)) (PP-LOC (IN in) (NP (NN β) (HYPH -) (NNS cells))))))) (VP (VBP do) (RB not) (VP (VB expand) (NP (PRP$ their) (NML (NN β) (HYPH -) (NNS cells)) (NN mass)) (PP-MNR (IN in) (NP (NP (NN response)) (PP (IN to) (NP (DT a) (NML (JJ high) (HYPH -) (NN fat)) (NN diet))))))))))))) (PRN (-LRB- [) (NP (CD 30)) (-RRB- ])))) (. .)) )
( (S (ADVP-TMP (RBR More) (RB recently)) (, ,) (NP-SBJ-2 (NP (PRP it)) (SBAR-1 (-NONE- *EXP*))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (NP-2 (-NONE- *)) (SBAR-1 (IN that) (S (NP-SBJ (JJ heterozygous) (NML (NN PPARg) (HYPH -) (JJ deficient)) (NNS mice)) (VP (VBP develop) (NP (NP (VBN impaired) (NN insulin) (NN secretion)) (, ,) (SBAR (WHNP-3 (WDT which)) (S (NP-SBJ-3 (-NONE- *T*)) (VP (VBZ is) (VP (VBN associated) (NP-3 (-NONE- *)) (PP (IN with) (NP (VBN increased) (NML (NML (NN islet) (NN triacylglycerol)) (-LRB- -LRB-) (NML (NN TAG))) (-RRB- -RRB-) (NN content))))))))))) (PRN (-LRB- [) (NP (CD 31)) (-RRB- ]))))) (. .)) )
( (S (ADVP (RB Here)) (NP-SBJ (PRP we)) (VP (VBP investigate) (NP (NP (DT the) (JJ physiological) (NN relevance)) (PP (IN of) (NP (NN PPARg2))) (PP (IN under) (NP (NP (NNS conditions)) (PP (IN of) (NP (JJ positive) (NN energy) (NN balance)))))) (PP-MNR (IN by) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG ablating) (NP (NN PPARg2)) (PP-LOC (IN in) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice))))))) (. .)) )
( (S (NP-SBJ (PRP We)) (VP (VBP use) (NP (NP (DT a) (JJ new) (NN approach)) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBZ integrates) (NP (JJ traditional) (JJ physiological) (NN phenotyping)) (PP (IN with) (NP (NP (VBN advanced) (JJ lipidomic) (NN technology)) (CC and) (NP (NNS transcriptomics))))))))) (. .)) )
( (S (NP-SBJ (PRP$ Our) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (PP (IN in) (NP (NP (DT the) (NN context)) (PP (IN of) (NP (JJ positive) (NN energy) (NN balance))))) (, ,) (NP-SBJ (NP (DT the) (NN absence)) (PP (IN of) (NP (NN PPARg2)))) (VP (VBZ results) (PP (IN in) (NP (DT a) (JJ major) (JJ metabolic) (NN failure))))))) (. .)) )
( (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ (PRP we)) (VP (VBP provide) (NP (NN evidence) (SBAR (IN that) (S (NP-SBJ (NP (NN control)) (PP (IN of) (NP (NN adipose) (NN tissue) (NN expansion))) (PP (IN by) (NP (NN PPARg2)))) (VP (MD may) (VP (VB be) (NP-PRD (NP (DT an) (JJ important) (NN variable)) (VP (VBG linking) (NP (JJ positive) (NN energy) (NN balance)) (PP (IN to) (NP (NP (PRP$ its) (JJ metabolic) (NNS complications)) (PP (VBG including) (NP (NP (NN insulin) (NN resistance)) (, ,) (NP (NML (NN β) (HYPH -) (NN cell)) (NN failure)) (, ,) (CC and) (NP (NN dyslipidaemia)))))))))))))) (. .)) )
( (S (ADVP (RB Similarly)) (, ,) (NP-SBJ (PRP$ our) (JJ lipidomic) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ-1 (NP (NN induction)) (PP (IN of) (NP (NN PPARg2))) (PP (IN in) (NP (JJ nonadipose) (NNS tissues)))) (VP (MD should) (VP (VB be) (VP (VBN considered) (S (NP-SBJ-1 (-NONE- *)) (PP-PRD (IN as) (NP (NP (DT a) (JJ physiological) (NN adaptation)) (SBAR (WHNP-2 (WDT that)) (S (NP-SBJ-2 (-NONE- *T*)) (VP (VBZ prevents) (NP (NP (DT the) (JJ toxic) (NNS effects)) (VP (VBN produced) (NP (-NONE- *)) (PP (IN by) (NP-LGS (JJ excess) (NNS nutrients))))))))))))))))) (. .)) )
( (S (NP-SBJ-1 (NP (DT This) (JJ antilipotoxic) (NN effect)) (PP (IN of) (NP (NN PPARg2)))) (VP (VBZ is) (VP (VBN achieved) (NP-1 (-NONE- *)) (PP-MNR (IN by) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VP (VBG increasing) (NP (NP (DT the) (ADJP (NN lipid) (HYPH -) (VBG buffering)) (NN capacity)) (PP (IN of) (NP (JJ peripheral) (NNS organs))))) (CC and) (VP (VBG facilitating) (NP (NML (NN β) (HYPH -) (NN cell)) (NN hyperplasia)) (PP (IN in) (NP (NP (NN response)) (PP (IN to) (NP (NN insulin) (NN resistance))))))))))) (. .)) )
( (HEADING (NP (NNS Results))) )
( (HEADING (S (NP-SBJ (NP (NN Ablation)) (PP (IN of) (NP (NN PPARg2)))) (PP-LOC (IN in) (NP (NP (NML (NN Ob) (HYPH /) (NN Ob)) (NNS Mice)) (-LRB- -LRB-) (NP (NN POKO) (NN Mouse)))) (-RRB- -RRB-) (VP (VBZ Prevents) (NP (NML (NN Adipose) (NN Tissue)) (NN Expansion)) (PP (IN in) (NP (NP (NN Response)) (PP (IN to) (NP (JJ Positive) (NN Energy) (NN Balance)))))))) )
( (S (NP-SBJ-1 (NP (NML (NN PPARg2) (SYM −) (HYPH /) (SYM −) (NN Lepob) (HYPH /) (NN Lepob)) (NNS mice)) (PP (IN with) (NP (NP (JJ genetic) (NN ablation)) (PP (IN of) (NP (NP (DT the) (NN PPARg2) (NN isoform)) (PP (IN on) (NP (NP (DT the) (JJ obese) (JJ hyperphagic) (NML (NN ob) (HYPH /) (NN ob)) (NN background)) (-LRB- -LRB-) (NP (NN POKO))))))))) (-RRB- -RRB-) (VP (VBD were) (VP (VBN generated) (NP-1 (-NONE- *)))) (. .)) )
( (S (NP-SBJ (NP (NNS Matings)) (PP (IN of) (NP (NML (NN PPARg2) (SYM +) (HYPH /) (SYM −) (NN Lepob) (HYPH /) (NN Lep) (SYM +)) (NNS mice)))) (VP (VBD followed) (NP (DT the) (VBN expected) (JJ Mendelian) (NN distribution)) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NP (NNP Fisher) (POS 's)) (NN test)) (VP (SYM =) (NP (CD 0.074) (CC and) (CD 0.135)) (PP (IN for) (NP (NNS males) (CC and) (NNS females))) (, ,) (ADVP (RB respectively)))) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ (NP (NN PPARg1) (NN gene) (NN expression)) (PP-LOC (IN in) (NP (NP (NP (JJ white) (NN adipose) (NN tissue)) (-LRB- -LRB-) (NP (NN WAT))) (-RRB- -RRB-) (PP (IN from) (NP (ADJP (NP (CD five) (HYPH -) (NN week)) (HYPH -) (JJ old)) (NN POKO) (NNS mice)))))) (VP (VP (VBD was) (ADJP-PRD (JJ similar) (PP (IN to) (NP (NN PPARg2) (NN KO) (NNS mice))))) (CC and) (VP (VBD was) (RB not) (ADJP-PRD (RB significantly) (JJ different) (PP (IN from) (NP (NML (NML (JJ wild) (HYPH -) (NN type)) (-LRB- -LRB-) (NML (NN WT))) (-RRB- -RRB-) (NNS mice))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN S1)) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ (NN Figure) (NN 1A)) (VP (VBZ shows) (NP (NP (NN growth) (NNS curves)) (PP (IN for) (NP (NP (ADJP (JJ male) (CC and) (JJ female)) (NNS mice)) (PP (IN of) (NP (CD four) (NNS genotypes) (PRN (-LRB- -LRB-) (NP (NP (NN WT)) (, ,) (NP (NN PPARg2) (NN KO)) (, ,) (NP (NN ob) (HYPH /) (NN ob)) (, ,) (CC and) (NP (NN POKO) (NNS mice))) (-RRB- -RRB-)))))) (PP-TMP (IN over) (NP (DT a) (NML (CD 12) (HYPH -) (NN week)) (NN period))))) (. .)) )
( (S (PP-TMP (IN At) (NP (NN birth))) (, ,) (NP-SBJ (NP (DT the) (NN body) (NN weight)) (PP (IN of) (NP (ADJP (JJ male) (CC and) (JJ female)) (NN POKO) (NNS mice)))) (VP (VBD was) (ADJP-PRD (JJ indistinguishable) (PP (IN from) (NP (JJ other) (NNS genotypes)))) (CIT (-LRB- -LRB-) (JJ unpublished) (NNS data) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ (DT The) (NML (NN ob) (HYPH /) (NN ob)) (NNS mice)) (ADVP (RB quickly)) (VP (VBD became) (ADJP-PRD (ADJP (JJR heavier)) (PP (IN than) (NP (PRP$ their) (NN WT) (NNS littermates)))) (, ,) (PP (IN with) (NP (ADJP (RB significantly) (VBN elevated)) (NN body) (NN weight))) (PP-TMP (IN by) (NP (NP (QP (CD four) (CC and) (CD six)) (NNS weeks)) (PP (IN of) (NP (NN age))))) (PP-LOC (IN in) (NP (ADJP (JJ female) (CC and) (JJ male)) (NNS mice))) (, ,) (ADVP (RB respectively))) (. .)) )
( (S (S (ADVP (RB However)) (, ,) (NP-SBJ (DT the) (NN POKO) (NNS mice)) (VP (VBD did) (RB not) (VP (VB become) (ADJP-PRD (JJ obese))))) (, ,) (CC and) (S (NP-SBJ (PRP$ their) (NN body) (NN weight)) (VP (VBD remained) (ADJP-PRD (JJ close) (PP (IN to) (NP (NML (NML (NML (NN WT) (CC and) (NN PPARg2)) (NN KO)) (NN body) (NNS weights)) (NNS mice)))) (PP-TMP (IN during) (NP (DT the) (NML (CD 12) (HYPH -) (NN week)) (NN study))))) (. .)) )
( (S (NP-SBJ (NN POKO) (NNS mice)) (VP (VP (VBD were) (ADJP-PRD (ADJP (RB as) (JJ hyperphagic) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 1B)) (-RRB- -RRB-))) (PP (IN as) (NP (DT the) (NML (NN ob) (HYPH /) (NN ob)) (NNS mice))))) (CC but) (VP (VBP drank) (NP (ADJP (RB far) (JJR more)) (NN water)) (PP (VBN compared) (PP (IN with) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS littermates) (PRN (-LRB- -LRB-) (NP (NP (QP (QP (CD 81.85) (SYM ±) (CD 15.14)) (CC versus) (QP (CD 9.05) (SYM ±) (CD 2.32))) (NNS ml)) (PP (SYM /) (NP (CD 70) (NN h)))) (, ,) (S-FRM (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.01)))) (, ,) (NP (NP (JJ female) (NN POKO)) (CC versus) (NP (NN ob) (HYPH /) (NN ob))) (, ,) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (CD 4)) (PP-TMP (IN at) (NP (CD 20) (NN wk))))) (-RRB- -RRB-)))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN S2A)) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ (NML (JJ Dual) (HYPH -) (NN energy)) (NN X-ray) (NN absorptiometry) (NN analysis)) (PP-TMP (IN at) (NP (CD 20) (NNS wk) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 1C)) (-RRB- -RRB-)))) (VP (VBD confirmed) (SBAR (IN that) (S (NP-SBJ (JJ female) (NN POKO) (NNS mice)) (VP (VBD had) (NP (NP (NP (ADJP (RB slightly) (VBN increased)) (NN fat) (NN content) (PRN (-LRB- -LRB-) (NP (CD 4) (NN %)) (-RRB- -RRB-))) (PP (VBN compared) (PP (IN to) (NP (NML (NML (NN WT)) (CC and) (NML (NN PPARg2) (NN KO))) (NNS mice))))) (, ,) (CC but) (NP (NP (ADJP (RB significantly) (VBN reduced)) (NN fat) (NN mass)) (PP (VBN compared) (PP (IN to) (NP (NP (DT the) (NML (CD 40) (NN %)) (NN increase)) (VP (VBN observed) (NP (-NONE- *)) (PP-LOC (IN in) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice))))))))))))) (. .)) )
( (S (PP-TMP (IN At) (NP (NP (DT the) (NN age)) (PP (IN of) (NP (CD 20) (NNS wk))))) (, ,) (NP-SBJ (NML (NML (NN POKO)) (CC and) (NML (NN ob) (HYPH /) (NN ob))) (NNS mice)) (VP (VBD had) (NP (NP (DT a) (NN trend)) (PP (IN to) (NP (DT a) (VBN decreased) (JJ total) (NN locomotor) (NN activity)))) (PP-TMP (IN during) (NP (NML (NN dark) (CC and) (NN light)) (NNS cycles))) (PP (VBN compared) (PP (IN with) (NP (DT the) (NML (NML (NN WT)) (CC and) (NML (NN PPARg2) (NN KO))) (NNS mice)))) (PP-TMP (IN over) (NP (DT the) (NML (CD 72) (HYPH -) (NN h)) (NN period)))) (. .)) )
( (S (ADVP (RB However)) (NP-SBJ (NN POKO)) (VP (VBD had) (NP (JJ similar) (JJ total) (NN locomotor) (NN activity)) (PP (VBN compared) (PP (IN with) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice)))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN S2B)) (-RRB- -RRB-))) (. .)) )
( (S (PP-TMP (IN At) (NP (NP (CD six) (NNS weeks)) (PP (IN of) (NP (NN age))))) (, ,) (NP-SBJ (JJ female) (NN POKO) (NNS mice)) (VP (VBD consumed) (NP (NP (DT a) (JJ similar) (NN amount)) (PP (IN of) (NP (NN oxygen))) (PP (IN as) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice))) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN vO2)) (VP (SYM =) (NP (NP (QP (QP (CD 25.06) (SYM ±) (CD 0.89)) (CC versus) (QP (CD 23.10) (SYM ±) (CD 0.99))) (NN ml)) (PP (SYM /) (NP (NN kg) (NN bodyweight))) (NP-ADV (NP (CD 0.75)) (PP (SYM /) (NP (NN min))))))) (, ,) (S-FRM (NP-SBJ (NN p)) (VP (SYM =) (NP (CD 0.07)))) (NP (NP (NN POKO)) (CC versus) (NP (NN ob) (HYPH /) (NN ob))) (, ,) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (NP (CD 6)) (PP (SYM –) (NP (CD 8)))))) (-RRB- -RRB-))) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG showing) (NP (NP (NP (DT a) (JJR lower) (JJ respiratory) (NN exchange) (NN ratio) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 0.916) (SYM ±) (CD 0.011))) (CC versus) (NP (QP (CD 0.952) (SYM ±) (CD 0.007)))) (, ,) (S-FRM (NP-SBJ (NN p)) (VP (SYM =) (NP (CD 0.01)))) (, ,) (NP (JJ female) (NML (NML (NN POKO)) (CC versus) (NML (NN ob) (HYPH /) (NN ob)))) (-RRB- -RRB-))) (PP (IN in) (NP (DT the) (VBN fed) (NN state)))) (, ,) (CC but) (NP (NP (JJ similar) (JJ respiratory) (NN exchange) (NN ratio)) (PP (IN in) (NP (DT the) (VBN fasted) (NN state))) (PRN (-LRB- -LRB-) (NP (NP (QP (CD 0.73) (SYM ±) (CD 0.014))) (CC versus) (NP (QP (CD 0.75) (SYM ±) (CD 0.018)))) (, ,) (S-FRM (NP-SBJ (NN p) (HYPH -) (NN value)) (VP (SYM =) (NP (CD 0.59)))) (NP (NML (NML (NN POKO)) (CC versus) (NML (NN ob) (HYPH /) (NN ob))) (NNS mice)) (-RRB- -RRB-))))))) (. .)) )
( (S (NP-SBJ-1 (NN Water) (NN intake)) (VP (VBD was) (ADVP (RB already)) (ADVP (RB significantly)) (VP (VBN increased) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NP (NN POKO) (NML-2 (-NONE- *RNR*))) (PP (VBN compared) (PP (IN to) (NP (NML (NN ob) (HYPH /) (NN ob)) (NML-2 (-NONE- *RNR*))))) (NML-2 (NNS mice)))) (PRN (-LRB- -LRB-) (NP (NP (QP (QP (CD 13.59) (SYM ±) (CD 1.88)) (CC versus) (QP (CD 8.15) (SYM ±) (CD 0.89))) (NN ml)) (PP (SYM /) (NP (NN d)))) (, ,) (S-FRM (NP-SBJ (NN p) (HYPH -) (NN value)) (VP (SYM <) (NP (CD 0.05)))) (, ,) (NP (NP (NN POKO)) (CC versus) (NP (NN ob) (HYPH /) (NN ob))) (-RRB- -RRB-)))) (. .)) )
( (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ (NP (NNS levels)) (PP (IN of) (NP (NN glucose))) (PP-LOC (IN in) (NP (NN urine)))) (VP (VBD were) (ADJP-PRD (JJR higher)) (PP-LOC (IN in) (NP (NN POKO) (NNS mice))) (PP (VBN compared) (PP (IN with) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice)))) (PRN (-LRB- -LRB-) (NP (NP (QP (QP (CD 403.4) (SYM ±) (CD 49.2)) (CC versus) (QP (CD 34.13) (SYM ±) (CD 13.5))) (NN mMol)) (PP (SYM /) (NP (NN l)))) (, ,) (NP (NML (NML (NN POKO)) (CC versus) (NML (NN ob) (HYPH /) (NN ob))) (NNS mice)) (, ,) (S-FRM (NP-SBJ (NN p) (HYPH -) (NN value)) (VP (SYM =) (NP (CD 0.001)))) (-RRB- -RRB-)) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG showing) (NP (NP (DT an) (NN energy) (NN loss)) (PP (IN of) (NP (NP (QP (CD 15.43) (SYM ±) (CD 3.06)) (NN kJ)) (PP (SYM /) (NP (NN d))))) (PP (IN through) (NP (NN urine)))) (PP (VBN compared) (PP (IN with) (NP (NP (QP (CD 0.70) (SYM ±) (CD 0.19)) (NN kJ)) (PP (SYM /) (NP (NN d))) (PP-LOC (IN in) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice))))))))) (. .)) )
( (S (PP-TMP (IN At) (NP (DT this) (NN age))) (, ,) (NP-SBJ (NN POKO) (NNS mice)) (VP (VP (VBD showed) (NP (JJ similar) (NN locomotor) (NN activity)) (PP (VBN compared) (PP (IN with) (NP (DT the) (NML (NN ob) (HYPH /) (NN ob)) (NNS mice)))) (PP-TMP (IN during) (NP (DT the) (NN day)))) (, ,) (CC but) (VP (VBD increased) (NP (NN locomotor) (NN activity)) (PP-TMP (IN during) (NP (DT the) (NN night))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN S2C)) (-RRB- -RRB-)))) (. .)) )
( (S (NP-SBJ (NP (JJ Histomorphometric) (NN analysis)) (PP (IN of) (NP (NN adipose) (NN tissue))) (PP (IN from) (NP (ADJP (NP (CD 16) (HYPH -) (NN wk)) (HYPH -) (JJ old)) (JJ male) (NNS mice)))) (VP (VBD revealed) (SBAR (IN that) (S (NP-SBJ (NN POKO) (NNS mice)) (VP (VBD had) (NP (NP (JJR fewer) (JJ small) (NNS adipocytes)) (PP (IN than) (NP (DT the) (NML (NN ob) (HYPH /) (NN ob)) (NNS mice))))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NML (NN 1D) (CC and) (NN 1E))) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ (NP (DT This) (NN analysis)) (PP (IN of) (NP (NN adipocyte) (NN size)))) (VP (VBZ suggests) (SBAR (IN that) (S (NP-SBJ (NP (NN ablation)) (PP (IN of) (NP (NN PPARg2))) (PP-LOC (IN in) (NP (DT the) (NML (NN ob) (HYPH /) (NN ob)) (NN background)))) (VP (VBZ impairs) (NP (NP (DT the) (NN potential)) (PP (IN for) (NP (NN adipocyte) (NN recruitment)))))))) (. .)) )
( (HEADING (NP (NP (NP (JJ Early) (NN Insulin) (NN Resistance)) (PP-LOC (IN in) (NP (NN POKO) (NNS Mice)))) (ADJP (JJ Independent) (PP (IN of) (NP (NN Body) (NN Weight)))))) )
( (S (SBAR-ADV (IN As) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBN expected) (NP-1 (-NONE- *))))) (NP-SBJ-2 (NP (DT the) (VBN reduced) (NML (NN adipose) (NN tissue)) (NN expandability)) (PP (IN of) (NP (DT the) (NN POKO) (NN mouse)))) (VP (VBD was) (VP (VBN associated) (NP-2 (-NONE- *)) (PP (IN with) (NP (JJ severe) (NN insulin) (NN resistance))))) (. .)) )
( (S (ADVP (RB Surprisingly)) (NP-SBJ (NN insulin) (NN resistance)) (VP (VBD developed) (ADVP-TMP (RB very) (RB early)) (PP (IN in) (NP (NN life))) (PP (IN with) (NP (NP (VBN elevated) (NN insulin) (NNS levels)) (CC and) (NP (NN blood) (NN glucose)))) (PP (VBN compared) (PP (IN to) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice)))) (PRN (-LRB- -LRB-) (NP (NN Table) (CD 1)) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ (PRP We)) (VP (VBD investigated) (SBAR-NOM (IN whether) (S (NP-SBJ (NP (JJ peripheral) (NN insulin) (NN resistance)) (CONJP (CC and) (HYPH /) (CC or)) (NP (NP (DT a) (JJ severe) (NN defect)) (PP (IN in) (NP (NN insulin) (NN secretion))))) (VP (MD may) (VP (VB cause) (NP (NN hyperglycaemia)) (PP-LOC (IN in) (NP (DT the) (NN POKO) (NN mouse)))))))) (. .)) )
( (S (NP-SBJ-1 (NP (DT No) (NNS differences)) (PP (IN in) (NP (NN plasma) (NN glucose) (NNS levels)))) (VP (VBD were) (VP (VBN detected) (NP-1 (-NONE- *)) (PP (NP-ADV (QP (CD three) (IN to) (CD five)) (NNS days)) (IN after) (NP (NN birth))) (PP (IN amongst) (NP (NP (DT the) (CD four) (NNS genotypes)) (PP (IN for) (NP (DT both) (NNS genders))))) (CIT (-LRB- -LRB-) (JJ unpublished) (NNS data) (-RRB- -RRB-)))) (. .)) )
( (S (PP-TMP (IN At) (NP (NN weaning) (PRN (-LRB- -LRB-) (NP (NP (CD three) (NNS weeks)) (PP (IN of) (NP (NN age)))) (-RRB- -RRB-)))) (S (S (NP-SBJ (JJ total) (NN body) (NN weight)) (VP (VBD was) (ADJP-PRD (JJ indistinguishable)) (PP (IN amongst) (NP (DT the) (CD four) (NNS genotypes))))) (, ,) (CC and) (S (NP-SBJ (NN blood) (NN glucose) (NNS levels)) (VP (VBD were) (ADJP-PRD (JJ similar)) (PP-LOC (IN in) (NP (NNS males) (CC and) (NNS females))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 2A)) (-RRB- -RRB-))) (. .)) )
( (S (ADVP (RB However)) (, ,) (PP-TMP (IN by) (NP (NP (DT the) (NN age)) (PP (IN of) (NP (CD four) (NNS weeks))))) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (ADJP-PRD (JJ coincident) (PP (IN with) (NP (NP (DT the) (NN change)) (PP (IN to) (NP (DT a) (NN chow) (NN diet))))))) (, ,) (NP-SBJ (ADJP (JJ male) (CC and) (JJ female)) (NN POKO) (NNS mice)) (VP (VBD developed) (NP (JJ severe) (NN hyperglycaemia)) (PP (VBN compared) (PP (IN to) (NP (DT the) (JJ other) (NNS genotypes))))) (. .)) )
( (S (NP-SBJ (NP (NN Insulin) (NN plasma) (NNS levels)) (PP-LOC (IN in) (NP (NP (DT the) (NN POKO) (NNS mice)) (PP-TMP (IN at) (NP (NP (CD four) (NNS weeks)) (PP (IN of) (NP (NN age)))))))) (VP (VBD were) (ADJP-PRD (JJ increased)) (PP (VBN compared) (PP (IN to) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice)))) (PRN (-LRB- -LRB-) (NP (NN Table) (CD 1)) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ-1 (NP (NN Insulin) (NN resistance)) (PP-LOC (IN in) (NP (NN POKO) (NNS mice)))) (VP (VBD was) (VP (VBN confirmed) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NP (DT an) (NN insulin) (NN tolerance) (NN test)) (-LRB- -LRB-) (NP (NN ITT))) (-RRB- -RRB-)) (PP-LOC (IN in) (NP (ADJP (NP (CD four) (HYPH -) (NN week)) (HYPH -) (JJ old)) (NML (JJ male) (CC and) (JJ female)) (NNS mice))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 2B)) (-RRB- -RRB-)))) (. .)) )
( (S (NP-SBJ-1 (NP (RB Furthermore) (NN insulin) (NN resistance)) (PP-LOC (IN in) (NP (NN adipose) (NN tissue)))) (VP (VBD was) (VP (VBN demonstrated) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NP (DT the) (ADJP (RB extremely) (JJ low)) (NNS levels)) (PP (IN of) (NP (NP (NML (NML (NN glucose) (NN transporter4)) (-LRB- -LRB-) (NML (NN GLUT4))) (-RRB- -RRB-) (NN protein)) (PP-LOC (IN in) (NP (NN POKO) (NN adipose) (NN tissue))))))) (SBAR-ADV (WHADVP-3 (WRB when)) (S (NP-SBJ-2 (-NONE- *PRO*)) (VP (VBN compared) (NP-2 (-NONE- *)) (PP (IN with) (NP (NP (NN GLUT4) (NNS levels)) (PP-LOC (IN in) (NP (NP (NN adipose) (NN tissue)) (PP (IN from) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice))))))) (ADVP-TMP-3 (-NONE- *T*))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN S3)) (-RRB- -RRB-)))) (. .)) )
( (S (PP (IN Of) (NP (NN note))) (, ,) (NP-SBJ-1 (NP (NN insulin) (NN resistance)) (PP-LOC (IN in) (NP (DT the) (NN POKO) (NNS mice)))) (VP (VBD was) (VP (VBN associated) (NP-1 (-NONE- *)) (PP (IN with) (NP (NN hypertriglyceridaemia))) (ADVP-TMP (ADVP (RB as) (RB early)) (PP (IN as) (NP (NP (CD four) (HYPH -) (NNS weeks)) (PP (IN of) (NP (NN age)))))) (PRN (-LRB- -LRB-) (NP (NN Table) (CD 1)) (-RRB- -RRB-)))) (. .)) )
( (HEADING (S (NP-SBJ (JJ Adult) (NN POKO) (NNS Mice)) (VP (VP (VBP are) (ADJP-PRD (JJ Hyperglycaemic))) (CC and) (VP (VBP Have) (NP (JJ Low) (NN Plasma) (NN Insulin) (NNS Levels)))))) )
( (S (PP (VBN Given) (NP (NP (NP (DT the) (JJ early) (NN insulin) (NN resistance)) (CC and) (NP (NN hyperinsulinaemia))) (PP-LOC (IN in) (NP (DT the) (JJ young) (NN POKO) (NNS mice))))) (, ,) (NP-SBJ-1 (PRP we)) (VP (VBD expected) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (TO to) (VP (VB see) (NP (VBN increased) (NN insulin) (NNS levels)) (PP-LOC (IN in) (NP (JJ mature) (NN POKO) (NNS mice))))))) (. .)) )
( (S (PP-TMP (IN At) (NP (CD 16) (NNS weeks))) (, ,) (NP-SBJ (JJ male) (NN POKO) (NNS mice)) (VP (VBD exhibited) (NP (JJ severe) (NN hyperglycaemia)) (PP-LOC (IN in) (NP (DT the) (ADJP (VBN fasted) (CC and) (VBN fed)) (NNS states))) (PP (VBN compared) (PP (IN to) (NP (NN littermate) (NNS controls))))) (. .)) )
( (S (NP-SBJ (JJ Male) (NN POKO) (NNS mice)) (VP (VBD had) (NP (NP (ADJP (RB inappropriately) (JJ low)) (NNS levels)) (PP (IN of) (NP (NN insulin)))) (PRN (-LRB- -LRB-) (NP (NN Table) (CD 2)) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ-1 (DT A) (ADJP (JJ similar) (, ,) (CC but) (JJR milder)) (NN phenotype)) (VP (VBD was) (ADVP (RB also)) (VP (VBN observed) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NN POKO) (JJ female) (NNS mice))) (PRN (-LRB- -LRB-) (NP (JJ unpublished) (NNS data)) (-RRB- -RRB-)))) (. .)) )
( (S (PP (IN Of) (NP (NN note))) (, ,) (NP-SBJ (JJ adult) (NML (NN ob) (HYPH /) (NN ob)) (NNS mice)) (VP (VBN compensated) (PP (IN for) (NP (PRP$ their) (NN insulin) (NN resistance))) (PP-MNR (IN with) (NP (VBN increased) (NN insulin) (NNS levels))) (PRN (-LRB- -LRB-) (NP (NN Table) (CD 2)) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ (NN POKO) (NNS mice)) (ADVP (RB also)) (VP (VBD had) (NP (NN hypertriglyceridaemia)) (SBAR-TMP (WHADVP-2 (WRB when)) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBN compared) (NP-1 (-NONE- *)) (PP (IN to) (NP (NML (NML (NN WT)) (, ,) (NML (NN ob) (HYPH /) (NN ob)) (, ,) (CC or) (NML (NN PPARg2) (NN KO))) (NNS mice))) (ADVP-TMP-2 (-NONE- *T*)))))) (. .)) )
( (HEADING (NP (NP (VBN Impaired) (NML (NN Beta) (HYPH -) (NN Cell)) (NN Function)) (PP-LOC (IN in) (NP (DT the) (NN POKO) (NNS Mice))))) )
( (S (NP-SBJ (NP (DT The) (ADJP (RB inappropriately) (JJ low)) (NN insulin) (NNS levels)) (PP-LOC (IN in) (NP (DT the) (JJ adult) (NN POKO) (NNS mice)))) (VP (VBD suggested) (NP (NP (DT a) (NN defect)) (PP (IN in) (NP (NN β) (HYPH -) (NNS cells))))) (. .)) )
( (S (NP-SBJ-1 (NP (NN Insulin) (NN resistance)) (PP (IN in) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice)))) (VP (VBD was) (VP (VBN compensated) (PP (IN for) (NP-1 (-NONE- *))) (PP-MNR (IN by) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG increasing) (NP (JJ pancreatic) (NML (NML (NN insulin) (NN secretion)) (, ,) (NML (NN islet) (NN number)) (, ,) (CC and) (NML (NN size))))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 3A)) (-RRB- -RRB-)))) (. .)) )
( (S (ADVP (RB However)) (, ,) (PP (IN despite) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG being) (ADJP-PRD (ADJP (JJR more) (NN insulin) (JJ resistant)) (PP (IN than) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice))))))) (, ,) (NP-SBJ (NN POKO) (NNS mice)) (VP (VBD did) (RB not) (VP (VB increase) (NP (PRP$ their) (NML (NN β) (HYPH -) (NN cell)) (NN mass)) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG resulting) (PP (IN in) (NP (NP (JJR lower) (NN plasma) (NN insulin) (NNS levels)) (PP (IN than) (NP (DT the) (NML (NN ob) (HYPH /) (NN ob)) (NNS controls))))))))) (. .)) )
( (S (NP-SBJ (NP (JJ Morphometric) (NN analysis)) (PP (IN of) (NP (NP (JJ pancreatic) (NNS sections)) (PP (IN from) (NP (ADJP (NP (CD 16) (HYPH -) (NN week)) (HYPH -) (JJ old)) (JJ male) (NNS mice)))))) (VP (VBD confirmed) (SBAR (IN that) (S (NP-SBJ (DT the) (NML (NML (NN islet)) (HYPH -) (PP (IN to) (HYPH -) (NP (NN pancreas)))) (NN volume) (NNS ratios)) (VP (VBD were) (ADJP-PRD (ADJP (JJ similar) (PP-LOC (IN in) (NP (DT the) (NML (NN POKO) (, ,) (NN WT) (, ,) (CC and) (NN PPARg2)) (NN KO) (NNS mice))) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 0.023) (SYM ±) (CD 0.005)) (, ,) (NP (CD 0.013) (SYM ±) (CD 0.006)) (, ,) (CC and) (NP (CD 0.016) (SYM ±) (CD 0.005))) (, ,) (ADVP (RB respectively))) (-RRB- -RRB-))) (CC and) (ADJP (RB markedly) (VBD increased) (PP-LOC (IN in) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice))) (PRN (-LRB- -LRB-) (NP (QP (CD 0.077) (SYM ±) (CD 0.017))) (, ,) (S-FRM (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.01)))) (NP (NP (NN ob) (HYPH /) (NN ob)) (CC versus) (NP (NN POKO))) (-RRB- -RRB-)))))))) (. .)) )
( (S (ADVP (RB Additionally)) (, ,) (NP-SBJ (NN POKO) (NNS mice)) (VP (VBD had) (NP (ADJP (RB significantly) (VBN decreased)) (NML (NML (NN islet) (NN number)) (CC and) (NML (NN size))) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NP (JJ average) (NN area)) (PP (IN of) (NP (NNS islets) (NN POKO)))) (VP (SYM =) (NP (QP (CD 18.40) (SYM ±) (CD 2)) (NN mm2)))) (-RRB- -RRB-))) (PP (VBN compared) (PP (IN to) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN ob) (HYPH /) (NN ob)) (VP (SYM =) (NP (QP (CD 61.59) (SYM ±) (CD 8)) (NN mm2)))) (-RRB- -RRB-)))))) (. .)) )
( (S (NP-SBJ (NN Insulin) (NN staining)) (VP (VBD demonstrated) (SBAR (IN that) (S (NP-SBJ (NP (NNS islets)) (PP (IN from) (NP (NN POKO) (NNS mice)))) (VP (VBD contained) (NP (NP (JJR fewer) (ADJP (NN insulin) (HYPH -) (JJ positive)) (NNS cells)) (PP (IN than) (NP (NP (NNS islets)) (PP (IN from) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice))))))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 3A)) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ-1 (NP (DT The) (JJ normal) (JJ cellular) (NN organization)) (PP (IN of) (NP (NP (NP (DT the) (NN islet) (, ,) (JJ abundant) (NML (NN β) (HYPH -) (NNS cells)) (PRN (-LRB- -LRB-) (NP (NN insulin) (NN staining)) (-RRB- -RRB-))) (PP-LOC (IN in) (NP (NP (DT the) (NN centre)) (PP (IN of) (NP (DT the) (NN islet)))))) (CC and) (NP (NP (DT a) (NN rim)) (PP (IN of) (NP (NN α) (HYPH -) (NNS cells))) (PP-LOC (IN at) (NP (DT the) (NN periphery))) (PRN (-LRB- -LRB-) (NP (NN glucagon) (NN staining)) (-RRB- -RRB-)))))) (, ,) (VP (VP (VBD was) (VP (VBN retained) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (DT the) (ADJP (NN insulin) (JJ resistant)) (NML (NN ob) (HYPH /) (NN ob)) (NNS mice))))) (CC but) (VP (VBD was) (VP (VBN disrupted) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NP (DT the) (NNS islets)) (PP (IN of) (NP (NN POKO) (NNS mice))))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 3A)) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ (NP (NNS Islets)) (PP (IN from) (NP (NN POKO) (NNS mice)))) (VP (VBD had) (NP (NP (NP (VBN decreased) (NN number)) (PP (IN of) (NP (NN insulin) (JJ positive) (NML (NN β) (HYPH -) (NNS cells)))) (SBAR-TMP (WHADVP-2 (WRB when)) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBN compared) (NP-1 (-NONE- *)) (PP (IN to) (NP (NP (NNS islets)) (PP (IN from) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice))))) (ADVP-TMP-2 (-NONE- *T*)))))) (CC and) (NP (NP (NP (DT a) (VBN scattered) (NN pattern)) (PP (IN of) (NP (NN α) (HYPH -) (NNS cells)))) (, ,) (SBAR (WHNP-3 (WDT which)) (S (NP-SBJ-3 (-NONE- *T*)) (VP (VBP are) (NP-PRD (NP (JJ morphological) (NNS changes)) (VP (VBN associated) (NP (-NONE- *)) (PP (IN with) (NP (NN islet) (VBG remodelling))) (PP (IN in) (NP (NP (DT the) (NN context)) (PP (IN of) (NP (NML (NN β) (HYPH -) (NN cell)) (NN failure))))))))))))) (. .)) )
( (S (NP-SBJ (NP (NML (NN Gene) (NN expression)) (NN analysis)) (PP (IN of) (NP (NP (NNS islets)) (PP (IN from) (NP (ADJP (NP (CD 16) (HYPH -) (NN week)) (HYPH -) (JJ old)) (NNS mice)))))) (VP (VBD revealed) (NP (NP (VBN decreased) (NN expression)) (PP (IN of) (NP (NP (JJ pancreatic) (JJ duodenal) (NML (NN homeobox) (HYPH -) (CD 1))) (, ,) (NP (NN insulin) (NN receptor) (NN substrate) (CD 2)) (, ,) (NP (NN Glut2)) (, ,) (CC and) (NP (NN insulin)))) (PP (IN in) (NP (NP (NNS islets)) (PP (IN from) (NP (NN POKO) (NNS mice)))))) (SBAR-TMP (WHADVP-2 (WRB when)) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBN compared) (NP-1 (-NONE- *)) (PP (IN with) (NP (NP (DT those)) (PP (IN from) (NP (NP (NN WT)) (CC or) (NP (NN ob) (HYPH /) (NN ob)))))) (ADVP-TMP-2 (-NONE- *T*))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN S4)) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ (NP (DT The) (NNS changes)) (VP (VBN seen) (NP (-NONE- *)) (PP-LOC (IN in) (NP (NP (DT the) (NN β) (HYPH -) (NNS cells)) (PP (IN of) (NP (NN POKO) (NNS mice))))))) (VP (VBD were) (RB not) (NP-PRD (NP (DT the) (NN result)) (PP (IN of) (NP (NP (DT an) (JJ inherent) (NN failure) (S-4 (-NONE- *ICH*))) (PP (IN of) (NP (DT the) (NN β) (HYPH -) (NN cell))) (S-4 (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB develop) (ADVP (RB properly)))))))) (SBAR-ADV (IN as) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBN indicated) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NP (JJ histological) (NNS studies)) (PP (IN of) (NP (NP (JJ neonatal) (NN pancreas) (PRN (-LRB- -LRB-) (NP (NP (NN day) (CD 3)) (PP (IN to) (NP (NN day) (CD 5)))) (-RRB- -RRB-)) (CIT (-LRB- -LRB-) (JJ unpublished) (NNS data) (-RRB- -RRB-))) (CC and) (NP (ADJP (NP (CD four) (HYPH -) (NN week)) (HYPH -) (JJ old)) (NN pancreas) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 2C)) (-RRB- -RRB-)))))))))) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG showing) (NP (NP (DT no) (JJ morphological) (NNS differences)) (PP (IN in) (NP (NP (DT the) (NML (NML (NN size)) (, ,) (NML (NN number)) (, ,) (CC or) (NML (NN insulin) (NN staining)))) (PP (IN of) (NP (NP (NNS islets)) (PP (IN from) (NP (NN POKO) (NNS mice)))))))) (SBAR-TMP (WHADVP-3 (WRB when)) (S (NP-SBJ-2 (-NONE- *PRO*)) (VP (VBN compared) (NP-2 (-NONE- *)) (PP (IN to) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS controls))) (ADVP-TMP-3 (-NONE- *T*)))))))) (. .)) )
( (HEADING (NP (NP (VBN Impaired) (ADJP (NN Glucose) (HYPH -) (VBN Stimulated)) (NN Insulin) (NN Secretion)) (PP (IN in) (NP (NN POKO) (NN Mouse) (NNS Islets))))) )
( (S (NP-SBJ (PRP We)) (VP (VBD measured) (NP (ADJP (NN glucose) (HYPH -) (VBN stimulated)) (NN insulin) (NN secretion)) (PP-LOC (IN in) (NP (NP (ADJP (NP (CD 16) (HYPH -) (NN week)) (HYPH -) (JJ old)) (JJ female) (NN POKO) (NNS mice)) (CC and) (NP (PRP$ their) (NML (NN ob) (HYPH /) (NN ob)) (NNS littermates))))) (. .)) )
( (S (NP-SBJ (NP (NNS Islets)) (VP (VBN isolated) (NP (-NONE- *)) (PP (IN from) (NP (NN POKO) (NNS mice))))) (VP (VBD were) (ADJP-PRD (ADJP (NP (CD 30) (NN %)) (JJR smaller)) (PP (IN than) (NP (NP (DT those)) (PP (IN from) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice))))))) (. .)) )
( (S (S (ADVP (RB Moreover)) (, ,) (SBAR-ADV (IN whereas) (S (NP-SBJ (JJ normal) (NNS islets)) (VP (VBD were) (ADJP-PRD (JJ pure) (JJ white)) (PP (IN with) (NP (DT a) (JJ smooth) (NN surface)))))) (, ,) (NP-SBJ (NP (NNS islets)) (PP (IN from) (NP (NN POKO) (NNS mice)))) (VP (VBD were) (ADJP-PRD (JJ gray)))) (: ;) (S (NP-SBJ (PRP$ their) (NN surface)) (VP (VBD was) (UCP-PRD (ADJP (JJ irregular)) (CC and) (VP (VBD required) (NP (NP (JJR less) (NN time)) (PP (IN for) (NP (NN collagenase) (NN digestion) (PRN (-LRB- -LRB-) (NP (NP (QP (RB only) (CD ten)) (NNS minutes)) (PP (RB instead) (IN of) (NP (CD 30) (NNS minutes)))) (-RRB- -RRB-))))) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ (PRP they)) (VP (VBD were) (ADVP (RB also)) (ADJP-PRD (RBR more) (JJ fragile))))))))))) (. .)) )
( (S (NP-SBJ (NP (NN Insulin) (NN content)) (PP-LOC (IN in) (NP (NP (NNS islets)) (PP (IN from) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice)))))) (VP (VBD was) (ADJP-PRD (ADJP (QP (RBR more) (IN than) (RB 30-fold)) (JJR greater)) (PP (IN than) (PP-LOC (IN in) (NP (NP (DT those)) (PP (IN from) (NP (NN POKO) (NNS mice))))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 3B)) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ-1 (NP (NN Insulin) (NN secretion)) (PP (IN from) (NP (NP (DT the) (NNS islets)) (PP (IN of) (NP (NN POKO) (NNS mice)))))) (VP (VBD was) (ADVP (RB strikingly)) (VP (VBN impaired) (NP-1 (-NONE- *)) (PP (VBN compared) (PP (IN to) (NP (NP (DT those)) (PP (IN of) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice)))))) (, ,) (SBAR-ADV (ADVP (RB even)) (WHADVP-3 (WRB when)) (S (NP-SBJ-2 (-NONE- *PRO*)) (VP (VBN expressed) (NP-2 (-NONE- *)) (S-ADV (NP-SBJ (-NONE- *PRO*)) (ADJP-PRD (JJ relative) (PP (IN to) (NP (NN insulin) (NN content))))) (ADVP-TMP-3 (-NONE- *T*))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 3C)) (-RRB- -RRB-)))) (. .)) )
( (S (NP-SBJ-1 (DT This)) (VP (VBD was) (VP (VBN observed) (NP-1 (-NONE- *)) (PP-MNR (IN under) (NP (ADJP (ADJP (JJ basal) (PRN (-LRB- -LRB-) (NP (NML (CD 1) (NN mM)) (NN glucose)) (-RRB- -RRB-))) (CC and) (ADJP (VBN stimulated) (PRN (-LRB- -LRB-) (NP (NML (CD 16) (NN mM)) (NN glucose)) (, ,) (NP (NML (CD 16) (NN mM)) (NN glucose) (SYM +) (NN tolbutamide)) (-RRB- -RRB-)))) (NN release))))) (. .)) )
( (HEADING (NP (NP (VBN Decreased) (NN Steatosis)) (PP-LOC (IN in) (NP (NN POKO) (NNS Mice))) (PP (VBN Compared) (PP (IN to) (NP (NML (NN Ob) (HYPH /) (NN Ob)) (NNS Mice)))))) )
( (S (S (SBAR-ADV (IN As) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBN expected) (NP-1 (-NONE- *))))) (, ,) (NP-SBJ (DT the) (NN POKO) (NNS mice)) (VP (VBD had) (NP (VBN increased) (NML (JJ hepatic) (NN fat)) (NN deposition)) (PP (VBN compared) (PP (IN to) (NP (NP (NN WT)) (CC and) (NP (NML (NN PPARg2) (NN KO)) (NNS mice))))) (PRN (-LRB- -LRB-) (NP (NN Table) (NN S1)) (-RRB- -RRB-)))) (, ,) (CC but) (S (ADVP (RB surprisingly)) (NP-SBJ (DT the) (NN POKO) (NN mouse)) (VP (VBD had) (NP (NP (ADJP (RB much) (JJR milder)) (NN hepatosteatosis)) (PP (IN than) (NP (DT the) (NML (NN ob) (HYPH /) (NN ob)) (NN mouse)))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 3D)) (-RRB- -RRB-)) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ (NP (JJ ectopic) (NN expression)) (PP (IN of) (NP (DT the) (NN PPARg2) (NN isoform))) (PP-LOC (IN in) (NP (NP (DT the) (NN liver)) (PP (IN of) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice)))))) (PRN (-LRB- -LRB-) (S-IMP (NP-SBJ (-NONE- *PRO*)) (VP (VB see) (ADVP (RB below)))) (-RRB- -RRB-)) (, ,) (VP (MD might) (VP (VB contribute) (PP (IN to) (NP (NP (DT the) (NN deposition)) (PP (IN of) (NP (NNS TAGs))) (PP-LOC (IN in) (NP (DT the) (NN liver))))))))))))) (. .)) )
( (HEADING (S (NP-SBJ (NP (NN Ablation)) (PP (IN of) (NP (NN PPARg2)))) (VP (VBZ Induces) (NP (NP (DT a) (JJ Lipotoxic) (NN Lipid) (NN Profile)) (PP-LOC (IN in) (NP (NP (NN Adipose) (NN Tissue)) (, ,) (NP (JJ Pancreatic) (NNS Islets)) (, ,) (NP (NN Liver)) (, ,) (CC and) (NP (JJ Skeletal) (NN Muscle)))))))) )
( (S (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO To) (VP (VB investigate) (NP (NN lipotoxicity)) (PP (IN as) (NP (DT a) (JJ potential) (JJ pathogenic) (NN mechanism)))))) (NP-SBJ (PRP we)) (VP (VBD used) (NP (NP (NP (JJ liquid) (NN chromatography)) (HYPH /) (NP (NN mass) (NN spectrometry))) (-LRB- -LRB-) (NP (NN LC) (HYPH /) (NN MS)) (-RRB- -RRB-) (PRN (-LRB- [) (NP (CD 32)) (-RRB- ]))) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB compare) (NP (NP (DT a) (JJ broad) (NN spectrum)) (PP (IN of) (NP (NP (JJ cellular) (NNS lipids)) (PP-LOC (IN in) (NP (NP (DT the) (NN adipose) (NN tissue)) (, ,) (NP (JJ pancreatic) (NNS islets)) (, ,) (NP (NN liver)) (, ,) (CC and) (NP (JJ skeletal) (NN muscle))))))) (PP (IN between) (NP (NP (DT the) (NN POKO) (NN mouse)) (CC and) (NP (NNS controls))))))) (PRN (-LRB- -LRB-) (NP (NN Protocol) (NN S1)) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ (NP (NN Adipose) (NN tissue)) (PP (IN from) (NP (NN POKO) (NNS mice)))) (VP (VBZ has) (NP (NP (VBN decreased) (NN TAG)) (CC but) (NP (NP (VBN increased) (NML (NML (NN DAG)) (, ,) (NML (NNS ceramides)) (, ,) (CC and) (NML (JJ other) (JJ reactive) (NN lipid) (NNS species)))) (VP (VBN associated) (NP (-NONE- *)) (PP (IN with) (NP (NN insulin) (NN resistance))))))) (. .)) )
( (S (NP-SBJ (NP (JJ Lipidomic) (NN analysis)) (VP (VBG using) (NP (NN LC) (HYPH /) (NN MS)))) (VP (VBD identified) (NP (NP (CD 74) (JJ molecular) (NNS species)) (RRC (ADJP-PRD (RB differentially) (JJ present)) (PP-LOC (IN in) (NP (NML (NML (NN POKO)) (, ,) (NML (NN ob) (HYPH /) (NN ob)) (, ,) (CC and) (NML (NN WT))) (NNS mice))))) (PRN (-LRB- -LRB-) (NP (NN Protocol) (NN S1)) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ (NN POKO) (NN adipose) (NN tissue)) (VP (VBD had) (NP (VBN decreased) (NML (JJ short) (NN chain)) (NNS TAGs)) (PP (VBN compared) (PP (IN to) (NP (NML (NN ob) (HYPH /) (NN ob)) (NN adipose) (NN tissue)))) (PRN (-LRB- -LRB-) (NP (NN Protocol) (NN S1)) (-RRB- -RRB-))) (. .)) )
( (S (ADVP (RB Conversely)) (, ,) (NP-SBJ-1 (NP (DT the) (NN concentration)) (PP (IN of) (NP (NNS DAGs)))) (VP (VBD was) (VP (VBN increased) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NP (DT the) (NN WAT)) (PP (IN of) (NP (DT the) (NN POKO) (NNS mice))))) (PP (VBN compared) (PP (IN to) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS littermates)))))) (. .)) )
( (S (NP-SBJ (EX There)) (VP (VBD was) (ADVP (RB also)) (NP-PRD (NP (DT an) (VBN increased) (NN concentration)) (PP (IN of) (NP (JJ reactive) (NN lipid) (NNS species)))) (PP-LOC (IN in) (NP (NP (DT the) (NN WAT)) (PP (IN of) (NP (NN POKO) (NNS mice))))) (PP (VBN compared) (PP (IN to) (NP (NP (DT that)) (PP (IN of) (NP (NN ob) (HYPH /) (NN ob))))))) (. .)) )
( (S (NP-SBJ (NP (DT The) (NN WAT)) (PP (IN of) (NP (CC both) (NML (NN POKO)) (CC and) (NML (NN ob) (HYPH /) (NN ob)) (NNS mice))) (PRN (-LRB- -LRB-) (NP (NN Protocol) (NN S1)) (-RRB- -RRB-))) (VP (VBD had) (NP (NP (VBN increased) (NNS levels)) (PP (IN of) (NP (NP (NP (CD two) (NN ceramide) (NNS species)) (-LRB- -LRB-) (PP (IN with) (NP (NP (NML (NML (NML (CD 16)) (PP (SYM :) (NP (CD 0)))) (CC and) (NML (NML (CD 24)) (PP (SYM :) (NP (CD 1))))) (NML (JJ fatty) (NN acid)) (NNS chains)) (, ,) (ADVP (RB respectively))))) (-RRB- -RRB-) (CC and) (NP (CD three) (JJ proinflammatory) (NN lysophosphatidylcholine) (NN species) (PRN (-LRB- [) (NP (CD 33)) (-RRB- ])))))) (PP (VBN compared) (PP (IN to) (NP (NN WT) (NNS mice))))) (. .)) )
( (S (NP-SBJ (JJ Partial) (NML (JJS least) (NNS squares)) (NN discriminant) (NN analysis)) (VP (VBD indicated) (SBAR (-NONE- *0*) (S (NP-SBJ (NP (DT these) (NNS changes)) (PP (IN in) (NP (NNS ceramides)))) (VP (VBD were) (ADJP-PRD (ADJP (JJR greater)) (PP-1 (-NONE- *ICH*))) (PP-LOC (IN in) (NP (DT the) (NN POKO))) (PP-1 (IN than) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice)))))) (PRN (-LRB- -LRB-) (NP (NN Protocol) (NN S1)) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ-1 (NP (NN Sphingomyelin) (PRN (-LRB- -LRB-) (NP (NN d18) (: :) (CD 1) (HYPH /) (CD 16) (: :) (CD 0)) (-RRB- -RRB-))) (, ,) (NP (NP (DT the) (NN precursor)) (PP (IN of) (NP (NP (NN ceramide) (PRN (-LRB- -LRB-) (NP (NN d18) (: :) (CD 1) (HYPH /) (CD 16) (: :) (CD 0)) (-RRB- -RRB-))) (CC and) (NP (NN antioxidant) (NN ethanolamine) (NN plasmalogen) (PRN (-LRB- -LRB-) (NP (CD 36) (: :) (CD 1)) (-RRB- -RRB-)))))) (PRN (-LRB- [) (NP (CD 34)) (-RRB- ]))) (VP (VBD were) (ADVP (RB markedly)) (VP (VBN decreased) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NML (NML (NN POKO)) (CC and) (NML (NN ob) (HYPH /) (NN ob))) (NNS mice))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 4A)) (-RRB- -RRB-)))) (. .)) )
( (HEADING (NP (NP (NP (VBN Decreased) (NN TAG)) (CC and) (NP (NP (NN accumulation)) (PP (IN of) (NP (JJ reactive) (NN lipid) (NNS species))))) (PP-LOC (IN in) (NP (NP (NNS islets)) (PP (IN from) (NP (NN POKO) (NNS mice))))) (. .))) )
( (S (NP-SBJ (NP (JJ Partial) (NML (JJS least) (HYPH -) (NNS squares)) (NN discriminant) (NN analysis)) (PP (IN of) (NP (NP (JJ lipidomic) (NNS profiles)) (PP (IN of) (NP (NP (VBN isolated) (JJ pancreatic) (NNS islets)) (PP (IN of) (NP (ADJP (NP (CD 16) (HYPH -) (NN week)) (HYPH -) (JJ old)) (NNS mice)))))))) (VP (VBD identified) (NP (NP (CD 44) (NN lipid) (NNS species)) (VP (VBN accumulated) (NP (-NONE- *)) (PP (IN at) (NP (JJ different) (NNS concentrations))))) (PP-LOC (IN in) (NP (NML (NML (NN WT)) (, ,) (NML (NN PPARg2) (NN KO)) (, ,) (CC and) (NML (NN POKO))) (NNS mice))) (PRN (-LRB- -LRB-) (NP (NN Protocol) (NN S1)) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ-1 (NML (JJ Short) (NN chain)) (NNS TAGs)) (VP (VBD were) (VP (VBN decreased) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NP (NNS islets)) (PP (IN from) (NP (NML (NN POKO) (CC and) (NN PPARg2)) (NN KO) (NNS mice))))) (SBAR-TMP (WHADVP-3 (WRB when)) (S (NP-SBJ-2 (-NONE- *PRO*)) (VP (VBN compared) (NP-2 (-NONE- *)) (PP (IN to) (NP (NP (DT those)) (PP (IN from) (NP (NN WT))))) (ADVP-TMP-3 (-NONE- *T*))))))) (. .)) )
( (S (NP-SBJ-1 (DT This)) (VP (VBD was) (VP (VBN associated) (NP-1 (-NONE- *)) (PP (IN with) (NP (NP (NP (JJ up) (HYPH -) (NN regulation)) (PP (IN of) (NP (NN phosphatidylethanolamine))) (PRN (-LRB- -LRB-) (NP (NP (CD 36)) (PP (SYM :) (NP (CD 2)))) (-RRB- -RRB-))) (, ,) (NP (NP (JJ down) (HYPH -) (NN regulation)) (PP (IN of) (NP (NN ethanolamine) (NN plasmalogen))) (PRN (-LRB- -LRB-) (NP (NP (CD 36)) (PP (SYM :) (NP (CD 2)))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ preferential) (NN accumulation)) (PP (IN of) (NP (NP (JJ reactive) (NN lipid) (NNS species)) (, ,) (PP (ADVP (RB particularly)) (IN of) (NP (NP (CD two) (NNS ceramides) (PRN (-LRB- -LRB-) (NP (NML (NML (NML (CD 20)) (PP (SYM :) (NP (CD 0)))) (CC and) (NML (NML (CD 22)) (PP (SYM :) (NP (CD 0))))) (JJ fatty) (NNS acids)) (-RRB- -RRB-))) (PP-LOC (IN in) (NP (NP (NNS islets)) (PP (IN from) (NP (NN POKO) (NNS mice)))))))))))) (PRN (-LRB- -LRB-) (NP (NP (NN Figure) (NN 5A)) (CC and) (NP (NN Protocol) (NN S1))) (-RRB- -RRB-)))) (. .)) )
( (HEADING (NP (NP (NP (VBN Decreased) (NN TAG)) (CC and) (NP (VBN increased) (JJ reactive) (NN lipid) (NNS species))) (PP-LOC (IN in) (NP (NP (NN liver)) (PP (IN of) (NP (NN POKO) (NNS mice))))) (. .))) )
( (S (NP-SBJ (NP (JJ Multivariate) (NN analysis)) (PP (IN of) (NP (JJ lipidomic) (NNS profiles))) (PRN (-LRB- -LRB-) (NP (CD 192) (NN lipid) (NNS species)) (-RRB- -RRB-))) (VP (VBD revealed) (NP (JJ large) (NNS changes)) (PP-LOC (IN between) (NP (DT the) (NML (NML (NN POKO)) (, ,) (NML (NN PPARg2) (NN KO)) (, ,) (NML (NN ob) (HYPH /) (NN ob)) (, ,) (CC and) (NML (NN WT))) (NNS genotypes))) (PRN (-LRB- -LRB-) (NP (NN Protocol) (NN S1)) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ (DT These)) (VP (VBD included) (NP (NP (VBN decreased) (NNS levels)) (PP (IN of) (NP (NML (ADJP (JJ short) (CC and) (NN medium)) (NN chain)) (NML (NNS TAGs) (CC and) (NNS DAGs)))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 5B)) (-RRB- -RRB-)) (PP-LOC (IN in) (NP (NP (NNS livers)) (PP (IN from) (NP (NN POKO) (NNS mice)))))) (PP (VBN compared) (PP (IN to) (NP (NP (DT those)) (PP (IN of) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice))))))) (. .)) )
( (S (NP-SBJ (NP (NNS Livers)) (PP (IN from) (NP (NN POKO) (NNS mice)))) (ADVP (RB also)) (VP (VBD had) (NP (NP (NP (NN decrease) (NNS levels)) (PP (IN of) (NP (NN phosphatidylcholine) (NN lipid) (NNS species))) (PRN (-LRB- -LRB-) (NP (NN Protocol) (NN S1)) (-RRB- -RRB-))) (VP (VBN utilised) (NP (-NONE- *)) (PP-TMP (IN during) (NP (NP (DT the) (NML (NN formation) (CC and) (NN secretion))) (PP (IN of) (NP (ADJP (RB very) (JJ low)) (NN density) (NNS lipoproteins))))))) (PRN (-LRB- [) (NP (CD 35)) (-RRB- ]))) (. .)) )
( (S (ADVP (RB Conversely)) (, ,) (NP-SBJ-1 (NN POKO) (NNS livers)) (VP (VBD were) (VP (VBN enriched) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NNS ceramides))) (PP (VBN compared) (PP (IN to) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS livers)))) (, ,) (SBAR-ADV (WHNP-2 (WDT which)) (S (NP-SBJ-2 (-NONE- *T*)) (VP (VBD correlated) (PP (IN with) (NP (NP (DT the) (NN extent)) (PP (IN of) (NP (NP (VBN increased) (NNS levels)) (PP (IN of) (NP (NNS lysophosphatidylcholines))) (PP-LOC (IN in) (NP (NML (NML (NN POKO)) (CC and) (NML (NN ob) (HYPH /) (NN ob))) (NNS mice)))))))))) (PRN (-LRB- -LRB-) (NP (NN Protocol) (NN S1)) (-RRB- -RRB-)))) (. .)) )
( (HEADING (NP (NP (NP (VBN Decreased) (NN TAG)) (CC and) (NP (NP (NN accumulation)) (PP (IN of) (NP (JJ reactive) (NN lipid) (NNS species))))) (PP-LOC (IN in) (NP (NN POKO) (JJ skeletal) (NN muscle))) (. .))) )
( (S (NP-SBJ-1 (NP (NP (DT The) (JJ same) (JJ lipidomic) (NN pattern)) (PP (IN of) (NP (VBN decreased) (NN TAG)))) (CC and) (NP (NP (VBN increased) (JJ reactive) (NN lipid) (NNS species)) (VP (ADVP (RB previously)) (VBN observed) (NP (-NONE- *)) (PP-LOC (IN in) (NP (NP (NN adipose) (NN tissue)) (, ,) (NP (NN β) (HYPH -) (NN cell)) (, ,) (CC and) (NP (NN liver))))))) (VP (VBD was) (VP (VBN found) (NP-1 (-NONE- *)) (PP (IN to) (NP (DT a) (JJR milder) (NN degree))) (PP-LOC (IN in) (NP (NP (DT the) (JJ skeletal) (NN muscle)) (PP (IN of) (NP (NN POKO) (NNS mice))))) (PRN (-LRB- -LRB-) (NP (NN Protocol) (NN S1)) (-RRB- -RRB-)))) (. .)) )
( (S (ADVP (RB Briefly)) (, ,) (SBAR-TMP (WHADVP-2 (WRB when)) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBN compared) (NP-1 (-NONE- *)) (PP (IN to) (NP (NML (NN ob) (HYPH /) (NN ob)) (JJ skeletal) (NN muscle))) (ADVP-TMP-2 (-NONE- *T*))))) (, ,) (NP-SBJ (NN POKO) (JJ skeletal) (NN muscle)) (VP (VBD showed) (NP (NP (NP (DT a) (NN decrease)) (PP (IN in) (NP (NML (RB very) (JJ short) (HYPH -) (NN chain)) (JJ fatty) (NN acid) (NNS TAGs)))) (CC and) (NP (NP (DT a) (JJ slight) (NN decrease)) (PP (IN in) (NP (NP (NNS levels)) (PP (IN of) (NP (NML (ADJP (NN medium) (CC and) (JJ long)) (NN chain)) (NNS TAGs))))))) (PRN (-LRB- -LRB-) (NP (NN Protocol) (NN S1)) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ (NP (DT The) (JJ skeletal) (NN muscle)) (PP (IN of) (NP (NN POKO) (NNS mice)))) (ADVP (RB also)) (VP (VBD had) (NP (NP (VBN increased) (JJ reactive) (NNS lipids)) (PP (VBG including) (NP (NP (NP (NN ceramide) (PRN (-LRB- -LRB-) (NP (NN d18) (: :) (CD 1) (HYPH /) (CD 18) (: :) (CD 0)) (-RRB- -RRB-))) (, ,) (NP (NNS DAGs)) (, ,) (NP (NNS lysophosphatidylcholines)) (, ,) (CC and) (NP (NNS sphingomyelins))) (-LRB- -LRB-) (NP (NP (NNS precursors)) (PP (IN of) (NP (NNS ceramides)))) (-RRB- -RRB-)))) (SBAR-TMP (WHADVP-2 (WRB when)) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBN compared) (NP-1 (-NONE- *)) (PP (IN to) (NP (NP (DT that)) (PP (IN of) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice))))) (ADVP-TMP-2 (-NONE- *T*)))))) (. .)) )
( (HEADING (S (NP-SBJ (NP (JJ Transcriptomic) (NN Analysis)) (PP-LOC (IN in) (NP (NN POKO) (NNS Mice)))) (VP (VBZ Correlates) (PP (IN with) (NP (JJ Lipidomic) (NNS Changes)))))) )
( (S (PP (VBN Given) (NP (NP (DT the) (JJ lipotoxic) (NNS profiles)) (VP (VBN identified) (NP (-NONE- *)) (PP-LOC (IN in) (NP (DT the) (NN POKO) (NN mouse)))))) (, ,) (NP-SBJ (PRP we)) (VP (VBD hypothesised) (NP (NP (NP (NNS changes)) (PP (IN in) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (JJ metabolic) (NNS genes)) (ADJP (RB directly) (VBN related) (PP (IN to) (NP (NN PPARg2) (NN ablation))))))))) (CONJP (CC and) (RB also)) (NP (NP (JJ compensatory) (NNS changes)) (PP-LOC (IN in) (NP (NP (NNS genes)) (VP (VBN associated) (NP (-NONE- *)) (PP (IN with) (NP (JJ cellular) (NN stress)))))))) (PRN (-LRB- -LRB-) (NP (NN Table) (NN S4)) (-RRB- -RRB-))) (. .)) )
( (HEADING (NP (NP (NML (NN Gene) (NN expression)) (NN analysis)) (PP-LOC (IN in) (NP (NN WAT))) (. .))) )
( (S (NP-SBJ-1 (NP (NN Target) (NNS genes)) (PP (IN of) (NP (NN PPARg))) (PP (JJ such) (IN as) (NP (NN Glut4) (, ,) (NN adipsin) (, ,) (NN aP2) (, ,) (CC and) (NN adiponectin)))) (VP (VBD were) (VP (VBN decreased) (NP-1 (-NONE- *)) (PP (IN to) (NP (NP (DT a) (JJR larger) (NN extent)) (PP-2 (-NONE- *ICH*)))) (PP-LOC (IN in) (NP (NP (DT the) (NN WAT)) (PP (IN of) (NP (ADJP (NP (NML (CD five) (HYPH -) (CC and) (CD 16)) (HYPH -) (NN week)) (HYPH -) (JJ old)) (NN POKO) (NNS mice))))) (PP-2 (IN than) (PP-LOC (IN in) (NP (NN PPARg2) (NN KO) (NNS mice)))) (PRN (-LRB- -LRB-) (NP (NP (NN Figure) (NN S1)) (CC and) (NP (NN Figure) (NN 4B))) (-RRB- -RRB-)))) (. .)) )
( (S (PP-TMP (IN At) (NP (NP (CD five) (NNS weeks)) (PP (IN of) (NP (NN age))))) (, ,) (SBAR-TMP (WHADVP-1 (WRB when)) (S (NP-SBJ-3 (NP (NNS differences)) (PP (IN in) (NP (NN body) (NN fat))) (PP (IN between) (NP (JJ female) (NML (NML (NN WT)) (, ,) (NML (NN ob) (HYPH /) (NN ob)) (, ,) (CC and) (NML (NN POKO))) (NNS mice)))) (VP (VBP are) (ADVP (RB only)) (VP (VBG starting) (S (NP-SBJ-3 (-NONE- *)) (VP (TO to) (VP (VB become) (ADJP-PRD (JJ evident)) (ADVP-TMP-1 (-NONE- *T*))))))))) (, ,) (NP-SBJ-2 (NP (NNS levels)) (PP (IN of) (NP (NML (NN GLUT4) (, ,) (NN aP2) (, ,) (CC and) (NN adiponectin)) (NN mRNA) (NNS levels)))) (VP (VP (VBD were) (ADJP-PRD (JJ similar)) (PP-LOC (IN in) (NP (NML (NML (NN WT)) (CC and) (NML (NN ob) (HYPH /) (NN ob))) (NNS mice)))) (, ,) (CC yet) (VP (VBD were) (VP (ADVP (RB markedly)) (VBN decreased) (NP-2 (-NONE- *)) (PP-LOC (IN in) (NP (NN POKO) (NNS mice)))))) (. .)) )
( (S (SBAR-TMP (IN As) (S (NP-SBJ (DT the) (NML (NN ob) (HYPH /) (NN ob)) (NNS mice)) (VP (VP (VBD aged) (PRN (-LRB- -LRB-) (NP (CD 16) (NN wk)) (-RRB- -RRB-))) (CC and) (VP (VBD became) (ADJP-PRD (ADJP (JJ obese)) (CC and) (ADJP (NN insulin) (JJ resistant))))))) (, ,) (NP-SBJ (NP (DT the) (NN expression) (NN pattern)) (PP (IN of) (NP (NP (DT these) (NN PPARg) (NNS targets)) (PP-LOC (IN in) (NP (NP (DT the) (NN WAT)) (PP (IN of) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice)))))))) (VP (VBD became) (ADJP-PRD (JJ similar) (PP (IN to) (NP (NP (DT that)) (PP (IN of) (NP (DT the) (NN POKO) (NNS mice))))))) (. .)) )
( (S (NP-SBJ (NP (NNS Results)) (PP (IN from) (NP (DT the) (JJ lipidomic) (NN analysis)))) (VP (VBD suggested) (NP (NP (JJ major) (NNS changes)) (PP (IN in) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NNS genes)) (VP (VBN involved) (NP (-NONE- *)) (PP (IN in) (NP (NN lipid) (NN metabolism))))))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 4B)) (-RRB- -RRB-))) (. .)) )
( (S (NP-SBJ (NP (NN Expression)) (PP (IN of) (NP (NP (NP (NN stearoyl) (HYPH -) (NN coenzyme) (NN A) (NN desaturase) (CD 1)) (-LRB- -LRB-) (NP (NN Scd1))) (-RRB- -RRB-) (CC and) (NP (NP (NN sterol) (JJ regulatory) (NML (NN element) (HYPH -) (VBG binding)) (NN protein) (HYPH -) (NN 1c)) (-LRB- -LRB-) (NP (NN SREBP1c)))))) (-RRB- -RRB-) (VP (VBD were) (ADJP-PRD (RB significantly) (JJR lower)) (PP-LOC (IN in) (NP (NP (NN WAT)) (PP (IN from) (NP (NN POKO) (NNS mice))))) (PP (VBN compared) (PP (IN to) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice))))) (. .)) )
( (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ (NP (NP (DT the) (NN decrease)) (PP (IN in) (NP (NNS TAGs)))) (CC and) (NP (VBN increased) (NNS DAGs))) (VP (VBD correlated) (PP (IN with) (NP (NP (VBN decreased) (NN expression)) (PP (IN of) (NP (NP (NN DAG) (NN acyltransferase) (CD 2)) (, ,) (NP (NP (DT a) (JJ key) (NN enzyme)) (VP (VBG catalysing) (NP (NP (DT the) (JJ final) (NN step)) (PP (IN in) (NP (NN TAG) (NN synthesis)))) (, ,) (PP-LOC (IN in) (NP (NP (DT the) (NN WAT)) (PP (IN of) (NP (NN POKO) (NNS mice))))) (PP (VBN compared) (PP (IN with) (NP (NP (NN WAT)) (PP (IN from) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice))))))))))))) (. .)) )
( (S (ADVP (RB Again)) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG supporting) (NP (DT the) (JJ lipidomic) (NN profile)))) (, ,) (NP-SBJ-1 (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (ADJP (NN hormone) (HYPH -) (JJ sensitive)) (NN lipase)) (, ,) (NP (NP (DT a) (ADJP (NN rate) (HYPH -) (VBG limiting)) (NN enzyme)) (PP (IN for) (NP (NP (NN hydrolysis)) (PP (IN of) (NP (NNS diacylglycerides))))))))) (, ,) (VP (VBD was) (VP (VBN decreased) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NP (DT the) (NN WAT)) (PP (IN of) (NP (NML (NML (NN POKO)) (, ,) (NML (NN PPARg2) (NN KO)) (, ,) (CC and) (NML (NN ob) (HYPH /) (NN ob))) (NNS mice))))) (PP (VBN compared) (PP (IN with) (NP (NN WT) (NNS mice)))) (, ,) (SBAR-ADV (IN with) (S (NP-SBJ-2 (DT the) (JJS lowest) (NNS levels)) (VP (VBN observed) (NP-2 (-NONE- *)) (PP-LOC (IN in) (NP (DT the) (NN POKO) (NNS mice)))))))) (. .)) )
( (S (NP-SBJ-1 (NML (NN Adipose) (NN triglyceride) (NN lipase)) (NNS levels)) (VP (VBD were) (VP (VBN decreased) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NP (NN ob) (HYPH /) (NN ob)) (CC and) (NP (NN POKO)))) (PP (VBN compared) (PP (IN with) (NP (NML (NML (NN WT)) (CC and) (NML (NN PPARg2) (NN KO))) (NNS mice)))) (, ,) (NAC (CC but) (PP (IN without) (NP (NP (JJ significant) (NNS differences)) (PP (IN between) (NP (NP (NN ob) (HYPH /) (NN ob)) (CC and) (NP (NN POKO) (NNS mice))))))))) (. .)) )
( (S (NP-SBJ-1 (JJ Oxidative) (NN stress)) (VP (VBZ has) (ADVP (RB recently)) (VP (VBN been) (VP (VBN suggested) (NP-1 (-NONE- *)) (PP (IN as) (NP (NP (DT a) (JJ common) (NN mechanism)) (PP (IN of) (NP (NN insulin) (NN resistance)))))))) (. .)) )
( (S (NP-SBJ (NP (NN Adipose) (NN tissue)) (PP (IN from) (NP (NN POKO) (NNS mice)))) (VP (VBD had) (VP (VBN increased) (NP (JJ oxidative) (NN stress)) (PP (VBN compared) (PP (IN to) (NP (NP (DT that)) (PP (IN of) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice)))))) (SBAR-ADV (IN as) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBN indicated) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NP (NP (VBN decreased) (NML (NN gene) (NN expression)) (NNS levels)) (PP (IN of) (NP (JJ extracellular) (NML (NN CuZn) (HYPH -) (NN superoxide)) (NN dismutase)))) (, ,) (NP (NP (NN disruption)) (PP (IN of) (NP (DT the) (NN glutathione) (NN pathway))) (SBAR-ADV (IN as) (S (NP-SBJ-2 (-NONE- *PRO*)) (VP (VBN indicated) (NP-2 (-NONE- *)) (PP (IN by) (NP-LGS (NP (VBN decreased) (NNS levels)) (PP (IN of) (NP (NN gluthatione) (NN synthase))))))))) (, ,) (CC and) (NP (NP (VBN increased) (NNS levels)) (PP (IN of) (NP (NP (NN peroxidase)) (CC and) (NP (JJ several) (NN gluthatione) (NNS transferases)))))))))) (PRN (-LRB- -LRB-) (NP (NN Table) (NN S2)) (-RRB- -RRB-)))) (. .)) )
( (S (NP-SBJ (PRP We)) (VP (VBD examined) (NP (NP (NN macrophage) (NN infiltration)) (PP (IN of) (NP (NN adipose) (NN tissue)))) (PP (IN as) (NP (NP (DT a) (JJ potential) (NN marker)) (PP (IN of) (NP (ADJP (NN inflammation) (VBN associated)) (NN insulin) (NN resistance)))))) (. .)) )
( (S (NP-SBJ-1 (NP (NN Expression)) (PP (IN of) (NP (NP (NP (NN CD68)) (CC and) (NP (NN F4) (HYPH /) (CD 80))) (, ,) (NP (DT both) (NN macrophage) (NNS markers))))) (, ,) (VP (VBD was) (VP (VBN increased) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NP (DT the) (NN WAT)) (PP (IN of) (NP (NML (CC both) (NML (NN POKO)) (CC and) (NML (NN ob) (HYPH /) (NN ob))) (NNS mice))))) (PP (VBN compared) (PP (IN with) (NP (NML (NML (NN WT)) (CC and) (NML (NN PPARg2) (NN KO))) (NNS mice)))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 4B)) (-RRB- -RRB-)))) (. .)) )
( (S (ADVP (RB However)) (NP-SBJ (PRP$ their) (NN expression) (NNS levels)) (VP (VBD were) (ADJP-PRD (ADJP (JJR lower)) (PP-1 (-NONE- *ICH*))) (PP-LOC (IN in) (NP (DT the) (NN POKO) (NNS mice))) (PP-1 (IN than) (NP (DT the) (NML (NN ob) (HYPH /) (NN ob)) (NNS mice))) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ (NN macrophage) (NN infiltration)) (VP (VBD was) (RB not) (ADJP-PRD (RB directly) (JJ related) (PP (IN to) (NP (NP (DT the) (JJ exacerbated) (NN insulin) (NN resistance)) (PP (IN of) (NP (DT the) (NN POKO) (NN mouse)))))) (PP (VBN compared) (PP (IN to) (NP (DT the) (NML (NN ob) (HYPH /) (NN ob)) (NN mouse)))))))))) (. .)) )
( (HEADING (NP (NP (NN Gene) (NN expression)) (PP-LOC (IN in) (NP (DT the) (NN POKO) (NN liver))) (. .))) )
( (S (NP-SBJ (NP (VBN Reduced) (JJ hepatic) (NN steatosis)) (VP (VBN accompanied) (NP (-NONE- *)) (PP (IN by) (NP-LGS (VBN altered) (NN lipid) (NNS profiles))))) (VP (VBD suggested) (SBAR (IN that) (S (NP-SBJ (NP (NN lack)) (PP (IN of) (NP (NP (JJ hepatic) (JJ ectopic) (NN expression)) (PP (IN of) (NP (NN PPARg2)))))) (VP (MD might) (VP (VB be) (VP (VBG affecting) (NP (NP (NP (NN lipid) (NN storage)) (CC and) (NP (NN metabolism))) (PP-LOC (IN in) (NP (NP (DT the) (NN liver)) (PP (IN of) (NP (DT the) (NN POKO) (NNS mice)))))))))))) (. .)) )
( (S (NP-SBJ (NP (NN Expression)) (PP (IN of) (NP (NP (NNS genes)) (VP (VBN involved) (NP (-NONE- *)) (PP (IN in) (NP (NP (NN lipid) (NN metabolism)) (PP-LOC (IN in) (NP (NN liver)))))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (NN 5C)) (-RRB- -RRB-))) (VP (VBD revealed) (SBAR (IN that) (, ,) (S (S-ADV (NP-SBJ (-NONE- *PRO*)) (ADJP-PRD (JJ proportional) (PP (IN to) (NP (NP (DT the) (NN accumulation)) (PP (IN of) (NP (NNS TAGs))) (PP-LOC (IN in) (NP (DT the) (NN liver)))))) (, ,)) (NP-SBJ-2 (NP (NP (JJ fatty) (NN acid) (NN synthase)) (, ,) (NP (NN Scd1))) (, ,) (CC and) (NP (NP (DT the) (JJ fatty) (NN acid) (NN translocase)) (-LRB- -LRB-) (NP (NN FAT) (HYPH /) (NN CD36)))) (-RRB- -RRB-) (VP (VP (VBD were) (VP (VBN increased) (NP-2 (-NONE- *)) (PP-LOC (IN in) (NP (NML (NML (NN ob) (HYPH /) (NN ob)) (CC and) (NML (NN POKO))) (NNS livers))) (PP (VBN compared) (PP (IN to) (NP (NN WT) (NNS mice)))))) (CC and) (VP (VBD were) (ADVP (RB significantly)) (VP (VBN decreased) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NP (NN liver)) (PP (IN from) (NP (NN POKO) (NNS mice))))) (PP (VBN compared) (PP (IN with) (NP (NP (NN liver)) (PP (IN from) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice)))))))))))) (. .)) )
( (S (NP-SBJ-1 (NP (JJ Other) (JJ lipogenic) (NN PPARg) (NN target) (NNS genes)) (PP (JJ such) (IN as) (NP (NN Lpl)))) (VP (VBD were) (ADVP (RB also)) (VP (VBN decreased) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (DT the) (NN POKO) (NN liver))) (PP (VBN compared) (PP (IN to) (NP (DT the) (NML (NN ob) (HYPH /) (NN ob)) (NNS mice)))))) (. .)) )
( (S (NP-SBJ (DT The) (NML (NN ob) (HYPH /) (NN ob)) (NNS mice)) (ADVP (RB also)) (VP (VBD had) (NP (DT a) (JJ compensatory) (NN increase)) (PP (IN in) (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NP (NP (NNS genes)) (VP (VBN involved) (NP (-NONE- *)) (PP (IN in) (NP (NN β) (HYPH -) (NN oxidation))))) (-LRB- -LRB-) (NP (ADVP (FW e.g.)) (, ,) (NN Pparg) (, ,) (NN Lcad) (, ,) (NN Aox) (, ,) (NN Cpt1) (, ,) (CC and) (NN Ucp2))))))) (-RRB- -RRB-) (. .)) )
( (S (ADVP (RB Interestingly)) (NP-SBJ-1 (NP (NN expression)) (PP (IN of) (NP (DT these) (JJ pro-oxidative) (NNS genes)))) (VP (VBD was) (VP (VBN decreased) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NP (DT the) (NN liver)) (PP (IN of) (NP (NN POKO) (NNS mice))))) (SBAR-TMP (WHADVP-3 (WRB when)) (S (NP-SBJ-2 (-NONE- *PRO*)) (VP (VBN compared) (NP-2 (-NONE- *)) (PP (IN to) (NP (NP (DT that)) (PP (IN of) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice))))) (ADVP-TMP-3 (-NONE- *T*))))) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG suggesting) (SBAR (-NONE- *0*) (S (NP-SBJ (NN PPARg2)) (VP (MD may) (VP (VB contribute) (PP (IN to) (NP (PRP$ their) (NN regulation))))))))) (PRN (-LRB- [) (NP (CD 36)) (-RRB- ])))) (. .)) )
( (S (SBAR-ADV (IN Although) (S (NP-SBJ (NML (NN β) (HYPH -) (NN cell)) (NN failure)) (VP (MD could) (VP (VB account) (PP (IN for) (NP (NP (DT the) (JJ severe) (NN hyperglycaemia)) (VP (VBN observed) (NP (-NONE- *)) (PP-LOC (IN in) (NP (DT the) (NN POKO) (NN genotype)))))))))) (, ,) (NP-SBJ-1 (JJ hepatic) (NN gluconeogenesis) (NN function)) (VP (MD might) (VP (VB be) (VP (VBN affected) (NP-1 (-NONE- *))))) (. .)) )
( (S (NP-SBJ (PRP We)) (VP (VBD observed) (NP (NP (DT a) (JJ robust) (JJ up) (HYPH -) (NN regulation)) (PP (IN of) (NP (NP (NML (NML (NN PPARg) (NN coactivator) (CD 1) (NN alpha)) (-LRB- -LRB-) (NML (NML (NN PPARGC1a)) (, ,) (VP (ADVP (RB also)) (VBN known) (NP (-NONE- *)) (PP (IN as) (NP (NN PGC1a)))))) (-RRB- -RRB-) (NN expression)) (PP-LOC (IN in) (NP (DT the) (NN POKO) (NN liver)))))) (PP (VBN compared) (PP (IN with) (NP (DT the) (NML (NML (NN WT)) (CC and) (NML (NN ob) (HYPH /) (NN ob))) (NNS mice))))) (. .)) )
( (S (NP-SBJ-1 (NN PPARGC1a)) (VP (VP (VBZ is) (VP (RB up) (HYPH -) (VBN regulated) (NP-1 (-NONE- *)) (PP-TMP (IN in) (NP (NN fasting))))) (CC and) (VP (VBZ is) (VP (VBN thought) (S (NP-SBJ-1 (-NONE- *)) (VP (TO to) (VP (VB induce) (NP (NN gluconeogenesis))))))) (PRN (-LRB- [) (NP (CD 37)) (-RRB- ]))) (. .)) )
( (S (PP (IN In) (NP (NP (NN parallel)) (PP (IN with) (NP (NP (DT the) (NN increase)) (PP (IN in) (NP (NN PPARGC1a))))))) (, ,) (NP-SBJ (NN microarray) (NN analysis)) (VP (VBD revealed) (NP (NP (VBN increased) (NN mRNA) (NNS levels)) (PP (IN of) (NP (NP (NP (DT the) (JJ progluconeogenic) (NNS genes)) (NP (NP (NP (NN phosphoenolpyruvate) (NN carboxykinase) (CD 1)) (-LRB- -LRB-) (NP (NN Pepck1))) (-RRB- -RRB-) (CC and) (NP (NP (NN glucose) (HYPH -) (CD 6) (HYPH -) (NN phosphatase)) (-LRB- -LRB-) (NP (NN G6pc))))) (-RRB- -RRB-) (PP-LOC (IN in) (NP (NP (DT the) (NNS livers)) (PP (IN of) (NP (NN POKO) (NNS mice)))))))) (SBAR-TMP (WHADVP-2 (WRB when)) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBN compared) (NP-1 (-NONE- *)) (PP (IN to) (NP (NP (DT those)) (PP (IN of) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice))))) (ADVP-TMP-2 (-NONE- *T*)) (PRN (-LRB- -LRB-) (NP (NN Table) (NN S2)) (-RRB- -RRB-))))) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG suggesting) (SBAR (-NONE- *0*) (S (NP-SBJ (JJ hepatic) (NN gluconeogenesis)) (VP (MD may) (VP (VB contribute) (PP (IN to) (NP (NP (DT the) (NN hyperglycaemia)) (VP (VBN observed) (NP (-NONE- *)) (PP-LOC (IN in) (NP (NN POKO) (NNS mice))))))))))))) (. .)) )
( (HEADING (NP (NP (NML (NN Gene) (NN expression)) (NN analysis)) (PP-LOC (IN in) (NP (NP (JJ skeletal) (NN muscle)) (PP (IN of) (NP (NN POKO) (NNS mice))))) (. .))) )
( (S (PP-LOC (IN In) (NP (NML (ADJP (NP (CD 16) (HYPH -) (NN week)) (HYPH -) (JJ old)) (NN POKO) (HYPH -) (NNS mice)) (JJ skeletal) (NN muscle))) (NP-SBJ (PRP we)) (VP (VBD observed) (NP (NP (NP (JJ down) (HYPH -) (NN regulation)) (PP (IN of) (NP (NN Srebp1c) (CC and) (NN Ppargc1a)))) (CC and) (NP (NP (JJ up) (HYPH -) (NN regulation)) (PP (IN of) (NP (NN Ucp2) (NN expression))))) (PP-LOC (IN in) (NP (NP (JJ skeletal) (NN muscle)) (PP (IN from) (NP (NN POKO) (NNS mice))))) (PP (VBN compared) (PP (IN to) (NP (NP (DT that)) (PP (IN of) (NP (NN WT) (NNS mice))))))) (. .)) )
( (S (ADVP (RB Similarly)) (, ,) (NP-SBJ-3 (NP (NN expression)) (PP (IN of) (NP (NN Lpl) (CC and) (NN Scd1)))) (VP (VBD was) (VP (RB down) (HYPH -) (VBN regulated) (NP-3 (-NONE- *)) (PP-LOC (IN in) (NP (NP (DT the) (JJ skeletal) (NN muscle)) (PP (IN of) (NP (NN POKO) (NNS mice))))) (SBAR-TMP (WHADVP-2 (WRB when)) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBN compared) (NP-1 (-NONE- *)) (PP (IN with) (NP (NP (DT that)) (PP (IN from) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice))))) (ADVP-TMP-2 (-NONE- *T*))))) (PRN (-LRB- -LRB-) (NP (NP (NN Figure) (NN S5)) (: ;) (NP (NN Table) (NN S2))) (-RRB- -RRB-)))) (. .)) )
( (S (NP-SBJ (NP (NML (NML (NN Gene) (NN set)) (NN enrichment)) (NN analysis)) (PP (IN of) (NP (NN microarray) (NNS data)))) (VP (VBD showed) (NP (NP (VBN decreased) (NN expression)) (PP (IN of) (NP (NP (JJ oxidative) (NN phosphorylation)) (CC and) (NP (NP (JJ mitochondrial) (NNS components)) (PP (VBG including) (NP (NML (NML (NN electron) (NN transport)) (NN chain)) (NN complex) (NNS components))))))) (, ,) (PP-LOC (IN in) (NP (NP (JJ skeletal) (NN muscle)) (PP (IN from) (NP (NN POKO) (NNS mice))))) (SBAR-TMP (WHADVP-2 (WRB when)) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBN compared) (NP-1 (-NONE- *)) (PP (IN with) (NP (NP (DT that)) (PP (IN from) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice))))) (ADVP-TMP-2 (-NONE- *T*))))) (PRN (-LRB- -LRB-) (NP (NN Table) (NN S3)) (-RRB- -RRB-))) (. .)) )
( (HEADING (NP (NN Discussion))) )
( (S (NP-SBJ-1 (NP (DT The) (NN link)) (PP (IN between) (NP (NP (NN obesity)) (, ,) (NP (NN insulin) (NN resistance)) (, ,) (CC and) (NP (NN diabetes))))) (SBAR-ADV (IN while) (FRAG (ADVP (RB epidemiologically)) (ADJP (RB very) (JJ clear)))) (VP (VBZ is) (ADVP (RB still)) (RB not) (VP (ADVP (RB properly)) (VBN understood) (NP-1 (-NONE- *)) (PP (IN at) (NP (DT a) (JJ mechanistic) (NN level))))) (. .)) )
( (S (NP-SBJ (DT An) (VBG emerging) (NN concept)) (VP (VBZ is) (SBAR-PRD (IN that) (S (NP-SBJ (NP (DT the) (JJ absolute) (NN amount)) (PP (IN of) (NP (NP (NN fat)) (VP (VBN stored) (NP (-NONE- *)))))) (VP (MD may) (VP (VB be) (ADJP-PRD (ADJP (RBR less) (JJ important)) (PP (IN than) (NP (NP (DT the) (VBG remaining) (NN storage) (NN capacity)) (PP (IN of) (NP (DT the) (NN adipose) (NN tissue))))))))))) (. .)) )
( (S (ADVP (RB Here)) (NP-SBJ (PRP we)) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ (DT the) (NN PPARg2) (NN isoform)) (VP (MD may) (VP (VB be) (NP-PRD (NP (DT an) (JJ important) (NN factor)) (VP (VBG controlling) (NP (ADJP (NN obesity) (HYPH -) (VBN induced)) (NNS comorbidities)) (PP-MNR (PP (IN through) (NP (CD two) (NNS mechanisms))) (: :) (PP (PP (LST (-LRB- -LRB-) (LS a) (-RRB- -RRB-)) (IN by) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG regulating) (NP (ADJP (RB nutritionally) (VBN induced)) (NML (NN adipose) (NN tissue)) (NN expandability))))) (CC and) (PP (LST (-LRB- -LRB-) (LS b) (-RRB- -RRB-)) (SBAR-TMP (WHADVP-2 (WRB when)) (S (NP-SBJ-1 (-NONE- *PRO*)) (ADVP (FW de) (FW novo)) (VP (VBN expressed) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NN nonadipose) (NNS tissues)) (ADVP-TMP-2 (-NONE- *T*)))))) (, ,) (IN by) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG allowing) (NP (NP (DT the) (NN storage)) (PP (IN of) (NP (NN energy)))) (PP (IN in) (NP (NP (DT the) (NN form)) (PP (IN of) (NP (ADJP (RB relatively) (JJ harmless)) (NN TAG) (NNS species))))))))))))))))) (. .)) )
( (S (ADVP (RB Previously)) (NP-SBJ (PRP we)) (VP (VBD described) (NP (NP (NP (DT the) (JJ metabolic) (NN phenotype)) (PP (IN of) (NP (DT the) (JJ adult) (NML (NN PPARg2) (NN KO)) (NN mouse))) (PRN (-LRB- [) (NP (CD 2)) (-RRB- ]))) (, ,) (VP (VBN characterised) (NP (-NONE- *)) (PP (IN by) (NP-LGS (NP (JJ mild) (NN insulin) (NN resistance)) (VP (VBN observed) (NP (-NONE- *)) (PP-LOC (ADVP (RB only)) (IN in) (NP (NNS males))))))))) (. .)) )
( (S (PP (VBN Given) (NP (NP (DT the) (JJR greater) (JJ adipogenic) (NN potency)) (PP (IN of) (NP (NN PPARg2))) (PP (VBN compared) (PP (IN with) (NP (NN PPARg1)))) (ADVP (FW in) (FW vitro)))) (, ,) (NP-SBJ (PRP we)) (VP (VBD expected) (S (NP-SBJ (NML (NN PPARg2) (NN KO)) (NNS mice)) (VP (TO to) (VP (VB have) (NP (NP (NP (JJ many) (ADJP (JJR more) (JJ severe)) (NNS defects)) (PP-LOC (IN in) (NP (NN adipose) (NN tissue))) (SBAR (IN than) (S (NP-SBJ (PRP we)) (VP (VBD observed) (NP (-NONE- *?*)))))) (, ,) (CC and) (NP (ADVP (RB therefore)) (NN insulin) (NN sensitivity))))))) (. .)) )
( (S (SBAR-ADV (IN As) (S (NP-SBJ (NN PPARg2)) (VP (VBZ is) (NP-PRD (NP (DT the) (NN PPARg) (NN isoform)) (VP (VBN regulated) (NP (-NONE- *)) (PP (IN in) (NP (NP (NN response)) (PP (IN to) (NP (NN nutrition) (CC and) (NN obesity)))))) (PRN (-LRB- [) (NP (NP (CD 17)) (PP (SYM –) (NP (CD 20)))) (-RRB- ])))))) (, ,) (NP-SBJ (PRP we)) (VP (VBD hypothesised) (SBAR (IN that) (S (NP-SBJ (NN PPARg2)) (VP (MD would) (ADVP (RB only)) (VP (VB become) (ADJP-PRD (JJ essential)) (PP-PRP (IN for) (NP (NN adipose) (NN tissue) (NN function))) (PP (IN in) (NP (NP (DT the) (NN face)) (PP (IN of) (NP (NML (JJ positive) (NN energy)) (NN balance)))))))))) (. .)) )
( (S (NP-SBJ (NP (DT The) (JJ metabolic) (NN challenge)) (SBAR (WHNP-1 (-NONE- *0*)) (S (NP-SBJ (PRP we)) (VP (VBD opted) (PP (IN for) (NP-1 (-NONE- *T*))))))) (VP (VBD was) (NP-PRD (NN PPARg2) (NN ablation)) (PP-LOC (IN in) (NP (NP (DT the) (NML (NML (JJ obese)) (-LRB- -LRB-) (NML (NN ob) (HYPH /) (NN ob))) (-RRB- -RRB-) (NN background)) (-LRB- -LRB-) (NP (NML (NML (NML (NN PPARg2) (SYM −) (HYPH /) (SYM −)) (NN Lepob) (HYPH /) (NN Lepob)) (, ,) (NML (NN POKO))) (NN mouse))))) (-RRB- -RRB-) (. .)) )
( (S (NP-SBJ (DT The) (NN POKO) (NN mouse)) (VP (VBD had) (ADVP (RB severely)) (VP (VBN decreased) (NP (-NONE- *)) (NP (NML (NN body) (HYPH -) (NN fat)) (NN mass)) (PP-PRP (IN due) (IN to) (NP (VBN impaired) (NML (NN adipose) (NN tissue)) (NN expandability))))) (. .)) )
( (S (PP (IN Despite) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VP (VBG eating) (NP (NP (RB as) (JJ much)) (PP (IN as) (NP (DT an) (NML (NN ob) (HYPH /) (NN ob)) (NN mouse))))) (CC and) (VP (VBG expending) (NP (NP (DT a) (JJ similar) (NN amount)) (PP (IN of) (NP (NN energy)))))))) (, ,) (NP-SBJ-1 (DT the) (NN POKO) (NN mouse)) (VP (VBD was) (ADJP-PRD (JJ unable) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (TO to) (VP (VB store) (NP (NN fat)) (ADVP (RB efficiently)) (PP-LOC (IN in) (NP (PRP$ its) (NN adipose) (NN tissue)))))))) (. .)) )
( (S (NP-SBJ (NP (DT This) (NN mismatch)) (PP (IN between) (NP (NP (VBN increased) (NN energy) (NN availability)) (CC and) (NP (NP (NN lack)) (PP (IN of) (NP (NML (NN adipose) (NN tissue)) (NN expandability))))))) (VP (VBP lead) (PP (IN to) (NP (NP (DT a) (JJ global) (JJ metabolic) (NN failure)) (VP (VBN characterised) (NP (-NONE- *)) (PP (IN by) (NP-LGS (NP (JJ severe) (NN insulin) (NN resistance)) (, ,) (NP (NML (NN β) (HYPH -) (NN cell)) (NN failure)) (, ,) (CC and) (NP (NN dyslipidaemia)))))))) (. .)) )
( (S (NP-SBJ (NP (DT The) (NN observation)) (PP (IN of) (NP (NP (VBN reduced) (NN fat) (NN mass)) (CC and) (NP (VBN increased) (NN insulin) (NN resistance)))) (PP-LOC (IN in) (NP (NP (DT the) (NN POKO) (NN mouse)) (PP (VBN compared) (PP (IN to) (NP (DT the) (NML (NN ob) (HYPH /) (NN ob)) (NN mouse))))))) (ADVP (RB strongly)) (VP (VBZ supports) (NP (NP (CD two)) (PP (IN of) (NP (PRP$ our) (NNS hypotheses))))) (. .)) )
( (S (S (ADVP (RB First)) (, ,) (NP-SBJ (PRP we)) (VP (VBD hypothesised) (SBAR (IN that) (S (NP-SBJ-1 (NN PPARg2)) (VP (VBZ is) (VP (VBN required) (NP-1 (-NONE- *)) (S-PRP (NP-SBJ-1 (-NONE- *PRO*)) (VP (TO to) (VP (VB recruit) (NP (JJ new) (NNS adipocytes)) (PP (IN in) (NP (NN overnutrition)))))))))))) (, ,) (CC but) (S (NP-SBJ-2 (PRP it)) (VP (VBZ is) (RB not) (VP (VBN required) (NP-2 (-NONE- *)) (S-PRP (NP-SBJ-2 (-NONE- *PRO*)) (VP (TO to) (VP (VB make) (NP (NNS adipocytes)) (PP-TMP (IN during) (NP (NN development))))))))) (. .)) )
( (S (NP-SBJ-1 (DT This)) (VP (VBZ is) (VP (VBN reflected) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NP (JJ similar) (NN expression)) (PP (IN of) (NP (NP (NN aP2)) (, ,) (NP (NP (DT a) (JJ late) (NN marker)) (PP (IN of) (NP (NN adipocyte) (NN differentiation)))))) (, ,) (PP-LOC (IN in) (NP (NML (NML (NN POKO)) (CC and) (NML (NN ob) (HYPH /) (NN ob))) (NNS mice))))))) (. .)) )
( (S (NP-SBJ (NP (DT The) (NN absence)) (PP (IN of) (NP (JJ small) (NNS adipocytes)))) (VP (VBD was) (ADJP-PRD (RB markedly) (JJ different) (PP (IN to) (NP (NP (JJ other) (NNS forms)) (PP (IN of) (NP (NN lipodystrophy)))))) (PRN (-LRB- [) (NP (CD 38) (, ,) (CD 39)) (-RRB- ]))) (. .)) )
( (S (UCP-ADV (ADVP (RB Additionally)) (, ,) (CC and) (PP (ADVP (RB again)) (IN in) (NP (NP (NN contrast)) (PP (IN with) (NP (NP (JJ other) (JJ lipodystrophic) (NNS models)) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBP have) (NP (NP (ADJP (RB markedly) (JJR less)) (NN adipose) (NN tissue)) (PP (IN than) (NP (NN WT) (NNS controls)))) (PRN (-LRB- [) (NP (NP (CD 38)) (PP (SYM –) (NP (CD 40)))) (-RRB- ])))))))))) (, ,) (NP-SBJ (DT the) (NN POKO) (NNS mice)) (VP (VBD had) (NP (NP (DT a) (NN percentage) (NN body) (NN fat)) (SBAR (WHNP-2 (WDT that)) (S (NP-SBJ-2 (-NONE- *T*)) (VP (VBD was) (ADJP-PRD (JJ similar) (PRN (-LRB- -LRB-) (NP (RB only) (NML (CD 4) (NN %)) (JJR more)) (-RRB- -RRB-)) (PP (IN to) (NP (NML (NN WT) (CC and) (NN PPARg2)) (NN KO) (NNS mice)))))))) (, ,) (PP (IN as) (PP (VBN opposed) (PP (IN to) (NP (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice)) (, ,) (SBAR (WHNP-3 (WDT which)) (S (NP-SBJ-3 (-NONE- *T*)) (VP (VBD had) (NP (NML (CD 40) (NN %)) (NN fat)) (PP (IN as) (NP (NP (DT a) (NN proportion)) (PP (IN of) (NP (NN body) (NN mass))))))))))))) (. .)) )
( (S (NP-SBJ (DT This)) (VP (VBZ suggests) (SBAR (IN that) (S (NP-SBJ-1 (DT the) (VBG remaining) (NN PPARg1) (NN isoform)) (VP (VBZ is) (ADJP-PRD (JJ sufficient) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (TO to) (VP (VB support) (NP (NP (NP (NN development)) (PP (IN of) (NP (NN adipose) (NN tissue)))) (CC and) (NP (NP (NML (NN fat) (NN deposition)) (NNS requirements)) (PP (IN of) (NP (DT a) (JJ lean) (NN mouse) (NN model))))))))))))) (. .)) )
( (S (ADVP (RB However)) (, ,) (PP (IN under) (NP (NP (NNS conditions)) (PP (IN of) (NP (NML (JJ positive) (NN energy)) (NN balance))))) (, ,) (NP-SBJ (NML (NN adipose) (NN tissue)) (NN expandability)) (ADVP (RB mainly)) (VP (VBZ relies) (PP (IN on) (NP (DT the) (NN PPARg2) (NN isoform)))) (. .)) )
( (S (NP-SBJ-1 (DT This) (NN idea)) (VP (VBZ is) (ADVP (RB also)) (VP (VBN suggested) (NP-1 (-NONE- *)) (PP (IN by) (NP-LGS (NP (DT the) (NNS studies)) (PP-LOC (IN in) (NP (NP (JJ heterozygous) (NNS mice)) (VP (VBG harbouring) (NP (NP (DT the) (JJ murine) (NN equivalent)) (PP (IN of) (NP (NP (NP (DT the) (JJ human) (NN mutation)) (-LRB- -LRB-) (NP (NN P465L))) (-RRB- -RRB-) (PP-LOC (IN in) (NP (NN PPARg))) (PP (IN on) (NP (DT an) (NML (NN ob) (HYPH /) (NN ob)) (NN background))))))))))) (PRN (-LRB- [) (NP (CD 41)) (-RRB- ])))) (. .)) )
( (S (NP-SBJ-1 (DT These) (NNS mice)) (VP (VBD were) (ADJP-PRD (JJ able) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (TO to) (VP (VP (VP (VB accumulate) (NP (NN fat))) (CC and) (VP (VB become) (ADJP-PRD (JJ obese)))) (SBAR-ADV (ADVP (RB even)) (IN though) (S (NP-SBJ (-NONE- *PRO*)) (VP (VBG showing) (NP (NP (DT a) (NN body) (NN mass)) (ADJP (ADJP (NP (CD 14) (NN %)) (JJR lower)) (PP (IN than) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS controls))))))))))))) (. .)) )
( (S (PP-LOC (IN In) (NP (NNS humans))) (NP-SBJ (EX there)) (VP (VBZ is) (ADVP (RB also)) (NP-PRD (NP (NN evidence)) (PP (IN for) (NP (NP (DT a) (NN role)) (PP (IN for) (NP (NN PPARg2))))))) (. .)) )
( (S (NP-SBJ (PRP We)) (VP (VBP have) (VP (VBN observed) (SBAR (IN that) (S (NP-SBJ (ADJP (RB metabolically) (JJ healthy)) (, ,) (JJ nondiabetic) (, ,) (ADJP (RB morbidly) (JJ obese)) (NNS individuals)) (VP (VBP have) (NP (NP (VBN elevated) (NNS levels)) (PP (IN of) (NP (NN PPARg2)))) (PP-LOC (IN in) (NP (PRP$ their) (NN adipose) (NN tissue))) (SBAR-TMP (WHADVP-1 (WRB when)) (S (NP-SBJ-2 (-NONE- *PRO*)) (VP (VBN compared) (NP-2 (-NONE- *)) (PP (IN to) (NP (JJ lean) (NNS individuals))) (ADVP-TMP-1 (-NONE- *T*)))))))) (PRN (-LRB- [) (NP (CD 19)) (-RRB- ])))) (. .)) )
( (S (NP-SBJ-1 (PRP$ Our) (JJ second) (NN hypothesis) (, ,) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN mismatch)) (PP (IN between) (NP (NP (NN energy) (NN availability)) (CC and) (NP (NML (NN adipose) (NN tissue)) (NN expandability))))) (VP (VBZ is) (ADJP-PRD (ADJP (RBR more) (JJ important)) (PP (IN than) (NP (NP (NN fat) (NN mass)) (NP (PRP itself))))) (PP (IN as) (NP (NP (DT a) (NN predictor)) (PP (IN of) (NP (NN insulin) (NN resistance))))))))) (, ,) (VP (VBZ is) (ADVP (RB also)) (VP (VBN supported) (NP-1 (-NONE- *)) (PP (IN by) (NP-LGS (PRP$ our) (NNS data))))) (. .)) )
( (S (PP (IN In) (NP (NN fact))) (NP-SBJ (DT the) (NML (NN ob) (HYPH /) (NN ob)) (NN mouse)) (VP (VP (VBZ is) (ADJP-PRD (ADJP (ADVP (RB much) (RBR more)) (JJ obese)) (PP (IN than) (NP (DT the) (NN POKO) (NN mouse))))) (CC but) (VP (VBZ is) (ADJP-PRD (ADVP (RB much) (RBR less)) (NN insulin) (JJ resistant)))) (. .)) )
( (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ (DT the) (NN POKO) (NNS mice)) (VP (VBD were) (ADVP (RB already)) (ADJP-PRD (ADJP (JJR more) (NN insulin) (JJ resistant)) (PP (IN than) (NP (DT the) (NML (NN ob) (HYPH /) (NN ob)) (NNS mice)))) (PP-TMP (IN by) (NP (NP (DT the) (NN age)) (PP (IN of) (NP (CD four) (NNS weeks))))) (, ,) (PP (IN with) (NP (NP (ADJP (RB very) (JJ low)) (NNS levels)) (PP (IN of) (NP (NN GLUT4))) (PP-LOC (IN in) (NP (NN adipose) (NN tissue))))) (, ,) (SBAR-TMP (IN before) (S (NP-SBJ-1 (NP (JJ large) (NNS differences)) (PP (IN in) (NP (NN body) (NN weight)))) (VP (VBD developed) (NP-1 (-NONE- *))))) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (JJ bioenergetic) (NN mismatch)) (CONJP (RB rather) (IN than)) (NP (NP (DT the) (JJ total) (NN amount)) (PP (IN of) (NP (NP (NN fat)) (VP (VBN stored) (NP (-NONE- *))))))) (VP (VBZ is) (ADJP-PRD (JJ important) (PP (IN for) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NN insulin) (NN resistance)))))))))))) (. .)) )
( (S (SBAR-ADV (IN Although) (S (NP-SBJ (PRP we)) (VP (VBD hypothesised) (SBAR (IN that) (S (NP-SBJ (DT the) (NN POKO) (NNS mice)) (VP (MD would) (VP (VB become) (NP-PRD (NN insulin) (JJ resistant))))))))) (, ,) (NP-SBJ (NP (DT the) (NN degree)) (PP (IN of) (NP (NN hyperglycaemia))) (PP-LOC (IN in) (NP (DT these) (NNS animals)))) (VP (VBD was) (PP-PRD (IN in) (NP (NP (NN excess)) (PP (IN of) (SBAR-NOM (WHNP-1 (WP what)) (S (NP-SBJ (PRP we)) (VP (VBD expected) (NP-1 (-NONE- *T*))))))))) (. .)) )
( (S (NP-SBJ (PRP We)) (VP (VBD found) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (JJ normal) (JJ adaptive) (NN response)) (PP (IN of) (NP (NN β) (HYPH -) (NNS cells))) (PP (IN to) (NP (NN insulin) (NN resistance)))) (VP (VBD did) (RB not) (VP (VB occur) (PP-LOC (IN in) (NP (DT the) (NN POKO) (NNS mice))) (SBAR-ADV (IN as) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBN indicated) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NP (NP (DT the) (JJ pathological) (NNS changes)) (VP (VBN observed) (NP (-NONE- *)) (PP-MNR (IN by) (NP (NN histology))))) (CC and) (NP (NP (DT the) (NN lack)) (PP (IN of) (NP (NML (NN β) (HYPH -) (NN cell)) (NN hypertrophy)))))))))))))) (. .)) )
( (S (SBAR-ADV (IN Although) (S (NP-SBJ-2 (NP (PRP it)) (SBAR-1 (-NONE- *EXP*))) (VP (VBZ has) (VP (VBN been) (VP (VBN shown) (NP-2 (-NONE- *)) (SBAR-1 (IN that) (S (NP-SBJ (JJ genetic) (NN background)) (VP (MD can) (VP (VB affect) (NP (NP (DT the) (NN ability) (S-3 (-NONE- *ICH*))) (PP (IN of) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice))) (S-3 (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB undergo) (NP (NML (NN β) (HYPH -) (NN cell)) (NN hypertrophy)))))))))) (PRN (-LRB- [) (NP (CD 42) (, ,) (CD 43)) (-RRB- ]))))))) (, ,) (NP-SBJ (PRP we)) (VP (VBD found) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NML (NN ob) (HYPH /) (NN ob)) (NNS controls)) (PP (IN on) (NP (PRP$ our) (JJ mixed) (NML (NML (NN 129Sv)) (SYM ×) (NML (NN C57BL) (HYPH /) (NN 6J))) (NN background)))) (VP (VBD underwent) (NP (NP (JJ adaptive) (NML (NN β) (HYPH -) (NN cell)) (NN hyperplasia)) (CC and) (NP (NN hypertrophy))) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (NN lack)) (PP (IN of) (NP (NN PPARg2)))) (VP (VBD was) (ADJP-PRD (JJ responsible)) (PP (IN for) (NP (NP (DT the) (NN failure) (S-4 (-NONE- *ICH*))) (PP (IN of) (NP (DT the) (NN POKO) (NN β) (HYPH -) (NNS cells))) (S-4 (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB adapt) (PP (IN to) (NP (NN insulin) (NN resistance))))))))))))))))) (. .)) )
( (S (ADVP (RB Interestingly)) (NP-SBJ (NP (DT the) (NN mass)) (PP (IN of) (NP (NP (JJ pancreatic) (NNS islets)) (PP-LOC (IN in) (NP (NN POKO) (NNS mice)))))) (VP (VBD remained) (ADJP-PRD (JJ similar) (PP (IN to) (NP (DT the) (NML (ADJP (NN noninsulin) (JJ resistant)) (NML (NN WT) (CC and) (NN PPARg2))) (NN KO) (NNS mice))))) (. .)) )
( (S (ADVP (RB Furthermore)) (, ,) (NP-SBJ-1 (NP (DT these) (NNS defects)) (PP-LOC (IN in) (NP (NN POKO) (NN β) (HYPH -) (NNS cells)))) (VP (VBD did) (RB not) (VP (VB appear) (S (NP-SBJ-1 (-NONE- *)) (VP (TO to) (VP (VB be) (NP-PRD (NP (DT the) (NN result)) (PP (IN of) (NP (DT a) (JJ developmental) (NN defect))))))) (, ,) (SBAR-ADV (IN as) (S (NP-SBJ (ADJP (ADJP (JJ new) (JJ born)) (CC and) (ADJP (NP (CD four) (HYPH -) (NN week)) (HYPH -) (JJ old))) (NNS mice)) (VP (VBD had) (NP (ADJP (RB morphologically) (JJ normal)) (NNS islets))))))) (. .)) )
( (S (NP-SBJ (NP (DT The) (JJ severe) (NML (NN β) (HYPH -) (NN cell)) (NN phenotype)) (PP (IN of) (NP (DT the) (NN POKO) (NN mouse)))) (VP (VBZ contrasts) (PP (IN with) (NP (NP (NP (DT the) (NN absence)) (PP (IN of) (NP (NN hyperglycaemia)))) (VP (VBN observed) (NP (-NONE- *)) (PP-LOC (IN in) (NP (DT the) (JJ pancreatic) (ADJP (NP (NN β) (HYPH -) (NN cell)) (JJ specific)) (NML (NN PPARg) (NN KO)) (NN mouse)))))) (PRN (-LRB- [) (NP (CD 30)) (-RRB- ]))) (. .)) )
( (S (ADVP (RB However)) (NP-SBJ-6 (NP (PRP it)) (SBAR-1 (-NONE- *EXP*))) (VP (MD should) (VP (VB be) (VP (VBN kept) (NP-6 (-NONE- *)) (S-CLR (NP-SBJ-6 (-NONE- *PRO*)) (PP-PRD (IN in) (NP (NN mind)))) (SBAR-1 (SBAR (IN that) (S (PP-LOC (IN in) (NP (DT the) (ADJP (NP (NN β) (HYPH -) (NN cell)) (JJ specific)) (NML (NN PPARg) (NN KO)) (NN mouse))) (, ,) (NP-SBJ-2 (NP (NP (DT the) (NN expression)) (PP (IN of) (NP (NN PPARg)))) (CC and) (NP (NP (DT the) (NN lipid) (NN storage) (NN capacity)) (PP (IN of) (NP (NP (JJ other) (NNS tissues)) (, ,) (NP (ADVP (RBS most) (RB importantly)) (NN adipose) (NN tissue)))))) (, ,) (VP (VBD were) (RB not) (VP (VBN affected) (NP-2 (-NONE- *)))))) (, ,) (CC and) (SBAR (IN that) (S (NP-SBJ-3 (NN insulin) (NN sensitivity)) (VP (VBD was) (ADVP (RB only) (RB mildly)) (VP (VBN affected) (NP-3 (-NONE- *)) (PP (IN by) (NP-LGS (NML (JJ high) (NN fat)) (NN feeding))) (PP-LOC (IN in) (NP (DT these) (NNS mice))) (SBAR-TMP (WHADVP-5 (WRB when)) (S (NP-SBJ-4 (-NONE- *PRO*)) (VP (VBN compared) (NP-4 (-NONE- *)) (PP (IN to) (NP (NP (DT the) (JJ severe) (NN insulin) (NN resistance)) (VP (VBN observed) (NP (-NONE- *)) (PP-LOC (IN in) (NP (NN POKO) (NNS mice))) (ADVP-TMP-5 (-NONE- *T*)))))))))))))))) (. .)) )
( (S (ADVP (RB Therefore)) (NP-SBJ (NP (DT the) (NN challenge)) (PP (IN to) (NP (NP (DT the) (JJ pancreatic) (NN β) (HYPH -) (NNS cells)) (PP (IN in) (NP (DT this) (NN model)))))) (VP (VBD was) (ADJP-PRD (ADJP (JJR milder)) (PP (IN than) (PP-LOC (IN in) (NP (NN POKO) (NNS mice)))))) (. .)) )
( (S (NP-SBJ (DT This)) (VP (VBZ is) (NP-PRD (NP (DT a) (JJ clear) (NN example)) (PP (IN of) (SBAR-NOM (WHADVP-2 (WRB how)) (S (NP-SBJ (ADJP (NN tissue) (HYPH -) (JJ specific)) (JJ genetic) (NNS manipulations)) (VP (VBP are) (RB not) (ADVP (RB always)) (NP-PRD (NP (DT the) (JJS best) (NN approach)) (SBAR (WHADVP-1 (-NONE- *0*)) (S (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB understand) (NP (NP (DT the) (NN physiology)) (PP (IN of) (NP (DT an) (NN organ)))) (PP (IN in) (NP (NP (DT the) (NN context)) (PP (IN of) (NP (DT the) (JJ global) (NN energy) (NN homeostasis))))) (ADVP-MNR-1 (-NONE- *T*))))))) (ADVP-MNR-2 (-NONE- *T*)))))))) (. .)) )
( (S (NP-SBJ-1 (NP (DT The) (JJ potential) (NN importance)) (PP (IN of) (NP (NP (DT the) (ADJP (FW de) (FW novo)) (NN expression)) (PP (IN of) (NP (NN PPARg2) (NN isoform))) (PP-LOC (IN in) (NP (NN β) (HYPH -) (NNS cells)))))) (VP (VBZ is) (ADVP (RB also)) (VP (VBN supported) (NP-1 (-NONE- *)) (PP (IN by) (NP (DT the) (NN observation) (SBAR (IN that) (S (NP-SBJ-3 (NP (NNS humans)) (VP (VBG harbouring) (NP (DT the) (NN Pro12Ala) (NN mutation)) (PP-LOC (IN in) (NP (NP (NN PPARg2)) (, ,) (NP (NP (DT a) (NN mutation)) (SBAR (WHNP-2 (WDT that)) (S (NP-SBJ-2 (-NONE- *T*)) (VP (VP (VBZ is) (VP (VBN located) (NP-2 (-NONE- *)) (PP-LOC (IN in) (NP (DT the) (NN g2) (NN isoform))))) (CC and) (VP (VBZ makes) (S (NP-SBJ (NN PPARg2)) (ADJP-PRD (RBR less) (JJ active)))))))))))) (, ,) (VP (VBZ has) (ADVP (RB only)) (VP (VBN been) (VP (VBN associated) (NP-3 (-NONE- *)) (PP (IN with) (NP (NP (NP (NN insulin) (NN deficiency)) (CC and) (NP (NN disease) (NN severity))) (PP (IN in) (NP (NP (JJ obese) (NNS individuals)) (PP (IN with) (NP (NML (NN type) (CD 2)) (NN diabetes))))) (PRN (-LRB- [) (NP (CD 44)) (-RRB- ]))))))))))))) (. .)) )
( (S (NP-SBJ (NP (DT The) (NN liver)) (PP (IN of) (NP (DT the) (NN POKO) (NN mouse)))) (ADVP (RB also)) (VP (VBD displayed) (NP (DT an) (JJ unusual) (NN phenotype))) (. .)) )
( (S (NP-SBJ (PRP We)) (VP (VBD expected) (S (NP-SBJ (DT the) (NN POKO) (NNS mice)) (VP (TO to) (VP (VB have) (NP (JJR worse) (NN hepatosteatosis)) (PP (IN with) (NP (NP (VBN increased) (NN triglyceride) (NN deposition)) (PP-LOC (IN in) (NP (NN liver))))) (PP (VBN compared) (PP (IN to) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice))))))) (, ,) (SBAR-PRP (IN because) (S (NP-SBJ (DT the) (NN POKO) (NNS mice)) (VP (MD could) (RB not) (VP (VB store) (NP (NN fat)) (PP-LOC (IN in) (NP (NN adipose) (NN tissue)))))))) (. .)) )
( (S (ADVP (RB However)) (NP-SBJ (NN POKO) (NNS mice)) (VP (VBD had) (NP (NP (JJR less) (NN hepatosteatosis)) (PP (IN than) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice)))) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ (DT the) (NN PPARg2) (NN isoform)) (VP (MD may) (ADVP (RB directly)) (VP (VB contribute) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB facilitate) (NP (NN triglyceride) (NN deposition)) (PP-LOC (IN in) (NP (DT the) (NN liver))))))))))))) (. .)) )
( (S (NP-SBJ (NP (DT A) (JJ common) (JJ mechanistic) (NN link)) (PP (IN for) (NP (NP (DT the) (NNS phenotypes)) (VP (VBN observed) (NP (-NONE- *)) (PP-LOC (IN in) (NP (DT the) (NN POKO) (NML (NML (NN liver)) (CC and) (NML (NN β) (HYPH -) (NN cell))))))))) (VP (VBD was) (RB not) (ADJP-PRD (RB immediately) (JJ obvious))) (. .)) )
( (S (S-PRP (NP-SBJ-1 (-NONE- *PRO*)) (VP (TO To) (VP (VB try) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN role)) (PP (IN of) (NP (NN PPARg2))) (PP-LOC (IN in) (NP (DT these) (NNS locations)))))))))) (NP-SBJ (PRP we)) (VP (VBD performed) (NP (NP (UCP (JJ lipidomic) (CC and) (NN gene)) (NN expression) (NNS analyses)) (PP (IN of) (NP (NP (NP (DT the) (NN adipose) (NN tissue)) (, ,) (NP (JJ pancreatic) (NN islet)) (, ,) (NP (NN liver)) (, ,) (CC and) (NP (JJ skeletal) (NN muscle))) (PP (IN of) (NP (DT the) (NN POKO) (NN mouse))))))) (. .)) )
( (S (NP-SBJ-1 (NP (DT The) (NN lipid) (NN pattern)) (PP (IN of) (NP (NP (NN adipose) (NN tissue)) (PP (IN from) (NP (NN POKO) (NNS mice)))))) (VP (VBD was) (VP (VBN characterised) (NP-1 (-NONE- *)) (PP (IN by) (NP-LGS (NP (VBN decreased) (NNS TAGs)) (CC and) (NP (VBN increased) (NNS DAGs)))) (PP (IN in) (NP (NP (NN parallel)) (PP (IN with) (NP (NP (VBN decreased) (NN gene) (NN expression)) (PP (IN of) (NP (NP (NN DGAT2)) (, ,) (NP (ADJP (NN hormone) (HYPH -) (JJ sensitive)) (NN lipase)) (, ,) (CC and) (NP (NN adipose) (NN triglyceride) (NN lipase)))))))))) (. .)) )
( (S (NP-SBJ-1 (NP (DT This) (NN decrease)) (PP (IN in) (NP (NNS TAGs))) (PP-LOC (IN in) (NP (DT the) (NN POKO) (NN adipose) (NN tissue)))) (VP (VBD was) (VP (VBN associated) (NP-1 (-NONE- *)) (PP (IN with) (NP (NP (NP (VBN increased) (NNS levels)) (PP (IN of) (NP (JJ reactive) (NN lipid) (NNS species)))) (CC and) (NP (NP (DT a) (NN gene) (NN expression) (NN profile)) (ADJP (JJ suggestive) (PP (IN of) (NP (VBN increased) (JJ oxidative) (NN stress))))))) (PRN (-LRB- [) (NP (NP (CD 45)) (PP (SYM –) (NP (CD 49)))) (-RRB- ])))) (. .)) )
( (S (SBAR-ADV (IN Although) (S (NP-SBJ-2 (NP (PRP it)) (SBAR-1 (-NONE- *EXP*))) (VP (VBZ has) (VP (VBN been) (VP (VBN described) (NP-2 (-NONE- *)) (SBAR-1 (IN that) (S (NP-SBJ-3 (NP (JJ oxidative) (NN stress)) (CC and) (NP (NN insulin) (NN resistance))) (VP (MD may) (VP (VB be) (VP (VBN related) (NP-3 (-NONE- *)) (PP (IN to) (NP (NP (NN infiltration)) (PP (IN of) (NP (NN adipose) (NN tissue))) (PP (IN by) (NP (NNS macrophages))))) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG resulting) (PP (IN in) (NP (NP (DT a) (JJ chronic) (NN state)) (PP (IN of) (NP (NN inflammation)))))))))))) (PRN (-LRB- [) (NP (NP (CD 50)) (PP (SYM –) (NP (CD 52)))) (-RRB- ]))))))) (, ,) (NP-SBJ (PRP we)) (VP (VBD did) (RB not) (VP (VB observe) (NP (NP (VBN increased) (NN macrophage) (NN infiltration)) (PP-LOC (IN in) (NP (NP (DT the) (NN adipose) (NN tissue)) (PP (IN of) (NP (NN POKO) (NNS mice))))) (PP (VBN compared) (PP (IN to) (NP (NP (DT that)) (PP (IN of) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice))))))))) (. .)) )
( (S (NP-SBJ (NP (JJ Lipidomic) (NN analysis)) (PP (IN of) (NP (NN POKO) (VBN derived) (NNS islets)))) (ADVP (RB also)) (VP (VBD showed) (NP (NP (NP (VBN decreased) (NNS levels)) (PP (IN of) (NP (NN triacyl) (CC and) (NNS DAGs)))) (CC and) (NP (NP (VBN increased) (NNS levels)) (PP (IN of) (NP (NNS ceramides))))) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG suggesting) (SBAR (IN that) (S (NP-SBJ (NN PPARg2)) (VP (MD may) (VP (VB contribute) (PP (IN to) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG increasing) (NP (NP (DT the) (ADJP (NN lipid) (HYPH -) (VBG buffering)) (NN capacity)) (PP (IN of) (NP (NN β) (HYPH -) (NNS cells)))) (PP-MNR (IN by) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VP (VBG promoting) (NP (NP (NN formation)) (PP (IN of) (NP (NNS TAGs))))) (CC and) (VP (ADVP (RB thus)) (VBG preventing) (NP (JJ lipotoxic) (NNS insults)))))))))))))))) (. .)) )
( (S (NP-SBJ (NML (NML (NN Liver)) (CC and) (NML (JJ skeletal) (NN muscle))) (NNS lipidomics)) (ADVP (RB also)) (VP (VBD showed) (NP (NP (VBN reduced) (NN TAG)) (CC and) (NP (NP (VBN increased) (NN formation)) (PP (IN of) (NP (NP (JJ reactive) (NN lipid) (NNS species)) (PP (JJ such) (IN as) (NP (NNS ceramides) (CC and) (NNS lysophosphatidylcholines))))))) (PP-LOC (IN in) (NP (NN POKO) (NNS mice))) (PP (VBN compared) (PP (IN to) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice))))) (. .)) )
( (S (NP-SBJ-1 (DT This) (NN lipid) (NN profile)) (VP (VBD was) (VP (VBN associated) (NP-1 (-NONE- *)) (PP (IN with) (NP (NP (VBN impaired) (NN expression)) (PP (IN of) (NP (NP (NNS pathways)) (VP (VBG controlling) (NP (NP (ADJP (FW de) (FW novo)) (NN lipogenesis)) (, ,) (NP (NP (NN transport)) (PP (IN of) (NP (JJ fatty) (NNS acids)))) (, ,) (CC and) (NP (NN beta) (NN oxidation))) (PP-LOC (IN in) (NP (NP (DT the) (NN POKO) (NNS mice)) (PP (VBN compared) (PP (IN with) (NP (DT the) (NML (NN ob) (HYPH /) (NN ob)) (NNS mice))))))))))))) (. .)) )
( (S (PP (IN Of) (NP (NN interest))) (, ,) (NP-SBJ-1 (NP (NN Ppargc1a)) (CC and) (NP (JJ other) (JJ gluconeogenic) (NNS genes))) (VP (VBD were) (VP (VBN induced) (NP-1 (-NONE- *)) (PP-LOC (IN in) (NP (NP (DT the) (NN liver)) (PP (IN of) (NP (NN POKO) (NNS mice))) (PP (VBN compared) (PP (IN to) (NP (NP (DT that)) (PP (IN of) (NP (NML (NN ob) (HYPH /) (NN ob)) (NNS mice)))))))) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG suggesting) (NP (NP (DT a) (JJ potential) (NN mechanism)) (VP (VBG contributing) (PP (IN to) (NP (NP (JJ marked) (NN hyperglycaemia)) (PP-LOC (IN in) (NP (NN POKO) (NNS mice))))))))) (PRN (-LRB- [) (NP (CD 53) (, ,) (CD 54)) (-RRB- ])))) (. .)) )
( (S (ADVP (RB Overall)) (, ,) (NP-SBJ (PRP$ our) (JJ lipidomic) (NNS studies)) (VP (VBP identify) (NP (NP (DT a) (ADJP (RB remarkably) (JJ similar)) (NN pattern)) (PP (IN of) (NP (NP (NNS changes)) (PP (IN in) (NP (NN lipid) (NNS species)))))) (PP-LOC (IN in) (NP (NP (DT the) (CD four) (NNS tissues)) (VP (VBN studied) (NP (-NONE- *)))))) (. .)) )
( (S (NP-SBJ-1 (NP (NP (DT The) (VBN reduced) (NN adipose) (NN tissue) (NN mass)) (CC and) (NP (NN hepatosteatosis))) (PP-LOC (IN in) (NP (NP (DT the) (NN POKO) (NN mouse)) (PP (VBN compared) (PP (IN to) (NP (DT the) (NML (NN ob) (HYPH /) (NN ob)) (NN mouse))))))) (VP (VBZ is) (VP (VBN explained) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NP (VBN reduced) (NNS levels)) (PP (IN of) (NP (JJ mature) (NN TAG))) (PP-LOC (IN in) (NP (DT the) (NN POKO) (NN mouse))))))) (. .)) )
( (S (ADVP (RB Similarly)) (, ,) (NP-SBJ (NP (NN ablation)) (PP (IN of) (NP (NN PPARg2)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NP (NN accumulation)) (PP (IN of) (NP (JJ reactive) (NN lipid) (NNS species)))) (VP (VBN implicated) (NP (-NONE- *)) (PP (IN in) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG causing) (NP (NN insulin) (NN resistance)) (, ,) (PP-LOC (CONJP (RB not) (RB only)) (PP (IN in) (NP (NN adipose) (NN tissue))) (, ,) (CONJP (CC but) (RB also)) (PP (IN in) (NP (NP (JJ other) (NNS organs)) (VP (VBN involved) (NP (-NONE- *)) (PP (IN in) (NP (NML (JJ whole) (HYPH -) (NN organism)) (NN glucose) (NN metabolism)))))))))))))) (. .)) )
( (S (NP-SBJ (DT These) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ (NP (NN expression)) (PP (IN of) (NP (NN PPARg2))) (PP-LOC (IN in) (NP (NP (DT the) (NML (NN pancreas) (, ,) (NN liver) (, ,) (CC and) (NN muscle))) (PP (IN of) (NP (DT the) (NML (NN ob) (HYPH /) (NN ob)) (NN mouse)))))) (VP (MD may) (VP (VB be) (VP (VBG performing) (NP (DT a) (JJ protective) (NN role)) (, ,) (PP-MNR (IN by) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG increasing) (NP (NP (DT the) (NN capacity) (S-1 (-NONE- *ICH*))) (PP (IN of) (NP (DT these) (NNS organs))) (S-1 (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB buffer) (NP (JJ toxic) (NN lipid) (NNS species)) (PP-MNR (IN by) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG allowing) (NP (NP (NN accumulation)) (PP (IN of) (NP (ADJP (RB relatively) (JJ harmless)) (NNS TAGs)))))))))))))))))))) (. .)) )
( (S (NP-SBJ (NP (DT The) (NN importance)) (PP (IN of) (NP (NP (DT this) (JJ peripheral) (JJ antilipotoxic) (NN role)) (PP (IN of) (NP (NN PPARg2)))))) (VP (VBZ becomes) (ADJP-PRD (RBR more) (JJ evident)) (SBAR-ADV (IN if) (S (NP-SBJ (PRP we)) (VP (VBP consider) (SBAR (SBAR (IN that) (S (NP-SBJ (NML (NML (NN POKO)) (CC and) (NML (NN ob) (HYPH /) (NN ob))) (NNS mice)) (VP (VBP are) (PP-PRD (IN under) (NP (NP (DT the) (JJ same) (NN degree)) (PP (IN of) (NP (JJ positive) (NN energy) (NN balance))))) (SBAR-ADV (IN as) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBN determined) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NP (JJ similar) (NN food) (NN intake)) (, ,) (NP (NN locomotor) (NN activity)) (, ,) (CC and) (NP (NN energy) (NN expenditure)))))))))) (, ,) (SBAR (IN that) (S (NP-SBJ (DT both) (NNS models)) (VP (VBP lack) (NP (NN leptin))))) (, ,) (CC and) (SBAR (IN that) (S (NP-SBJ (NP (DT the) (JJ only) (NN difference)) (PP (IN between) (NP (NML (NML (NN ob) (HYPH /) (NN ob)) (CC and) (NML (NN POKO))) (NNS mice)))) (VP (VBZ is) (NP-PRD (NP (DT the) (NML (NN presence) (CC or) (NN absence))) (PP (IN of) (NP (NN PPARg2)))))))))))) (. .)) )
( (S (PP (VBN Given) (NP (NP (DT the) (VBN decreased) (NN adipose) (NN tissue) (NN expandability)) (PP (IN of) (NP (NP (DT the) (NN POKO) (NNS mice)) (PP (VBN compared) (PP (IN to) (NP (NN ob) (HYPH /) (NN ob)))))))) (, ,) (NP-SBJ-2 (NP (PRP it)) (SBAR-1 (-NONE- *EXP*))) (VP (VBD was) (VP (VBN anticipated) (NP-2 (-NONE- *)) (SBAR-1 (IN that) (, ,) (S (PP (IN as) (PP (IN in) (NP (NP (DT the) (NML (NML (NN liver)) (, ,) (NML (NN muscle)) (, ,) (CC or) (NML (NN β) (HYPH -) (NNS cells)))) (PP (IN of) (NP (JJ lipodistrophic) (NNS mice)))))) (, ,) (NP-SBJ (DT the) (NN POKO) (NN mouse)) (VP (MD would) (VP (VB accumulate) (NP (NP (JJR more) (NN fat)) (PP (IN than) (NP (DT the) (NN ob) (HYPH /) (NN ob)))))))))) (. .)) )
( (S (ADVP (RB However)) (, ,) (NP-SBJ (PRP$ our) (NNS results)) (ADVP (RB clearly)) (VP (VBP indicate) (SBAR (IN that) (S (NP-SBJ-1 (NP (NNS mice)) (VP (VBG lacking) (NP (NN PPARg2)))) (, ,) (PP (IN despite) (NP (JJ massive) (NN nutrient) (NN availability))) (, ,) (VP (VP (VBP are) (ADJP-PRD (JJ unable) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (TO to) (VP (VB deposit) (NP (NN TAG)) (PP-LOC (IN in) (NP (JJ peripheral) (NNS tissues)))))))) (CC and) (VP (ADVP (RB instead)) (VBP accumulate) (NP (JJ reactive) (NN lipid) (NNS species)) (PP-LOC (IN in) (NP (DT these) (NNS organs)))))))) (. .)) )
( (S (ADVP (RB Therefore)) (NP-SBJ (NP (DT the) (NNS pathologies)) (PP (IN of) (NP (NP (DT the) (NML (NML (NN liver)) (CC and) (NML (NN β) (HYPH -) (NN cell)))) (VP (VBN observed) (NP (-NONE- *)) (PP-LOC (IN in) (NP (DT the) (NN POKO) (NN mouse))))))) (VP (MD may) (VP (VB be) (NP-PRD (NP (DT a) (NN result)) (PP (IN of) (NP (NP (DT a) (JJ common) (JJ lipotoxic) (NN insult)) (VP (VBN facilitated) (NP (-NONE- *)) (PP (IN by) (NP-LGS (NP (DT the) (NN absence)) (PP (IN of) (NP (NN PPARg2))))))))) (PRN (-LRB- -LRB-) (NP (NN Figure) (CD 6)) (-RRB- -RRB-)))) (. .)) )
( (S (PP (IN In) (NP (NN summary))) (, ,) (PP (IN in) (NP (DT this) (NN study))) (NP-SBJ (PRP we)) (VP (VP (VBP provide) (NP (NP (JJ new) (NNS insights)) (PP (IN into) (NP (NP (DT the) (JJ physiological) (NN relevance)) (PP (IN of) (NP (DT the) (NN PPARg2) (NN isoform))))))) (CC and) (VP (VBP identify) (NP (NML (NN adipose) (NN tissue)) (NN expandability)) (PP (IN as) (NP (NP (DT an) (JJ important) (NN determinant)) (PP (IN of) (NP (JJ metabolic) (NNS complications))))))) (. .)) )
( (S (S (NP-SBJ (NP (NN Ablation)) (PP (IN of) (NP (NN PPARg2)))) (VP (VBZ decreases) (NP (NML (NN adipose) (NN tissue)) (NN expandability)))) (, ,) (CC but) (S (NP-SBJ (PRP$ its) (JJ pathophysiological) (NNS effects)) (ADVP (RB only)) (VP (VBP become) (ADJP-PRD (JJ relevant)) (PP (IN in) (NP (NP (DT the) (NN context)) (PP (IN of) (NP (NP (DT a) (NN mismatch)) (PP (IN between) (NP (NP (NN energy) (NN availability)) (CC and) (NP (NML (NN adipose) (NN tissue)) (NN expansion)))))))))) (. .)) )
( (S (NP-SBJ (PRP We)) (VP (VBP show) (SBAR (IN that) (S (NP-SBJ (NN PPARg2)) (ADVP (RB also)) (VP (VBZ plays) (NP (JJ protective) (NN role)) (SBAR-TMP (WHADVP-2 (WRB when)) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBN expressed) (NP-1 (-NONE- *)) (ADVP (FW de) (FW novo)) (ADVP-TMP-2 (-NONE- *T*)) (PP-LOC (IN in) (NP (JJ peripheral) (NNS organs))) (PP-MNR (IN by) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG increasing) (NP (PRP$ their) (NN capacity) (S (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB buffer) (NP (JJ toxic) (NNS lipids)))))))))))))))) (. .)) )
( (S (NP-SBJ (NP (NN Ablation)) (PP (IN of) (NP (NN PPARg2))) (PP (IN under) (NP (NP (NNS conditions)) (PP (IN of) (NP (NP (JJ positive) (NN energy) (NN balance)) (VP (VBN determined) (NP (-NONE- *)) (PP (IN by) (NP-LGS (NP (NN absence)) (PP (IN of) (NP (NN leptin))))))))))) (VP (VBD produced) (NP (NP (JJ early) (NN development)) (PP (IN of) (NP (NP (JJ severe) (NN insulin) (NN resistance)) (, ,) (NP (NML (NN β) (HYPH -) (NN cell)) (NN failure)) (, ,) (NP (NN diabetes)) (, ,) (CC and) (NP (NN hyperlipidaemia)))))) (. .)) )
( (S (NP-SBJ (NP (NN Extrapolation)) (PP (IN of) (NP (DT this) (NN model))) (PP (IN to) (NP (NNS humans)))) (VP (MD may) (VP (VB suggest) (SBAR (IN that) (S (NP-SBJ (NP (ADJP (JJ normal) (PP (IN to) (ADJP (JJ overweight)))) (NNS individuals)) (PP (IN with) (NP (NP (JJ positive) (NN energy) (NN balance)) (CC and) (NP (NP (ADJP (RB inappropriately) (JJ severe)) (NNS manifestations)) (PP (IN of) (NP (DT the) (NN MS))))))) (VP (MD may) (VP (VB have) (NP (DT a) (NN defect)) (PP (IN in) (NP (NP (NP (NN PPARg2)) (CONJP (CC and) (HYPH /) (CC or)) (NP (JJ alternative) (NNS mechanisms))) (SBAR (WHNP-1 (WDT that)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBP control) (NP (NML (NN adipose) (NN tissue)) (NN expandability))))))))))))) (. .)) )
( (HEADING (NP (NNS Materials) (CC and) (NNS Methods))) )
( (HEADING (NP (NP (NN Generation)) (PP (IN of) (NP (NP (NNS mice)) (ADJP (JJ homozygous) (PP (IN for) (NP (NP (NML (NML (NN PPARg2) (NN KO)) (CC and) (NML (NN leptin))) (NN deficiency)) (-LRB- -LRB-) (NP (NN ob) (HYPH /) (NN ob))))))) (-RRB- -RRB-) (. .))) )
( (S (NP-SBJ-1 (NP (NNS Mice)) (ADJP (JJ heterozygous) (PP (IN for) (NP (NP (NP (DT a) (NN disruption)) (PP-LOC (IN in) (NP (NP (NN exon) (NN B1)) (PP (IN of) (NP (NN PPARg2))))) (PP (IN on) (NP (DT a) (NN 129Sv) (NN background)))) (-LRB- -LRB-) (NP (NN PPARg2) (NML (SYM +) (HYPH /) (SYM −)))))) (-RRB- -RRB-) (PRN (-LRB- [) (NP (CD 2)) (-RRB- ]))) (VP (VBD were) (VP (VBN crossed) (NP-1 (-NONE- *)) (PP-MNR (IN with) (NP (NP (NML (NML (JJ heterozygous) (NN ob) (HYPH /) (NN ob)) (-LRB- -LRB-) (NML (NN Lepob) (HYPH /) (NN Lep) (SYM +))) (-RRB- -RRB-) (NNS mice)) (PP (IN on) (NP (DT a) (NML (NN C57Bl) (HYPH /) (CD 6)) (NN background))))) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB obtain) (NP (NP (NNS mice)) (ADJP (JJ heterozygous) (PP (IN for) (NP (NP (CC both) (NP (DT the) (NN PPARg2) (NN ablation)) (CC and) (NP (DT the) (NN leptin) (NN point) (NN mutation))) (-LRB- -LRB-) (NP (NML (NN PPARg2) (SYM +) (HYPH /) (SYM −)) (NN Lepob) (HYPH /) (NN Lep) (SYM +))))))))))) (-RRB- -RRB-) (. .)) )
( (S (NP-SBJ-1 (DT These) (NNS mice)) (VP (VBD were) (VP (VBN crossed) (NP-1 (-NONE- *)) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB obtain) (NP (NP (DT the) (CD four) (JJ experimental) (NNS genotypes)) (: :) (NP (NP (NP (NN WT)) (-LRB- -LRB-) (NP (NML (NN PPARg2) (SYM +) (HYPH /) (SYM +)) (NML (NN Lep) (SYM +)) (HYPH /) (NN Lep) (SYM +))) (-RRB- -RRB-) (, ,) (NP (NP (NN PPARg2) (NN KO)) (-LRB- -LRB-) (NP (NML (NN PPARg2) (SYM −) (HYPH /) (SYM −)) (NML (NN Lep) (SYM +)) (HYPH /) (NN Lep) (SYM +))) (-RRB- -RRB-) (, ,) (NP (NP (NN ob) (HYPH /) (NN ob)) (-LRB- -LRB-) (NP (NML (NN PPARg2) (SYM +) (HYPH /) (SYM +)) (NN Lepob) (HYPH /) (NN Lepob))) (-RRB- -RRB-) (, ,) (CC and) (NP (NP (NN POKO)) (-LRB- -LRB-) (NP (NML (NN PPARg2) (SYM −) (HYPH /) (SYM −)) (NN Lepob) (HYPH /) (NN Lepob)))))))))) (-RRB- -RRB-) (. .)) )
( (S (S-NOM-SBJ-1 (NP-SBJ (-NONE- *PRO*)) (VP (VBG Genotyping) (PP (IN for) (NP (NP (NN deletion)) (PP (IN of) (NP (NP (NN PPARg2)) (CC and) (NP (NP (DT the) (NN point) (NN mutation)) (PP-LOC (IN in) (NP (DT the) (NN ob) (NN gene)))))))))) (VP (VBD was) (VP (VBN performed) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (NN PCR))) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (JJ standard) (NNS protocols)))) (PRN (-LRB- [) (NP (CD 2) (, ,) (CD 55)) (-RRB- ])))) (. .)) )
( (HEADING (NP (NN Animal) (NN care) (. .))) )
( (S (NP-SBJ-1 (NNS Animals)) (VP (VBD were) (VP (VBN housed) (NP-1 (-NONE- *)) (PP-MNR (IN at) (NP (NP (DT a) (NN density)) (PP (IN of) (NP (NP (CD four) (NNS animals)) (PP (IN per) (NP (NN cage))))))) (PP-LOC (IN in) (NP (DT a) (ADJP (NN temperature) (HYPH -) (VBN controlled)) (NN room) (PRN (-LRB- -LRB-) (NP (QP (CD 20) (SYM –) (CD 22)) (NN °C)) (-RRB- -RRB-)))) (PP (IN with) (NP (NML (CD 12) (HYPH -) (NN h)) (NML (NN light) (HYPH /) (NN dark)) (NNS cycles))))) (. .)) )
( (S (NP-SBJ (NN Food) (CC and) (NN water)) (VP (VBD were) (ADJP-PRD (JJ available)) (ADVP (FW ad) (FW libitum)) (SBAR-ADV (IN unless) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBN noted) (NP-1 (-NONE- *)))))) (. .)) )
( (S (NP-SBJ-1 (NP (DT All) (NN animal) (NNS protocols)) (VP (VBN used) (NP (-NONE- *)) (PP (IN in) (NP (DT this) (NN study))))) (VP (VBD were) (VP (VBN approved) (NP-1 (-NONE- *)) (PP (IN by) (NP-LGS (NP (DT the) (NNP UK) (NNP Home) (NNP Office)) (CC and) (NP (NP (DT the) (NNP University)) (PP (IN of) (NP (NNP Cambridge)))))))) (. .)) )
( (HEADING (NP (NP (NML (NN Blood) (CC and) (NN urine)) (NN biochemistry)) (, ,) (NP (NN food) (NN intake)) (, ,) (CC and) (NP (NN body) (NN composition) (NN analysis)) (. .))) )
( (S (NP-SBJ-1 (NP (NNS Mice)) (PP (IN of) (NP (DT the) (CD four) (JJ experimental) (NNS genotypes)))) (VP (VBD were) (VP (VBN placed) (NP-1 (-NONE- *)) (PP-TMP (IN at) (NP (NP (NN weaning)) (-LRB- -LRB-) (NP (NP (CD three) (NNS weeks)) (PP (IN of) (NP (NN age)))) (-RRB- -RRB-))) (PP (IN on) (NP (DT a) (JJ normal) (NN chow) (NN diet))) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 10) (NN %)) (PP (IN of) (NP (NNS calories)))) (VP (VBN derived) (NP (-NONE- *)) (PP (IN from) (NP (NN fat))))) (: ;) (NP (NN D12450B)) (, ,) (NP (NP (NNP Research) (NNP Diets)) (, ,) (NP-ADV (NN http://www.researchdiets.com))) (-RRB- -RRB-)))) (. .)) )
( (S (NP-SBJ-1 (JJ Enzymatic) (NN assay) (NNS kits)) (VP (VBD were) (VP (VBN used) (NP-1 (-NONE- *)) (PP-PRP (IN for) (NP (NP (NN determination)) (PP (IN of) (NP (NP (NN plasma) (NNS FFAs) (PRN (-LRB- -LRB-) (NP (NP (NNP Roche)) (, ,) (NP-ADV (NN http://www.roche.com))) (-RRB- -RRB-))) (CC and) (NP (NNS TAGs) (PRN (-LRB- -LRB-) (NP (NP (NNP Sigma) (HYPH -) (NNP Aldrich)) (, ,) (NP-ADV (NN http://www.sigmaaldrich.com))) (-RRB- -RRB-))))))))) (. .)) )
( (S (NP-SBJ-1 (NN Elisa) (NNS kits)) (VP (VBD were) (VP (VBN used) (NP-1 (-NONE- *)) (PP-PRP (IN for) (NP (NP (NNS measurements)) (PP (IN of) (NP (NP (NN leptin) (PRN (-LRB- -LRB-) (NP (NP (NML (NNP R) (CC &) (NNP D)) (NNP Systems)) (, ,) (NP-ADV (NN http://www.rndsystems.com))) (-RRB- -RRB-))) (, ,) (NP (NN insulin) (PRN (-LRB- -LRB-) (NP (NP (NNP DRG) (NNP Diagnostics) (NNP International) (NNP Limited)) (, ,) (NP-ADV (NN http://www.drg-international.com))) (-RRB- -RRB-))) (, ,) (CC and) (NP (NN adiponectin) (PRN (-LRB- -LRB-) (NP (NP (NML (NNP B) (HYPH -) (NNP Bridge)) (NNP International)) (, ,) (NP-ADV (NN http://www.b-bridge.com))) (-RRB- -RRB-))))))) (PP-MNR (VBG according) (PP (IN to) (NP (NP (NNS manufacturers) (POS ')) (NNS instructions)))))) (. .)) )
( (S (S (NP-SBJ-1 (NML (JJ Dual) (HYPH -) (NN energy)) (NN X-ray) (NN absorptiometry) (PRN (-LRB- -LRB-) (NP (NN DEXA)) (, ,) (NP (NP (NNP Lunar) (NNP Corporation)) (, ,) (NP-ADV (NN http://www.lunarcorp.com))) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN used) (NP-1 (-NONE- *)) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB measure) (NP (NN body) (NN composition)))))))) (: ;) (S (NP-SBJ-2 (NP (NP (NN glucose)) (PP-LOC (PP (IN in) (NP (NN blood))) (CC and) (PP (IN in) (NP (NN urine))))) (CC and) (NP (NN food) (NN intake))) (VP (VBD were) (VP (VBN monitored) (NP-2 (-NONE- *)) (PP-LOC (IN in) (NP (DT the) (CD four) (JJ experimental) (NNS genotypes))) (SBAR-ADV (IN as) (S (NP-SBJ-3 (-NONE- *PRO*)) (ADVP (RB previously)) (VP (VBN shown) (NP-3 (-NONE- *)))))))) (PRN (-LRB- [) (NP (CD 2)) (-RRB- ])) (. .)) )
( (HEADING (NP (NP (NN Oxygen) (NN consumption)) (, ,) (NP (NN water) (NN intake)) (, ,) (CC and) (NP (NN locomotor) (NN activity)) (. .))) )
( (S (NP-SBJ-1 (NN Oxygen)) (VP (VBD was) (VP (VBN measured) (NP-1 (-NONE- *)) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (NP (DT an) (NML (CD eight) (HYPH -) (NN chamber)) (NML (JJ open) (HYPH -) (NN circuit)) (ADJP (NN oxygen) (HYPH -) (VBG monitoring)) (NN system)) (VP (VP (VP (VBN attached) (NP (-NONE- *)) (PP (IN to) (NP-2 (-NONE- *RNR*)))) (CC and) (VP (VBN sampled) (NP (-NONE- *)) (PP (IN from) (NP-2 (-NONE- *RNR*))))) (NP-2 (NP (DT the) (NNS chambers)) (PP (IN of) (NP (DT a) (NNP Comprehensive) (NML (NNP Laboratory) (NNP Animal)) (NNP Monitoring) (NNP System) (PRN (-LRB- -LRB-) (NP (NN CLAMS)) (: ;) (NP (NP (NNP Columbus) (NNP Instruments)) (, ,) (NP-ADV (NN http://www.colinst.com))) (-RRB- -RRB-))))))))))) (. .)) )
( (S (NP-SBJ-1 (NP (NN Water)) (VP (VBN consumed) (NP (-NONE- *)))) (VP (VBD was) (ADVP (RB also)) (VP (VBN measured) (NP-1 (-NONE- *)) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (NN CLAMS)))))) (. .)) )
( (S (NP-SBJ-1 (NNS Mice)) (VP (VBD were) (VP (VBN housed) (NP-1 (-NONE- *)) (ADVP (RB individually)) (PP-LOC (IN in) (NP (NP (ADJP (RB specially) (VBN built)) (NN Plexiglass) (NNS cages)) (VP (VBN maintained) (NP (-NONE- *)) (PP (IN at) (NP (CD 22) (NN °C))) (PP (IN under) (NP (DT an) (VBG alternating) (NML (NML (NML (CD 12)) (PP (SYM :) (NP (CD 12)))) (HYPH -) (NN h)) (NML (NN light) (SYM -) (NN dark)) (NN cycle) (PRN (-LRB- -LRB-) (NP (NN light) (NN period)) (NP (NP (CD 08:00)) (PP (SYM –) (NP (CD 20:00)))) (-RRB- -RRB-))))))))) (. .)) )
( (S (NP-SBJ-1 (NN Sample) (NN air)) (VP (VBD was) (ADVP (RB sequentially)) (VP (VBN passed) (NP-1 (-NONE- *)) (PP (IN through) (NP (NML (NML (NML (NN oxygen)) (-LRB- -LRB-) (NML (NN O2))) (-RRB- -RRB-) (CC and) (NML (NML (NN carbon) (NN dioxide)) (-LRB- -LRB-) (NML (NN CO2)))) (-RRB- -RRB-) (NNS sensors) (PRN (-LRB- -LRB-) (NP (NNP Columbus) (NNP Instruments)) (-RRB- -RRB-)))) (PP-PRP (IN for) (NP (NP (NN determination)) (PP (IN of) (NP (NML (NN O2) (CC and) (NN CO2)) (NN content))))))) (. .)) )
( (S (NP-SBJ-1 (NNS Mice)) (VP (VBD were) (VP (VBN acclimatized) (NP-1 (-NONE- *)) (PP (IN to) (NP (VBG monitoring) (NNS cages))) (PP-TMP (IN for) (NP (CD 72) (NN h))) (PP-TMP (IN before) (NP (NNS data) (NN collection))))) (. .)) )
( (S (NP-SBJ-1 (NNS Mice)) (VP (VBD were) (VP (VBN weighed) (NP-1 (-NONE- *)) (PP-TMP (IN before) (NP (DT each) (NN trial))))) (. .)) )
( (S (NP-SBJ-1 (NP (JJ Ambulatory) (NN activity)) (PP (IN of) (NP (ADJP (RB individually) (VBN housed)) (NNS mice)))) (VP (VBD was) (VP (VBN evaluated) (NP-1 (-NONE- *)) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (DT an) (NML (CD eight) (HYPH -) (NN cage)) (NN rack) (NML (NN OPTO) (HYPH -) (NN M3)) (NN Sensor) (NN system) (PRN (-LRB- -LRB-) (NP (NNP Columbus) (NNP Instruments)) (-RRB- -RRB-))))))) (. .)) )
( (S (NP-SBJ-1 (JJ Cumulative) (NML (JJ ambulatory) (NN activity)) (NNS counts)) (VP (VBD were) (VP (VBN recorded) (NP-1 (-NONE- *)) (NP-TMP (QP (DT every) (CD 5)) (NN min)) (PP (IN throughout) (NP (DT the) (NML (NN light) (CC and) (NN dark)) (NNS cycles))))) (. .)) )
( (HEADING (NP (NP (NNS Calculations)) (PP (IN of) (NP (NP (NN energy)) (VP (VBN lost) (NP (-NONE- *)) (PP (IN in) (NP (NN urine)))))) (. .))) )
( (S (NP-SBJ-1 (NP (NN Energy)) (VP (VBN lost) (NP (-NONE- *)) (PP-MNR (IN in) (NP (NN urine))))) (VP (VBD was) (VP (VBN calculated) (NP-1 (-NONE- *)) (ADVP (RB accordingly)) (SBAR-ADV (IN as) (S (NP-SBJ-2 (-NONE- *PRO*)) (ADVP-TMP (RB previously)) (VP (VBN shown) (NP-2 (-NONE- *)) (ADVP-TMP (RB before)) (PRN (-LRB- [) (NP (CD 56)) (-RRB- ]))))) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (DT the) (VBG following) (NNS calculations)))))) (: :)) )
( (FRAG (S-FRM (NP-SBJ (NP (NP (NN Energy)) (VP (VBN lost) (NP (-NONE- *)) (PP (IN in) (NP (NN urine))))) (NP-ADV (NP (NN kJ)) (PP (SYM /) (NP (NN day))))) (VP (SYM =) (-LRB- -LRB-) (NP (NP (NP (NN glucose)) (PP (IN in) (NP (NN urine))) (-LRB- [) (NP-ADV (NP (NN mMol)) (PP (SYM /) (NP (NN l)))) (-RRB- ]) (PP (SYM /) (NP (CD 1,000)))) (-RRB- -RRB-) (SYM ×) (NP (NML (JJ molecular) (NN weight)) (NN glucose)) (SYM ×) (-LRB- -LRB-) (NP (NP (NN water) (NN intake)) (-LRB- [) (NP-ADV (NP (NN ml)) (PP (SYM /) (NP (NN day)))) (-RRB- ]) (PP (SYM /) (NP (CD 1,000)))) (-RRB- -RRB-) (SYM ×) (NP (NN E) (NN densitycarb))))) (: ;) (S-FRM (NP-SBJ (NN E) (NN densitycarb)) (VP (SYM =) (NP (NP (NN energy) (NN density)) (VP (VBN related) (NP (-NONE- *)) (PP (IN to) (NP (NP (NNS oxidations)) (PP-LOC (IN within) (NP (DT the) (NN body))))))) (PP (IN for) (NP (NNS carbohydrates))) (SBAR-PRP (IN as) (S-FRM (NP-SBJ (NN glucose)) (VP (SYM =) (NP (NP (CD 15.76) (NNS kJ)) (PP (SYM /) (NP (NN g))))))))) (. .)) )
( (HEADING (NP (NP (NN RNA) (NN preparation)) (CC and) (NP (NML (JJ real) (HYPH -) (NN time)) (JJ quantitative) (NN RT) (HYPH -) (NN PCR)) (. .))) )
( (S (NP-SBJ-1 (JJ Total) (NN RNA)) (VP (VBD was) (VP (VBN isolated) (NP-1 (-NONE- *)) (PP (IN from) (NP (NP (NNS islets)) (CC and) (NP (NNS tissues) (NNS samples)))) (PP-MNR (VBG according) (PP (IN to) (NP (NP (NP (DT the) (NN manufacturer) (POS 's)) (NNS instructions) (PRN (-LRB- -LRB-) (NP (NNP RNAeasy) (NN kit)) (, ,) (NP (NP (NNP Qiagen)) (, ,) (NP-ADV (NN http://www.qiagen.com))) (-RRB- -RRB-))) (CC and) (NP (NN STAT60) (PRN (-LRB- -LRB-) (NP (NN Tel) (HYPH -) (NN Test)) (, ,) (NP-ADV (NN http://www.isotexdiagnostics.com/tel-test.html)) (-RRB- -RRB-)))))))) (. .)) )
( (S (NP-SBJ-1 (NML (JJ Real) (HYPH -) (NN time)) (JJ quantitative) (NN PCR)) (VP (VBD was) (VP (VBN performed) (NP-1 (-NONE- *)) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (DT a) (NN TaqMan) (CD 7900) (PRN (-LRB- -LRB-) (NP (NP (NNP Applied) (NNP Biosystems)) (, ,) (NP-ADV (NN http://www.appliedbiosystems.com))) (-RRB- -RRB-))) (PP-MNR (VBG according) (PP (IN to) (NP (JJ standard) (NNS protocols)))))))) (. .)) )
( (HEADING (NP (NML (NNP Western) (NN blot)) (NNS analyses) (. .))) )
( (S (NP-SBJ-1 (DT The) (NN tissue) (NNS samples) (PRN (-LRB- -LRB-) (NP (CD 40) (NN μg)) (-RRB- -RRB-))) (VP (VBD were) (VP (VBN subjected) (NP-1 (-NONE- *)) (PP (IN to) (NP (NP (NN SDS) (HYPH -) (NN PAGE)) (PP (IN on) (NP (NML (CD 8) (NN %)) (NN polyacrylamide) (NNS gels))))))) (. .)) )
( (S (NP-SBJ-1 (NNS Proteins)) (VP (VBD were) (ADVP (RB then)) (ADVP (RB electrophoretically)) (VP (VBN transferred) (NP-1 (-NONE- *)) (PP-DIR (IN to) (NP (NML (NN polyvinylidene) (NN difluoride)) (NNS filters))))) (. .)) )
( (S (PP-TMP (IN After) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG transferring)))) (, ,) (NP-SBJ-1 (DT the) (NNS filters)) (VP (VBD were) (VP (VBN blocked) (NP-1 (-NONE- *)) (PP-MNR (IN with) (NP (NP (NML (CD 5) (NN %)) (JJ nonfat) (JJ dry) (NN milk)) (PP (IN in) (NP (NML (NN TBS) (HYPH -) (NN Tween)) (CD 20))))) (S-ADV (NP-SBJ-2 (-NONE- *PRO*)) (VP (VBN followed) (NP-2 (-NONE- *)) (PP (IN by) (NP-LGS (NP (NN incubation)) (PP (IN with) (NP (NML (NML (JJ primary) (NN GLUT4)) (CC and) (NML (NML (JJ extracellular) (ADJP (NN signal) (HYPH -) (VBN regulated)) (NN kinase) (NML (CD 1) (SYM /) (CD 2))) (-LRB- -LRB-) (NML (NN ERK1) (HYPH /) (CD 2)))) (-RRB- -RRB-) (NNS antibodies) (PRN (-LRB- -LRB-) (NP (NP (NNP Promega)) (, ,) (NP-ADV (NN http://www.promega.com))) (-RRB- -RRB-)))))) (ADVP-TMP (RB overnight)))))) (. .)) )
( (S (NP-SBJ-1 (DT The) (NNS bands)) (VP (VBD were) (VP (VBN quantified) (NP-1 (-NONE- *)) (PP-MNR (IN by) (NP (VBG scanning) (NN densitometry))))) (. .)) )
( (HEADING (NP (NP (NN Light) (NN microscopy)) (CC and) (NP (JJ immunohistochemcal) (NN analysis)) (. .))) )
( (S (NP-SBJ-1 (NP (NN Tissue) (NNS samples)) (PP (IN for) (NP (ADJP (JJ morphological) (CC and) (JJ immunohistochemcal)) (NN analysis)))) (VP (VBD were) (VP (VBN prepared) (NP-1 (-NONE- *)) (PP-MNR (VBG according) (PP (IN to) (NP (VBN published) (NNS protocols)))) (PRN (-LRB- [) (NP (CD 2)) (-RRB- ])))) (. .)) )
( (S (S (NP-SBJ-1 (NP (JJ Morphometric) (NNS analyses)) (PP (IN of) (NP (NP (NN adipose) (NN tissue)) (CC and) (NP (NN pancreas) (NNS sections))))) (VP (VBD were) (VP (VBN acquired) (NP-1 (-NONE- *)) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (DT a) (NML (NML (JJ digital) (NN camera)) (CC and) (NML (NN microscope))) (PRN (-LRB- -LRB-) (NP (NP (NNP Olympus) (NN BX41)) (, ,) (NP-ADV (NN http://www.olympus.com))) (-RRB- -RRB-)))))))) (, ,) (CC and) (S (NP-SBJ-2 (NN cell) (NNS areas)) (VP (VBD were) (VP (VBN measured) (NP-2 (-NONE- *)) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (NN AnalySIS) (NN software) (PRN (-LRB- -LRB-) (NP (NP (NNP Soft) (NNP Imaging) (NNP System)) (, ,) (NP-ADV (NN http://www.soft-imaging.net))) (-RRB- -RRB-)))))))) (. .)) )
( (S (PP (IN For) (NP (NN adipose) (NN tissue))) (, ,) (NP-SBJ-1 (NP (CD two) (NNS fields)) (PP (IN from) (NP (DT each) (NN section)))) (VP (VBD were) (VP (VBN analysed) (NP-1 (-NONE- *)) (S-PRP (NP-SBJ (-NONE- *PRO*)) (VP (TO to) (VP (VB obtain) (NP (NP (DT the) (JJ mean) (NN cell) (HYPH -) (NN area)) (PP (IN per) (NP (NN animal))) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (NP (CD 5)) (PP (IN per) (NP (NN genotype)))))) (-RRB- -RRB-)))))))) (. .)) )
( (S (NP-SBJ-1 (NP (NML (NML (NML (DT The) (NN Computer) (VBN Assisted) (NN Stereology) (NN Toolbox)) (-LRB- -LRB-) (NML (NN CAST))) (-RRB- -RRB-) (CD 2.0)) (NN system)) (PP (IN from) (NP (NNP Olympus)))) (VP (VBD was) (VP (VBN used) (NP-1 (-NONE- *)) (S-PRP (NP-SBJ-1 (-NONE- *PRO*)) (VP (TO to) (VP (VB perform) (NP (NP (DT all) (NNS measurements)) (PP-LOC (IN in) (NP (DT the) (NN pancreas)))) (PP-MNR (VBG according) (PP (IN to) (NP (VBN published) (NNS protocols))))))) (PRN (-LRB- [) (NP (CD 57)) (-RRB- ])))) (. .)) )
( (HEADING (NP (NP (NN Isolation) (CC and) (NN culture)) (PP (IN of) (NP (JJ pancreatic) (NNS islets))) (. .))) )
( (S (NP-SBJ-1 (DT The) (NN pancreas)) (VP (VBD was) (VP (VBN injected) (NP-1 (-NONE- *)) (PP (IN via) (NP (DT the) (NN bile) (NN duct))) (PP-MNR (IN with) (NP (NP (JJ cold) (NP (NNP Hank) (POS 's)) (NN solution)) (VP (VBG containing) (NP (NML (CD 0.4) (NN %)) (PRN (-LRB- -LRB-) (NP (NN w) (SYM /) (NN v)) (-RRB- -RRB-)) (NN liberase) (PRN (-LRB- -LRB-) (NP (NNP Roche)) (-RRB- -RRB-)))))))) (. .)) )
( (S (S (NP-SBJ-1=3 (DT The) (NN pancreas)) (VP (VBD was) (VP=4 (VP (VBN removed) (NP-1 (-NONE- *))) (, ,) (VP (VBN digested) (NP-1 (-NONE- *)) (PP-TMP (IN for) (NP (QP (CD 15) (SYM –) (CD 30)) (NN min))))))) (, ,) (CC and) (S (NP-SBJ-2=3 (NNS islets)) (VP=4 (VBN collected) (NP-2 (-NONE- *)) (PP-MNR (IN by) (NP (VBG handpicking))))) (. .)) )
( (S (NP-SBJ-1 (VBN Isolated) (NNS islets)) (VP (VBD were) (VP (VBN cultured) (NP-1 (-NONE- *)) (ADVP-TMP (RB overnight)) (PP (IN in) (NP (NML (NN h) (HYPH -) (NN cell)) (NN medium) (PRN (-LRB- -LRB-) (NP (NN SBMI) (CD 06)) (, ,) (NP (NP (NN hcell) (NN technology)) (, ,) (NP-ADV (NN http://www.hcell.com))) (-RRB- -RRB-)))) (PP (IN at) (NP (CD 37) (NN °C))) (PP (IN in) (NP (NP (NML (CD 5) (NN %)) (NN CO2)) (PP (IN in) (NP (NN air))))))) (. .)) )
( (S (NP-SBJ-1 (NNS Islets)) (VP (VBD were) (VP (VBN used) (NP-1 (-NONE- *)) (NP-TMP (NP (DT the) (NN day)) (PP (IN after) (NP (NN isolation)))) (PP-PRP (IN for) (NP (NP (NML (NN insulin) (NN secretion)) (NNS studies)) (CC or) (NP (NN RNA) (NN extraction)))))) (. .)) )
( (HEADING (NP (NML (NN Insulin) (NN secretion)) (NNS studies) (. .))) )
( (S (NP-SBJ-1 (NP (NN Insulin) (NN secretion)) (PP (IN from) (NP (VBN isolated) (NNS islets) (PRN (-LRB- -LRB-) (NP (NP (CD five) (NNS islets)) (PP (SYM /) (NP (NN well)))) (-RRB- -RRB-))))) (VP (VBD was) (VP (VBN measured) (NP-1 (-NONE- *)) (PP-TMP (IN during) (NP (NP (NML (CD 1) (HYPH -) (NN hr)) (JJ static) (NNS incubations)) (PP (IN in) (NP (NP (NML (NNP Krebs) (HYPH —) (NNP Ringer)) (NNP Buffer)) (VP (VBG containing) (NP (NP (CC either) (NP (NML (CD 1) (NN mM)) (NN glucose)) (, ,) (NP (NML (CD 16.7) (NN mM)) (NN glucose)) (, ,) (CC or) (NP (NML (CD 16.7) (NN mM)) (NN glucose))) (CC plus) (NP (NP (NML (CD 200) (NN μM)) (NN tolbutamide)) (PP (IN in) (NP (NN DMSO)))))))))))) (. .)) )
( (S (NP-SBJ-1 (DT The) (NNS supernatants)) (VP (VBD were) (VP (VBN assayed) (NP-1 (-NONE- *)) (PP (IN for) (NP (NN insulin))))) (. .)) )
( (S (NP-SBJ-1 (NN Insulin) (NN content)) (VP (VBD was) (VP (VBN extracted) (NP-1 (-NONE- *)) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (NML (NML (CD 95)) (PP (SYM :) (NP (CD 5)))) (NML (NML (NN ethanol)) (PP (SYM /) (NP (JJ acetic) (NN acid))))))))) (. .)) )
( (S (NP-SBJ-1 (NN Insulin)) (VP (VBD was) (VP (VBN measured) (NP-1 (-NONE- *)) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (DT a) (NML (NN Mouse) (NN Insulin)) (NN ELISA) (NN kit) (PRN (-LRB- -LRB-) (NP (NP (NNP Mercodia)) (, ,) (NP-ADV (NN http://www.mercodia.com))) (-RRB- -RRB-))))))) (. .)) )
( (S (NP-SBJ-1 (NNS Islets)) (VP (VBD were) (VP (VBN isolated) (NP-1 (-NONE- *)) (PP (IN from) (NP (NP (CD three) (NNS mice)) (PP (IN of) (NP (DT each) (NN genotype))))) (PP (IN for) (NP (DT these) (NNS experiments))))) (. .)) )
( (S (ADVP (RB Thus)) (, ,) (NP-SBJ (DT the) (NNS data)) (VP (VBP are) (NP-PRD (NP (DT the) (NN mean)) (PP (IN of) (NP (NP (CD three) (JJ separate) (NNS experiments)) (, ,) (SBAR (WHPP-2 (IN in) (WHNP (WDT which))) (S (NP-SBJ-1 (NNS data)) (VP (VBD were) (VP (VBN collected) (NP-1 (-NONE- *)) (PP (IN for) (NP (DT each) (NN test) (NN solution))) (PP (IN from) (NP (NP (NP (CD six) (NNS samples)) (NP (DT each))) (PP (IN of) (NP (CD five) (NNS islets))))) (PP-LOC-2 (-NONE- *T*)))))))))) (. .)) )
( (S (PP (IN For) (NP (DT each) (NN sample))) (, ,) (NP-SBJ-1 (NN insulin) (NN release)) (VP (VBD was) (VP (VBN normalised) (NP-1 (-NONE- *)) (PP (IN to) (NP (NN insulin) (NN content))))) (. .)) )
( (HEADING (NP (NN ITT) (. .))) )
( (S (NP-SBJ-1 (NP (NNS ITTs)) (PP (IN on) (NP (ADJP (NP (CD four) (HYPH -) (NN week)) (HYPH -) (JJ old)) (NNS mice)))) (VP (VBD were) (VP (VBN performed) (NP-1 (-NONE- *)) (SBAR-ADV (IN as) (S (NP-SBJ-2 (-NONE- *PRO*)) (ADVP (RB previously)) (VP (VBN published) (NP-2 (-NONE- *))))) (PRN (-LRB- [) (NP (CD 58)) (-RRB- ])))) (. .)) )
( (HEADING (NP (NN Lipid) (NN profiling) (. .))) )
( (S (S (S (PP (IN For) (NP (NN WAT) (CC and) (NN muscle))) (, ,) (NP-SBJ-1 (DT the) (NN tissue) (NN sample) (PRN (-LRB- -LRB-) (NP (CD 50) (NN mg)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN homogenized) (NP-1 (-NONE- *)) (PP-MNR (IN with) (NP (NML (CD 0.15) (NN M)) (NN sodium) (NN chloride) (PRN (-LRB- -LRB-) (NP (CD 300) (NN μl)) (-RRB- -RRB-))))))) (, ,) (CC and) (S (NP-SBJ-2 (DT the) (NNS lipids)) (VP (VBD were) (VP (VP (VBN extracted) (NP-2 (-NONE- *)) (PP-MNR (IN with) (NP (NP (CD 2) (NN ml)) (PP (IN of) (NP (NP (NN chloroform)) (PP (SYM :) (NP (NN methanol))) (PRN (-LRB- -LRB-) (NP (NP (CD 2)) (PP (SYM :) (NP (CD 1)))) (-RRB- -RRB-))))))) (CC and) (VP (VBN used) (NP-2 (-NONE- *)) (PP (IN for) (NP (NN LC) (HYPH /) (NN MS)))))))) (SBAR-ADV (IN as) (S (NP-SBJ-3 (-NONE- *PRO*)) (ADVP (RB previously)) (VP (VBN described) (NP-3 (-NONE- *))))) (PRN (-LRB- [) (NP (CD 2)) (-RRB- ])) (. .)) )
( (S (PP (IN For) (NP (NN liver) (CC and) (NNS islets))) (, ,) (NP-SBJ-1 (NP (DT an) (NN aliquot) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 20) (NN μl)) (PP (IN for) (NP (NN liver)))) (CC or) (NP (NP (CD 10) (NN μl)) (PP (IN for) (NP (NNS islets))))) (-RRB- -RRB-))) (PP (IN of) (NP (NP (DT an) (JJ internal) (JJ standard) (NN mixture) (PRN (-LRB- -LRB-) (NP (NP (CD 11) (NN reference) (NNS compounds)) (PP (IN at) (NP (NP (NN concentration) (NN level)) (NP-ADV (NP (QP (CD 8) (SYM –) (CD 10)) (NN μg)) (PP (SYM /) (NP (NN ml))))))) (-RRB- -RRB-))) (, ,) (NP (NP (CD 50) (NN μl)) (PP (IN of) (NP (NML (CD 0.15) (NN M)) (NN sodium) (NN chloride))) (-LRB- -LRB-) (PP (IN for) (NP (NN liver)))) (-RRB- -RRB-) (, ,) (CC and) (NP (NP (NN chloroform)) (PP (SYM :) (NP (NN methanol))) (PRN (-LRB- -LRB-) (NP (NP (CD 2)) (PP (SYM :) (NP (CD 1)))) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 200) (NN μl)) (PP (IN for) (NP (NN liver)))) (CC or) (NP (NP (CD 90) (NN μl)) (PP (IN for) (NP (NNS islets))))) (-RRB- -RRB-)))))) (VP (VBD was) (VP (VBN added) (NP-1 (-NONE- *)) (PP (IN to) (NP (DT the) (NN tissue) (NN sample))) (PRN (-LRB- -LRB-) (NP (QP (CD 20) (SYM –) (CD 30)) (NN mg)) (-RRB- -RRB-)))) (. .)) )
( (S (NP-SBJ-1 (DT The) (NN sample)) (VP (VBD was) (VP (VP (VBN homogenized) (NP-1 (-NONE- *))) (, ,) (VP (VBN vortexed) (NP-1 (-NONE- *)) (-LRB- -LRB-) (NP-EXT (NP (NP (CD 2) (NNS min)) (PP (IN for) (NP (NN liver)))) (CC or) (NP (NP (CD 15) (NNS s)) (PP (IN for) (NP (NNS islets))))) (-RRB- -RRB-)) (, ,) (VP (VB let) (S (NP-SBJ-1 (-NONE- *)) (VP (TO to) (VP (VB stand) (-LRB- -LRB-) (NP-EXT (NP (NP (CD 1) (NN h)) (PP (IN for) (NP (NN liver)))) (, ,) (NP (NP (CD 20) (NN min)) (PP (IN for) (NP (NNS islets))))) (-RRB- -RRB-))))) (, ,) (CC and) (VP (VBN centrifuged) (NP-1 (-NONE- *)) (PP (IN at) (NP (CD 10,000) (NN RPM))) (PP-TMP (IN for) (NP (CD 3) (NNS min)))))) (. .)) )
( (S (S (PP (IN From) (NP (DT the) (VBN separated) (JJR lower) (NN phase))) (, ,) (NP-SBJ-1 (DT an) (NN aliquot)) (VP (VBD was) (VP (VBN mixed) (NP-1 (-NONE- *)) (PP (IN with) (NP (NP (CD 10) (NN μl)) (PP (IN of) (NP (NP (DT a) (VBN labelled) (JJ standard) (NN mixture)) (-LRB- -LRB-) (NP (NP (CD three) (JJ stable) (ADJP (NN isotope) (HYPH -) (VBN labelled)) (NN reference) (NNS compounds)) (PP (IN at) (NP (NP (NML (NN concentration) (NN level)) (QP (CD 9) (SYM –) (CD 11)) (NN μg)) (PP (SYM /) (NP (NN ml)))))) (-RRB- -RRB-)))))))) (, ,) (CC and) (S (NP-SBJ-2 (NML (QP (CD 0.5) (SYM –) (CD 1.0)) (NN μl)) (NN injection)) (VP (VBD was) (VP (VBN used) (NP-2 (-NONE- *)) (PP (IN for) (NP (NML (NN LC) (SYM /) (NN MS)) (NN analysis)))))) (. .)) )
( (S (NP-SBJ-1 (JJ Total) (NN lipid) (NNS extracts)) (VP (VBD were) (VP (VBN analysed) (NP-1 (-NONE- *)) (PP-MNR (IN on) (NP (NP (DT a) (NML (NNP Waters) (NML (NN Q) (HYPH -) (NN Tof)) (NN Premier)) (NN mass) (NN spectrometer) (PRN (-LRB- -LRB-) (NP (NN http://www.waters.com)) (-RRB- -RRB-))) (VP (VBN combined) (NP (-NONE- *)) (PP (IN with) (NP (DT an) (NNP Acquity) (NNP Ultra) (NNP Performance) (NNP LC) (PRN (-LRB- -LRB-) (NP (NN UPLC)) (-RRB- -RRB-))))))))) (. .)) )
( (S (NP-SBJ (NP (DT The) (NN column)) (, ,) (SBAR (WHNP-1 (WDT which)) (S (NP-SBJ-1 (-NONE- *T*)) (VP (VBD was) (VP (VBN kept) (NP-1 (-NONE- *)) (PP (IN at) (NP (CD 50) (NN °C)))))))) (, ,) (VP (VBD was) (NP-PRD (NP (DT an) (NML (NNP Acquity) (NN UPLC) (NN BEH) (NN C18)) (NML (NML (CD 10)) (PP (SYM ×) (NP (CD 50)))) (NN mm)) (PP (IN with) (NP (NML (CD 1.7) (NN μm)) (NNS particles))))) (. .)) )
( (S (NP-SBJ (DT The) (JJ binary) (NN solvent) (NN system) (PRN (-LRB- -LRB-) (NP (NP (NN flow) (NN rate)) (NP-ADV (NP (CD 0.200) (NN ml)) (PP (SYM /) (NP (NN min))))) (-RRB- -RRB-))) (VP (VBD included) (NP (LST (LS A)) (, ,) (NN water) (PRN (-LRB- -LRB-) (NP (NP (NML (CD 1) (NN %)) (CD 1) (NN M) (NN NH4Ac)) (, ,) (NP (NML (CD 0.1) (NN %)) (NN HCOOH))) (-RRB- -RRB-))) (, ,) (CC and) (NP (LST (LS B)) (, ,) (NML (NN LC) (SYM /) (NN MS) (NN grade) (PRN (-LRB- -LRB-) (NP (NP (NNP Rathburn)) (, ,) (NP-ADV (NN http://www.rathburn.co.uk))) (-RRB- -RRB-))) (NN acetonitrile) (HYPH /) (NN isopropanol) (PRN (-LRB- -LRB-) (NP (NP (CD 5)) (PP (SYM :) (NP (CD 2)))) (, ,) (NP (NP (NML (CD 1) (NN %)) (CD 1) (NN M) (NN NH4Ac)) (, ,) (NP (NML (CD 0.1) (NN %)) (NN HCOOH))) (-RRB- -RRB-)))) (. .)) )
( (S (NP-SBJ-1 (DT The) (NN gradient)) (VP (VP (VBD started) (PP (IN from) (NP (NP (NML (CD 65) (NN %)) (NN A)) (HYPH /) (NP (NML (CD 35) (NN %)) (NN B))))) (, ,) (VP (VBD reached) (NP (NML (CD 100) (NN %)) (NN B)) (PP-TMP (IN in) (NP (CD 6) (NNS min)))) (, ,) (CC and) (VP (VBD remained) (ADVP (RB there)) (PP-EXT (IN for) (NP (DT the) (JJ next) (CD 7) (NNS min))))) (. .)) )
( (S (NP-SBJ (NP (DT The) (JJ total) (NN run) (NN time)) (PP (IN per) (NP (NN sample))) (, ,) (PP (VBG including) (NP (DT a) (NML (CD 5) (NN min)) (NN re-equilibration) (NN step)))) (, ,) (VP (VBD was) (NP-PRD (CD 18) (NNS min))) (. .)) )
( (S (NP-SBJ-1 (NP (DT The) (NN temperature)) (PP (IN of) (NP (DT the) (NN sample) (NN organizer)))) (VP (VBD was) (VP (VBN set) (NP-1 (-NONE- *)) (PP (IN at) (NP (CD 10) (NN °C))))) (. .)) )
( (S (NP-SBJ-1 (NN Mass) (NN spectrometry)) (VP (VBD was) (VP (VBN carried) (NP-1 (-NONE- *)) (PRT (RP out)) (PP (IN on) (NP (NP (NML (NN Q) (HYPH -) (NN Tof)) (NN Premier) (PRN (-LRB- -LRB-) (NP (NNP Waters)) (-RRB- -RRB-))) (VP (VBN run) (NP (-NONE- *)) (PP (IN in) (NP (NML (NN ESI) (SYM +)) (NN mode)))))))) (. .)) )
( (S (NP-SBJ-1 (DT The) (NNS data)) (VP (VBD were) (VP (VBN collected) (NP-1 (-NONE- *)) (PP (IN over) (NP (NP (DT the) (NN mass) (NN range)) (PP (IN of) (NP (NML (NN m) (SYM /) (NN z)) (QP (CD 300) (HYPH –) (CD 1,200)))))) (PP (IN with) (NP (NP (NN scan) (NN duration)) (PP (IN of) (NP (CD 0.2) (NNS s))))))) (. .)) )
( (S (S (NP-SBJ-1 (DT The) (NN source) (NN temperature)) (VP (VBD was) (VP (VBN set) (NP-1 (-NONE- *)) (PP (IN at) (NP (CD 120) (NN °C)))))) (, ,) (CC and) (S (NP-SBJ-2 (NN nitrogen)) (VP (VBD was) (VP (VBN used) (NP-2 (-NONE- *)) (PP (IN as) (NP (NN desolvation) (NN gas) (PRN (-LRB- -LRB-) (NP (NP (CD 800) (NNS l)) (PP (SYM /) (NP (NN h)))) (-RRB- -RRB-)))) (PP (IN at) (NP (CD 250) (NN °C)))))) (. .)) )
( (S (NP-SBJ (NP (DT The) (NNS voltages)) (PP (IN of) (NP (NP (DT the) (NN sampling) (NN cone)) (CC and) (NP (NN capillary))))) (VP (VBD were) (NP-PRD (NP (CD 39) (CD V)) (CC and) (NP (CD 3.2) (NN kV))) (, ,) (ADVP (RB respectively))) (. .)) )
( (S (NP-SBJ-1 (NN Reserpine) (PRN (-LRB- -LRB-) (NP (NP (CD 50) (NN μg)) (PP (SYM /) (NP (NN l)))) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN used) (NP-1 (-NONE- *)) (PP (IN as) (NP (DT the) (NN lock) (NN spray) (NN reference) (NN compound) (PRN (-LRB- -LRB-) (NP (NP (CD 5) (NN μl)) (PP (SYM /) (NP (NN min)))) (: ;) (NP (NML (NML (CD 10) (NN s)) (HYPH -) (NN scan)) (NN frequency)) (-RRB- -RRB-)))))) (. .)) )
( (S (NP-SBJ-1 (NN Data) (NN processing)) (VP (VBD was) (VP (VBN performed) (NP-1 (-NONE- *)) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (DT the) (NN MZmine) (NN software)))) (PRN (-LRB- [) (NP (CD 59)) (-RRB- ])))) (. .)) )
( (S (NP-SBJ-1 (NN Identification)) (VP (VBD was) (VP (VBN performed) (NP-1 (-NONE- *)) (UCP-MNR (PP (VBN based) (PP (IN on) (NP (NP (DT an) (JJ internal) (NN reference) (NN database)) (PP (IN of) (NP (NN lipid) (NNS species)))))) (, ,) (CC or) (S (NP-SBJ (-NONE- *PRO*)) (ADVP (RB alternatively)) (VP (VBG utilizing) (NP (DT the) (JJ tandem) (NN mass) (NN spectrometry))))))) (. .)) )
( (S (NP-SBJ-1 (DT The) (JJ statistical) (NNS analyses)) (VP (VBD were) (VP (VBN performed) (NP-1 (-NONE- *)) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (NP (NNP Matlab) (PRN (-LRB- -LRB-) (NP (NP (NNS Mathworks)) (, ,) (NP-ADV (NN http://www.mathworks.com))) (-RRB- -RRB-))) (CC and) (NP (DT the) (NNP Matlab) (NN library) (NN PLS) (NN Toolbox) (PRN (-LRB- -LRB-) (NP (NP (NNP Eigenvector) (NNP Research)) (, ,) (NP-ADV (NN http://www.eigenvector.com))) (-RRB- -RRB-)))))))) (. .)) )
( (S (NP-SBJ-1 (JJ Tandem) (NN mass) (NN spectrometry)) (VP (VBD was) (VP (VBN used) (NP-1 (-NONE- *)) (PP (IN for) (NP (NP (DT the) (NN identification)) (PP (IN of) (NP (VBN selected) (NN lipid) (NNS species))))))) (. .)) )
( (S (NP-SBJ-1 (NML (NN MS) (HYPH /) (NN MS)) (NNS runs)) (VP (VBD were) (VP (VBN performed) (NP-1 (-NONE- *)) (PP-MNR (IN by) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (NP (NML (NN ESI) (SYM +)) (NN mode)) (, ,) (NP (NP (NN collision) (NN energy) (NN ramp)) (PP (IN from) (NP (QP (CD 15) (SYM –) (CD 30)) (NN V)))) (, ,) (CC and) (NP (NP (NN mass) (NN range)) (VP (VBG starting) (PP (IN from) (NP (NML (NN m) (SYM /) (NN z)) (CD 150))))))))))) (. .)) )
( (S (NP-SBJ (DT The) (JJ other) (NNS conditions)) (VP (VBD were) (SBAR-PRD (IN as) (S (NP-SBJ-1 (-NONE- *PRO*)) (VP (VBN shown) (NP-1 (-NONE- *)) (PP (IN in) (NP (DT the) (NNP Protocol) (NN S1))))))) (. .)) )
( (HEADING (NP (NNS Statistics) (. .))) )
( (S (NP-SBJ-1 (NNS Results)) (VP (VBD were) (VP (VBN expressed) (NP-1 (-NONE- *)) (PP (IN as) (NP (NP (NN mean)) (SYM ±) (NP (NP (JJ standard) (NN error)) (PP (IN of) (NP (NN mean)))))))) (. .)) )
( (S (S (NP-SBJ-1=4 (JJ Statistical) (NN analysis)) (VP (VBD was) (VP=3 (VBN performed) (NP-1 (-NONE- *)) (S-MNR (NP-SBJ (-NONE- *PRO*)) (VP (VBG using) (NP (NP (DT a) (ADJP (CD two) (HYPH -) (JJ tailed)) (JJ unpaired) (NN t) (HYPH -) (NN test)) (PP (IN between) (NP (NP (JJ appropriate) (NNS pairs)) (PP (IN of) (NP (NNS groups))))))))))) (, ,) (CC and) (S (NP-SBJ-2=4 (NN significance)) (VP=3 (VBD declared) (NP-2 (-NONE- *)) (SBAR-ADV (IN if) (S (NP-SBJ (NNS p) (HYPH -) (NNS values)) (VP (VBD were) (NP-PRD (QP (JJR less) (IN than) (CD 0.05)))))))) (. .)) )
( (HEADING (NP (JJ Supporting) (NN Information))) )
( (HEADING (NP (NN Figure) (NN S1))) )
( (HEADING (NP (NP (NN Adipose) (NN Tissue)) (CC and) (NP (NN Liver) (NN Gene) (NN Expression)))) )
( (CAPTION (NP (-LRB- -LRB-) (NML (CD 39) (NN KB)) (NN PPT) (-RRB- -RRB-))) )
( (CAPTION (S-IMP (NP-SBJ (-NONE- *PRO*)) (VP (VB Click) (ADVP (RB here)) (PP (IN for) (NP (JJ additional) (NNS data) (NN file)))) (. .))) )
( (HEADING (NP (NN Figure) (NN S2))) )
( (HEADING (NP (NP (NP (NN Water)) (VP (VBN Consumed) (NP (-NONE- *)))) (CC and) (NP (NN Locomotor) (NN Activity)))) )
( (CAPTION (NP (-LRB- -LRB-) (NML (CD 38) (NN KB)) (NN PPT) (-RRB- -RRB-))) )
( (CAPTION (S-IMP (NP-SBJ (-NONE- *PRO*)) (VP (VB Click) (ADVP (RB here)) (PP (IN for) (NP (JJ additional) (NNS data) (NN file)))) (. .))) )
( (HEADING (NP (NN Figure) (NN S3))) )
( (HEADING (NP (NP (NN GLUT4) (NN protein) (NN expression)) (PP-LOC (IN in) (NP (NN WAT))))) )
( (CAPTION (NP (-LRB- -LRB-) (NML (CD 65) (NN KB)) (NN PPT) (-RRB- -RRB-))) )
( (CAPTION (S-IMP (NP-SBJ (-NONE- *PRO*)) (VP (VB Click) (ADVP (RB here)) (PP (IN for) (NP (JJ additional) (NNS data) (NN file)))) (. .))) )
( (HEADING (NP (NN Figure) (NN S4))) )
( (HEADING (NP (NP (NN Gene) (NN Expression)) (PP-LOC (IN in) (NP (NNS Islets))))) )
( (CAPTION (NP (-LRB- -LRB-) (NML (CD 25) (NN KB)) (NN PPT) (-RRB- -RRB-))) )
( (CAPTION (S-IMP (NP-SBJ (-NONE- *PRO*)) (VP (VB Click) (ADVP (RB here)) (PP (IN for) (NP (JJ additional) (NNS data) (NN file)))) (. .))) )
( (HEADING (NP (NN Figure) (NN S5))) )
( (HEADING (NP (NP (NN Gene) (NN Expression)) (PP-LOC (IN in) (NP (NN Muscle))))) )
( (CAPTION (NP (-LRB- -LRB-) (NML (CD 32) (NN KB)) (NN PPT) (-RRB- -RRB-))) )
( (CAPTION (S-IMP (NP-SBJ (-NONE- *PRO*)) (VP (VB Click) (ADVP (RB here)) (PP (IN for) (NP (JJ additional) (NNS data) (NN file)))) (. .))) )
( (HEADING (NP (NN Protocol) (NN S1))) )
( (HEADING (NP (NN POKO) (NN Mouse) (NN Model) (NN Lipidomics) (NN Dataset))) )
( (CAPTION (NP (-LRB- -LRB-) (NML (CD 208) (NN KB)) (NN PDF) (-RRB- -RRB-))) )
( (CAPTION (S-IMP (NP-SBJ (-NONE- *PRO*)) (VP (VB Click) (ADVP (RB here)) (PP (IN for) (NP (JJ additional) (NNS data) (NN file)))) (. .))) )
( (HEADING (NP (NN Table) (NN S1))) )
( (HEADING (NP (NP (NN Tissue) (NNS Weights)) (PP (IN of) (NP (ADJP (NP (CD 16) (HYPH -) (NN Wk)) (HYPH -) (JJ Old)) (JJ Male) (NML (NML (NNP POKO)) (, ,) (NML (NN Ob) (HYPH /) (NN Ob)) (, ,) (NML (NN PPARg2) (NN KO)) (, ,) (CC and) (NML (NN WT))) (NNS mice))))) )
( (CAPTION (NP (-LRB- -LRB-) (NML (CD 29) (NN KB)) (NN PPT) (-RRB- -RRB-))) )
( (CAPTION (S-IMP (NP-SBJ (-NONE- *PRO*)) (VP (VB Click) (ADVP (RB here)) (PP (IN for) (NP (JJ additional) (NNS data) (NN file)))) (. .))) )
( (HEADING (NP (NN Table) (NN S2))) )
( (HEADING (NP (NN Microarray) (NNS Data))) )
( (CAPTION (NP (-LRB- -LRB-) (NML (CD 105) (NN KB)) (NN DOC) (-RRB- -RRB-))) )
( (CAPTION (S-IMP (NP-SBJ (-NONE- *PRO*)) (VP (VB Click) (ADVP (RB here)) (PP (IN for) (NP (JJ additional) (NNS data) (NN file)))) (. .))) )
( (HEADING (NP (NN Table) (NN S3))) )
( (HEADING (NP (NP (NN Pathway) (NN Analysis)) (PP (IN from) (NP (NN Microarray) (NNS Data))))) )
( (CAPTION (NP (-LRB- -LRB-) (NML (CD 112) (NN KB)) (NN XLS) (-RRB- -RRB-))) )
( (CAPTION (S-IMP (NP-SBJ (-NONE- *PRO*)) (VP (VB Click) (ADVP (RB here)) (PP (IN for) (NP (JJ additional) (NNS data) (NN file)))) (. .))) )
( (HEADING (NP (NN Table) (NN S4))) )
( (HEADING (NP (NN Accession) (NNS Numbers))) )
( (CAPTION (NP (NP (NNP GenBank) (PRN (-LRB- -LRB-) (NP (NN http://www.ncbi.nlm.nih.gov/Genbank)) (-RRB- -RRB-)) (NN accession) (NNS numbers)) (PP (IN for) (NP (NP (DT the) (NML (NML (NNS genes)) (CC and) (NML (NN gene) (NNS products)))) (VP (VBN discussed) (NP (-NONE- *)) (PP (IN in) (NP (DT this) (NN paper)))))) (. .))) )
( (CAPTION (NP (-LRB- -LRB-) (NML (CD 58) (NN KB)) (NN DOC) (-RRB- -RRB-))) )
( (CAPTION (S-IMP (NP-SBJ (-NONE- *PRO*)) (VP (VB Click) (ADVP (RB here)) (PP (IN for) (NP (JJ additional) (NNS data) (NN file)))) (. .))) )
( (HEADING (NP (NNS Acknowledgements))) )
( (S (NP-SBJ-1 (NN Animal) (NML (NN care) (CC and) (NN husbandry))) (VP (VBN provided) (NP-1 (-NONE- *)) (PP (IN by) (NP-LGS (NP (NNP J.) (NNP Carter)) (, ,) (NP (NNP S.) (NNP Shelton)) (, ,) (NP (NNP H.) (NNP Wetsby)) (, ,) (NP (NNP H.) (NNP Williams)) (, ,) (NP (NNP A.) (NNP Kant)) (, ,) (NP (NNP J.P.) (NNP Whiting)) (, ,) (CC and) (NP (NNP G.) (NNP Bevan))))) (. .)) )
( (S (NP-SBJ (PRP We)) (VP (VBP thank) (NP (NP (NNP D.) (NNP Lam)) (, ,) (NP (NNP M.) (NNP Dale)) (, ,) (CC and) (NP (NNP K.) (NNP Burling))) (PP (IN for) (NP (PRP$ their) (JJ technical) (NN assistance)))) (. .)) )
( (S (NP-SBJ (PRP We)) (ADVP (RB also)) (VP (VP (VBP thank) (NP=1 (NP (NNP J.) (NNP Skepper)) (CC and) (NP (NNP P.M.) (NNP Coan))) (PP=2 (IN for) (NP (NP (PRP$ their) (NN help)) (PP (IN with) (NP (NP (NN morphometry) (NN analysis)) (PP (IN in) (NP (NN pancreas)))))))) (CC and) (VP (NP=1 (NNP Peter) (NNP Murgatroyd)) (PP=2 (IN for) (NP (NP (PRP$ his) (NN help)) (PP (IN with) (NP (NML (NN oxygen) (NN consumption)) (NNS experiments))))))) (. .)) )
( (S (NP-SBJ (PRP We)) (VP (VBP acknowledge) (NP (NNP Paradigm) (NNP Therapeutics) (PRN (-LRB- -LRB-) (NP (NN http://www.paradigm-therapeutics.co.uk)) (-RRB- -RRB-))) (PP-PRP (IN for) (S-NOM (NP-SBJ (-NONE- *PRO*)) (VP (VBG generating) (NP (DT the) (NN PPARg2) (NN KO) (NN mouse)))))) (. .)) )
( (HEADING (NP (NNS Abbreviations))) )
( (NP (NP (NN DAG)) (: -) (NP (NN diacylglycerol))) )
( (NP (NP (NN GLUT)) (: -) (NP (NN glucose) (NN transporter))) )
( (NP (NP (NN H) (CC and) (NN E)) (: -) (NP (NN haematoxylin) (CC and) (NN eosin))) )
( (NP (NP (NN ITT)) (: -) (NP (NN insulin) (NN tolerance) (NN test))) )
( (NP (NP (NN LC) (HYPH /) (NN MS)) (: -) (NP (NP (NN liquid) (NN chromatography)) (HYPH /) (NP (NN mass) (NN spectrometry)))) )
( (NP (NP (NN MS)) (: -) (NP (JJ Metabolic) (NN Syndrome))) )
( (NP (NP (NN PPARg)) (: -) (NP (ADJP (NP (NN peroxisome) (NN proliferator)) (VBN activated)) (NN receptor) (NN gamma))) )
( (NP (NP (NN PPARg2)) (: -) (NP (ADJP (NP (NN peroxisome) (NN proliferator)) (VBN activated)) (NN receptor) (NN gamma) (CD 2))) )
( (NP (NP (NN PPARGC1a)) (: -) (NP (NN PPARg) (NN coactivator) (CD 1) (NN alpha))) )
( (NP (NP (NN Scd1)) (: -) (NP (NML (NN stearoyl) (HYPH -) (NML (NN coenzyme) (NN A))) (NN desaturase) (CD 1))) )
( (NP (NP (NN TAG)) (: -) (NP (NN triacylglycerol))) )
( (NP (NP (NN WAT)) (: -) (NP (JJ white) (NN adipose) (NN tissue))) )
( (NP (NP (NN WT)) (: -) (NP (JJ wild) (NN type))) )
( (HEADING (NP (NNS Figures) (CC and) (NNS Tables))) )
( (HEADING (NP (NN Figure) (CD 1))) )
( (HEADING (NP (NP (JJ Physiological) (NN Characterisation)) (PP (IN of) (NP (NN POKO) (NN Mouse))))) )
( (CAPTION (S (NP-SBJ-1 (-LRB- -LRB-) (LST (LS A)) (-RRB- -RRB-) (NN Body) (NNS weights) (PRN (-LRB- -LRB-) (FRAG (NP (JJ black) (NNS circles)) (, ,) (NP (NN WT))) (: ;) (FRAG (NP (JJ black) (NNS squares)) (, ,) (NP (NN ob) (HYPH /) (NN ob))) (: ;) (FRAG (NP (JJ white) (NNS circles)) (, ,) (NP (NN PPARg2) (NN KO))) (: ;) (FRAG (NP (JJ white) (NNS squares)) (, ,) (NP (NN POKO))) (-RRB- -RRB-))) (VP (VBP are) (VP (VBN shown) (NP-1 (-NONE- *)) (PP (IN for) (NP (NP (NNS males) (PRN (-LRB- -LRB-) (NP (JJ left)) (-RRB- -RRB-))) (CC or) (NP (NNS females) (PRN (-LRB- -LRB-) (NP (JJ right)) (-RRB- -RRB-))) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (QP (CD 5) (SYM –) (CD 12))))) (-RRB- -RRB-)))))) (. .))) )
( (CAPTION (S (S-FRM (LST (SYM *)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.05)) (NP-ADV (NP (NN POKO)) (CC versus) (NP (NN ob) (HYPH /) (NN ob))))) (CC and) (S-FRM (LST (SYM §)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.01)) (NP-ADV (NN POKO) (CC versus) (NN WT)))) (. .))) )
( (CAPTION (S (NP-SBJ-1 (LST (-LRB- -LRB-) (LS B) (-RRB- -RRB-)) (NP (NN Food) (NN intake)) (PP (IN from) (NP (ADJP (NP (CD 20) (HYPH -) (NN wk)) (HYPH -) (JJ old)) (JJ female) (NNS mice) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (CD 4)))) (-RRB- -RRB-))))) (VP (VBZ is) (VP (VBN shown) (NP-1 (-NONE- *)))) (. .))) )
( (CAPTION (FRAG (S (NP-SBJ-1 (LST (-LRB- -LRB-) (LS C) (-RRB- -RRB-)) (NP (NN Body) (NN composition) (NN analysis)) (PP (IN from) (NP (ADJP (NP (CD 20) (HYPH -) (NN wk)) (HYPH -) (JJ old)) (NNS females)))) (VP (VBZ is) (VP (VBN shown) (NP-1 (-NONE- *))))) (: :) (NP (NP (NML (NML (NN WT)) (, ,) (NML (NN ob) (HYPH /) (NN ob)) (, ,) (NML (NN PPARg2) (NN KO)) (, ,) (CC and) (NML (NN POKO))) (NNS mice)) (VP (VBN fed) (NP (-NONE- *)) (NP (NML (NN chow) (NN diet)) (NNS mice))) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (QP (CD 4) (SYM –) (CD 7))))) (-RRB- -RRB-))) (. .))) )
( (S (S-FRM (LST (SYM *)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.05)) (NP-ADV (NN POKO) (CC versus) (NN WT)))) (CC and) (S-FRM (LST (SYM #) (SYM #) (SYM #)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001)) (NP-ADV (NP (NN POKO)) (CC versus) (NP (NN ob) (HYPH /) (NN ob))))) (. .)) )
( (CAPTION (NP (LST (-LRB- -LRB-) (LS D) (-RRB- -RRB-)) (NP (ADJP (NP (NN Haematoxylin) (CC and) (NN eosin) (PRN (-LRB- -LRB-) (NP (NN H) (CC and) (NN E)) (-RRB- -RRB-))) (HYPH -) (VBN stained)) (NNS sections) (PRN (-LRB- -LRB-) (QP (CD 10) (SYM ×)) (-RRB- -RRB-))) (PP (IN from) (NP (NP (JJ epididymal) (NN WAT)) (PP (IN from) (NP (ADJP (NP (CD 16) (HYPH -)) (NN wk) (HYPH -) (JJ old)) (JJ male) (NML (NML (NN WT)) (, ,) (NML (NN ob) (HYPH /) (NN ob)) (, ,) (CC and) (NML (NN POKO))) (NNS mice))))) (. .))) )
( (CAPTION (NP (LST (-LRB- -LRB-) (LS E) (-RRB- -RRB-)) (NP (NP (NN Percent) (JJ relative) (JJ cumulative) (NN frequency) (NN analysis)) (-LRB- -LRB-) (NP (NN PRCF))) (-RRB- -RRB-) (PP (IN from) (NP (NP (JJ epididymal) (NN WAT) (NNS adipocytes)) (PP (IN from) (NP (ADJP (NP (CD 16) (HYPH -) (NN wk)) (HYPH -) (JJ old)) (JJ male) (NML (NML (NN WT)) (, ,) (NML (NN ob) (HYPH /) (NN ob)) (, ,) (NML (NN PPARg2) (NN KO)) (, ,) (CC and) (NML (NN POKO))) (NNS mice))))) (. .))) )
( (CAPTION (S-FRM (-LRB- -LRB-) (NP-SBJ (NN n)) (VP (SYM =) (NP (QP (CD 4) (SYM –) (CD 5)))) (-RRB- -RRB-) (. .))) )
( (HEADING (NP (NN Figure) (CD 2))) )
( (HEADING (NP (NP (NP (JJ Early) (NN Insulin) (NN Resistance)) (PP-LOC (IN in) (NP (NN POKO) (NNS Mice)))) (ADJP (JJ Independent) (PP (IN of) (NP (NN Body) (NN Weight)))))) )
( (CAPTION (NP (LST (-LRB- -LRB-) (LS A) (-RRB- -RRB-)) (NP (NP (NN Body) (NN weight)) (CC and) (NP (NN plasma) (NN glucose) (NNS levels))) (PP (IN from) (NP (ADJP (NP (NML (CD three) (, ,) (CD four) (, ,) (CC and) (CD five)) (HYPH -) (NN week)) (HYPH -) (JJ old)) (JJ female) (NML (NML (NN WT)) (, ,) (NML (NN ob) (HYPH /) (NN ob)) (, ,) (NML (NN PPARg2) (NN KO)) (, ,) (CC and) (NML (NN POKO))))) (. .))) )
( (CAPTION (FRAG (S-FRM (LST (SYM *)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.05)))) (: ;) (S-FRM (LST (SYM **)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.01)))) (: ;) (S-FRM (LST (SYM ***)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001)))) (NP (NP (NN POKO)) (CC versus) (NP (NN ob) (HYPH /) (NN ob))) (. .))) )
( (CAPTION (NP (LST (-LRB- -LRB-) (LS B) (-RRB- -RRB-)) (NP (NN Plasma) (NN glucose) (NNS levels)) (PP-TMP (IN during) (NP (NN ITT))) (PP (IN on) (NP (NP (ADJP (NP (CD 4) (HYPH -) (NN wk)) (HYPH -) (JJ old)) (NML (NML (JJ male) (PRN (-LRB- -LRB-) (NP (JJ left)) (-RRB- -RRB-))) (CC and) (NML (JJ female) (PRN (-LRB- -LRB-) (NP (JJ right)) (-RRB- -RRB-)))) (NNS mice)) (PP (IN on) (NP (NN chow) (NN diet))))) (PRN (-LRB- -LRB-) (FRAG (NP (JJ black) (NN triangle)) (, ,) (NP (NN WT))) (: ;) (FRAG (NP (JJ white) (NN triangle)) (, ,) (NP (NN PPARg2) (NN KO))) (: ;) (FRAG (NP (JJ black) (NN square)) (, ,) (NP (NN ob) (HYPH /) (NN ob))) (: ;) (FRAG (NP (JJ black) (NN diamond)) (, ,) (NP (NN POKO))) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (CD 7)))) (-RRB- -RRB-)) (. .))) )
( (CAPTION (S (S-FRM (LST (SYM *)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.05)))) (: ;) (S-FRM (LST (SYM **)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (NP (CD 0.01) (NN POKO)) (CC versus) (NP (NN ob) (HYPH /) (NN ob))))) (. .))) )
( (CAPTION (NP (LST (-LRB- -LRB-) (LS C) (-RRB- -RRB-)) (NP (JJ Morphological) (NN analysis)) (PP (IN of) (NP (NP (ADJP (NP (NN H) (CC and) (NN E)) (HYPH -) (VBN stained)) (NNS sections) (PRN (-LRB- -LRB-) (NP (QP (CD 10) (SYM ×))) (-RRB- -RRB-))) (PP (IN in) (NP (NP (NN pancreas)) (PP (IN from) (NP (ADJP (NP (CD 4) (HYPH -) (NN wk)) (HYPH -) (JJ old)) (NNS males) (NML (NML (NN ob) (HYPH /) (NN ob)) (CC and) (NML (NN POKO))) (NNS mice))))))) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (CD 5)))) (-RRB- -RRB-)) (. .))) )
( (HEADING (NP (NN Figure) (CD 3))) )
( (HEADING (NP (NP (NP (VBN Impaired) (NML (NN β) (HYPH -) (NN Cell)) (NN Function)) (CC and) (NP (JJ Hepatic) (JJ Morphological) (NN Analyis))) (PP-LOC (IN in) (NP (DT the) (NN POKO) (NNS Mice))))) )
( (CAPTION (NP (LST (-LRB- -LRB-) (LS A) (-RRB- -RRB-)) (NP (NP (ADJP (NP (NN H) (CC and) (NN E)) (HYPH -) (VBN stained)) (NNS sections) (PRN (-LRB- -LRB-) (NP (QP (CD 10) (SYM ×))) (-RRB- -RRB-))) (CC and) (NP (JJ immunohistochemical) (PRN (-LRB- -LRB-) (NP (QP (CD 20) (SYM ×))) (-RRB- -RRB-)) (NN analysis))) (PP (IN of) (NP (NN insulin) (CC and) (NN glucagon))) (PP-LOC (IN in) (NP (NP (NN pancreas)) (PP (IN from) (NP (ADJP (NP (CD 16) (HYPH -) (NN wk)) (HYPH -) (JJ old)) (NNS males) (NML (NML (NN WT)) (, ,) (NML (NN ob) (HYPH /) (NN ob)) (, ,) (CC and) (NML (NN POKO))) (NNS mice))))) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (CD 5)))) (-RRB- -RRB-)) (. .))) )
( (CAPTION (NP (LST (-LRB- -LRB-) (LS B) (-RRB- -RRB-)) (NP (NN Insulin) (NN content)) (PP (IN of) (NP (NP (NNS islets)) (VP (VBN isolated) (NP (-NONE- *)) (PP (IN from) (NP (NML (NML (NN POKO) (PRN (-LRB- -LRB-) (NP (JJ black) (NNS bars)) (-RRB- -RRB-))) (, ,) (CC and) (NML (NN ob) (HYPH /) (NN ob) (PRN (-LRB- -LRB-) (NP (JJ grey) (NNS bars)) (-RRB- -RRB-)))) (NNS mice)))))) (. .))) )
( (CAPTION (S (NP-SBJ (DT Each) (NNS data) (NN point)) (VP (VBZ is) (NP-PRD (NP (DT the) (NN mean)) (PP (IN of) (NP (NP (NP (CD six) (NNS samples)) (NP (DT each))) (PP (IN of) (NP (CD five) (NNS islets))))))) (. .))) )
( (CAPTION (NP (LST (-LRB- -LRB-) (LS C) (-RRB- -RRB-)) (NP (NN Insulin) (NN secretion)) (PP (IN from) (NP (NP (NNS islets)) (VP (VBN isolated) (NP (-NONE- *)) (PP (IN from) (NP (NML (NML (NN POKO) (PRN (-LRB- -LRB-) (NP (JJ black) (NNS bars) (-RRB- -RRB-)))) (CC and) (NML (NN ob) (HYPH /) (NN ob) (PRN (-LRB- -LRB-) (NP (JJ grey) (NNS bars)) (-RRB- -RRB-)))) (NNS mice))) (PP (IN in) (NP (NP (NN response)) (PP (IN to) (NP (NP (NN glucose) (PRN (-LRB- -LRB-) (NP (CD 1)) (, ,) (NP (CD 16) (NN mM)) (-RRB- -RRB-))) (CC or) (NP (NP (NN glucose) (CD 16) (NN mM)) (SYM +) (NP (NN tolbutamide)) (PRN (-LRB- -LRB-) (NP (CD 200) (NN μM)) (-RRB- -RRB-)))))))))) (. .))) )
( (CAPTION (S (NP-SBJ-1 (NNS Data)) (VP (VBD were) (VP (VBN collected) (NP-1 (-NONE- *)) (PP (IN from) (NP (NP (NP (CD six) (NNS samples)) (NP (DT each))) (PP (IN of) (NP (NP (CD five) (NNS islets)) (PP (IN from) (NP (NP (CD three) (NNS mice)) (PP (IN of) (NP (DT each) (NN genotype))))))))))) (. .))) )
( (CAPTION (S (PP (IN For) (NP (DT each) (NN sample))) (, ,) (NP-SBJ-1 (NN insulin) (NN release)) (VP (VBD was) (VP (VBN normalised) (NP-1 (-NONE- *)) (PP (IN to) (NP (NN insulin) (NN content))))) (. .))) )
( (CAPTION (FRAG (S-FRM (LST (SYM *)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.05)))) (: ;) (S-FRM (LST (SYM **)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.01)))) (: ;) (S-FRM (LST (SYM ***)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001)))) (NP (NP (NN POKO)) (CC versus) (NP (NN ob) (HYPH /) (NN ob))) (. .))) )
( (CAPTION (NP (LST (-LRB- -LRB-) (LS D) (-RRB- -RRB-)) (NP (ADJP (NP (NN H) (CC and) (NN E)) (HYPH -) (VBN stained)) (NNS sections) (PRN (-LRB- -LRB-) (QP (CD 4) (SYM ×)) (-RRB- -RRB-))) (PP-LOC (IN in) (NP (NP (NN liver)) (PP (IN from) (NP (ADJP (NP (CD 16) (HYPH -) (NN wk)) (HYPH -) (JJ old)) (NNS males) (NML (NML (NN WT)) (, ,) (NML (NN ob) (HYPH /) (NN ob)) (, ,) (CC and) (NML (NN POKO))) (NNS mice))))) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (CD 5)))) (-RRB- -RRB-)) (. .))) )
( (HEADING (NP (NN Figure) (CD 4))) )
( (HEADING (NP (NP (NML (NML (JJ Lipidomic)) (CC and) (NML (NN Gene) (NN Expression))) (NN Analysis)) (PP (IN of) (NP (NN POKO) (NN WAT))))) )
( (CAPTION (NP (LST (-LRB- -LRB-) (LS A) (-RRB- -RRB-)) (NP (JJ Lipidomic) (NN profiling)) (PP (IN of) (NP (NP (NN WAT)) (PP (IN from) (NP (ADJP (NP (CD 16) (HYPH -) (NN wk)) (HYPH -) (JJ old)) (NNS males) (NML (NML (NN WT)) (, ,) (NML (NN ob) (HYPH /) (NN ob)) (, ,) (CC and) (NML (NN POKO))) (NNS mice))))) (. .))) )
( (CAPTION (NP (LST (-LRB- -LRB-) (LS B) (-RRB- -RRB-)) (NP (NN Adipose) (NN tissue) (NN mRNA) (NNS levels)) (PP (IN from) (NP (NP (JJ different) (NNS genes)) (PP (IN from) (NP (ADJP (NP (CD 16) (HYPH -) (NN wk)) (HYPH -) (JJ old)) (JJ male) (NML (NML (NN WT)) (, ,) (NML (NN PPARg2) (NN KO)) (, ,) (NML (NN ob) (HYPH /) (NN ob)) (, ,) (CC and) (NML (NN POKO))) (NNS mice))))) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (QP (CD 6) (SYM –) (CD 8))))) (-RRB- -RRB-)) (. .))) )
( (FRAG (S-FRM (LST (SYM *)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.05)))) (: ;) (S-FRM (LST (SYM **)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.01)))) (: ;) (S-FRM (LST (SYM ***)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001)))) (NP (NP (NN POKO)) (CC versus) (NP (NN ob) (HYPH /) (NN ob))) (. .)) )
( (HEADING (NP (NN Figure) (CD 5))) )
( (HEADING (NP (NP (UCP (ADJP (JJ Lipidomic)) (CC and) (NP (NN Gene) (NN Expression))) (NN Analysis)) (PP-LOC (IN in) (NP (NP (NNS Islets) (CC and) (NN Liver)) (PP (IN from) (NP (NN POKO) (NNS Mice))))))) )
( (CAPTION (NP (NP (JJ Lipidomic) (NN profiling)) (PP (IN of) (NP (NP (NP (NNS islets) (PRN (-LRB- -LRB-) (NP (NN A)) (-RRB- -RRB-))) (CC and) (NP (NN liver) (PRN (-LRB- -LRB-) (NP (NN B)) (-RRB- -RRB-)))) (PP (IN from) (NP (ADJP (NP (CD 16) (HYPH -) (NN wk)) (HYPH -) (JJ old)) (NNS males) (NML (NML (NN WT)) (, ,) (NML (NN PPARg2) (NN KO)) (, ,) (NML (NN ob) (HYPH /) (NN ob)) (, ,) (CC and) (NML (NN POKO))) (NNS mice))))) (. .))) )
( (CAPTION (NP (NP (NP (NN TG)) (, ,) (NP (NNS TAGs))) (: ;) (NP (NP (NNS DAGs)) (, ,) (NP (NNS diacylglycerols))) (: ;) (NP (NP (NN SM)) (, ,) (NP (NNS sphingomyelins))) (. .))) )
( (CAPTION (NP (LST (-LRB- -LRB-) (LS C) (-RRB- -RRB-)) (NP (NN Liver) (NN gene) (NN expression)) (PP (IN from) (NP (NP (ADJP (NP (CD 16) (HYPH -) (NN wk)) (HYPH -) (JJ old)) (JJ male) (NML (NML (NN WT)) (, ,) (NML (NN ob) (HYPH /) (NN ob)) (, ,) (NML (NN PPARg2) (NN KO)) (, ,) (CC and) (NML (NN POKO))) (NNS mice)) (VP (VBN fed) (NP (-NONE- *)) (NP (NN chow))))) (PRN (-LRB- -LRB-) (S-FRM (NP-SBJ (NN n)) (VP (SYM =) (NP (QP (CD 6) (SYM –) (CD 8))))) (-RRB- -RRB-)) (. .))) )
( (CAPTION (FRAG (FRAG (S-FRM (LST (SYM *)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.05)))) (: ;) (S-FRM (LST (SYM **)) (, ,) (NP-SBJ (NN p)) (, ,) (VP (SYM <) (NP (CD 0.01)))) (: ;) (S-FRM (LST (SYM ***)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001)))) (NP (NP (NN POKO)) (CC versus) (NP (NN ob) (HYPH /) (NN ob)))) (: ;) (FRAG (S-FRM (LST (SYM #) (SYM #) (SYM #)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001)))) (NP (NN POKO) (CC versus) (NN WT))) (: ;) (FRAG (S-FRM (LST (SYM ‡‡‡)) (, ,) (NP-SBJ (NN p)) (VP (SYM <) (NP (CD 0.001)))) (NP (NP (NN ob) (HYPH /) (NN ob)) (CC versus) (NP (NN WT)))) (. .))) )
( (HEADING (NP (NN Figure) (CD 6))) )
( (HEADING (FRAG (NP (NP (NN Storage)) (PP (IN of) (NP (NNS Lipids)))) (: —) (NP (NP (JJ Antilipotoxic) (NN Role)) (PP (IN of) (NP (NN PPARg2)))))) )
( (CAPTION (NP (NP (NP (JJ Antilipotoxic) (NN role)) (PP (IN of) (NP (NN PPARg2)))) (VP (VBN mediated) (NP (-NONE- *)) (PP-MNR (IN by) (NP (NP (LST (-LRB- -LRB-) (LS a) (-RRB- -RRB-)) (NP (NP (NN expansion)) (PP (IN of) (NP (NN adipose) (NN tissue)))) (CC and) (NP (NP (NN facilitation)) (PP (IN of) (NP (NN triglyceride) (NN deposition))))) (CC and) (S-NOM (LST (-LRB- -LRB-) (LS b) (-RRB- -RRB-)) (NP-SBJ (-NONE- *PRO*)) (VP (VBG facilitating) (NP (NP (NN deposition)) (PP (IN of) (NP (NN fat))) (PP-LOC (IN in) (NP (NP (NN liver)) (, ,) (NP (JJ skeletal) (NN muscle)) (, ,) (CC and) (NP (NN pancreas))))) (PP (IN in) (NP (NP (DT the) (NN form)) (PP (IN of) (NP (NN TAG)))))))))) (. .))) )
( (CAPTION (S (NP-SBJ (NML (NN Ob) (HYPH /) (NN Ob)) (NNS mice)) (VP (MD can) (VP (VB induce) (NP (NN PPARg2) (NN expression)) (PP-LOC (IN in) (NP (NP (NN liver)) (, ,) (NP (NN muscle)) (, ,) (CC and) (NP (NN β) (HYPH -) (NN cell)))) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG facilitating) (NP (NP (NN deposition)) (PP (IN of) (NP (NP (NN excess)) (PP (IN of) (NP (NN energy))))) (PP-LOC (IN in) (NP (DT these) (NNS organs)))) (PP (IN in) (NP (NP (DT the) (NN form)) (PP (IN of) (NP (NN TAG))))))))) (. .))) )
( (CAPTION (S (NP-SBJ (NP (NN Absence)) (PP (IN of) (NP (NP (NN inducibility)) (PP (IN of) (NP (NN PPARg2))))) (PP-LOC (IN in) (NP (NN POKO) (NN mouse) (NML (NML (NN liver)) (, ,) (NML (NN muscle)) (, ,) (CC and) (NML (NN β) (HYPH -) (NNS cells)))))) (VP (VBZ results) (PP (IN in) (NP (NP (NP (VBN increased) (NN deposition)) (PP (IN of) (NP (JJ reactive) (NN lipid) (NNS species)))) (CC and) (NP (VBN decreased) (NN TAG)))) (, ,) (S-ADV (NP-SBJ (-NONE- *PRO*)) (VP (VBG leading) (PP (IN to) (NP (NP (JJ marked) (NN insulin) (NN resistance)) (CC and) (NP (NML (NN β) (HYPH -) (NN cell)) (NN failure))))))) (. .))) )
( (HEADING (NP (NN Table) (CD 1))) )
( (HEADING (NP (NP (JJ Metabolic) (NNS Parameters)) (PP-LOC (IN in) (NP (NN Fed) (ADJP (NP (CD 4) (HYPH -) (NN Wk)) (HYPH -) (JJ Old)) (ADJP (JJ Male) (CC and) (JJ Female)) (NML (NML (NN POKO)) (, ,) (NML (NN Ob) (HYPH /) (NN Ob)) (, ,) (NML (NN PPARg2) (NN KO)) (, ,) (CC and) (NML (NN WT))) (NNS Mice))))) )
( (HEADING (NP (NN Table) (CD 2))) )
( (HEADING (NP (NP (JJ Metabolic) (NNS Parameters)) (PP-LOC (IN in) (NP (ADJP (NP (CD 16) (HYPH -) (NN wk)) (HYPH -) (JJ Old)) (JJ Male) (NML (NML (NN POKO)) (, ,) (NML (NN Ob) (HYPH /) (NN Ob)) (, ,) (CC and) (NML (NN WT))) (NNS Mice))))) )
( (HEADING (NP (NNS Footnotes))) )
( (HEADING (NP (VBG Competing) (NNS interests) (. .))) )
( (S (NP-SBJ (DT The) (NNS authors)) (VP (VBP have) (VP (VBN declared) (SBAR (IN that) (S (NP-SBJ (DT no) (VBG competing) (NNS interests)) (VP (VBP exist)))))) (. .)) )
( (HEADING (NP (NN Author) (NNS contributions) (. .))) )
( (S (NP-SBJ (NNP GMG) (, ,) (NNP SLG) (, ,) (NNP FMA) (, ,) (CC and) (NNP AVP)) (VP (VBD conceived) (CC and) (VBD designed) (NP (DT the) (NNS experiments))) (. .)) )
( (S (NP-SBJ (NNP GMG) (, ,) (NNP SLG) (, ,) (NNP LY) (, ,) (NNP KS) (, ,) (NNP SV) (, ,) (NNP MB) (, ,) (NNP ML) (, ,) (CC and) (NNP MO)) (VP (VBD performed) (NP (DT the) (NNS experiments))) (. .)) )
( (S (NP-SBJ (NNP GMG) (, ,) (NNP SLG) (, ,) (NNP LY) (, ,) (NNP KS) (, ,) (NNP SV) (, ,) (NNP MC) (, ,) (NNP RKC) (, ,) (NNP MJL) (, ,) (NNP TSL) (, ,) (CC and) (NNP MO)) (VP (VBD analysed) (NP (DT the) (NNS data))) (. .)) )
( (S (NP-SBJ (NNP GMG) (, ,) (NNP LY) (, ,) (NNP KS) (, ,) (NNP SV) (, ,) (NNP MC) (, ,) (NNP RKC) (, ,) (NNP MB) (, ,) (CC and) (NNP GSHY)) (VP (VBD contributed) (NP (NP (NNS reagents)) (HYPH /) (NP (NNS materials)) (HYPH /) (NP (NN analysis) (NNS tools)))) (. .)) )
( (S (NP-SBJ (NNP GMG) (CC and) (NNP AVP)) (VP (VBD wrote) (NP (DT the) (NN paper))) (. .)) )
( (HEADING (NP (NN Funding) (. .))) )
( (S (NP-SBJ-1 (DT This) (NN work)) (VP (VBD was) (VP (VBN supported) (NP-1 (-NONE- *)) (PP (IN by) (NP-LGS (NP (DT the) (NML (NNP European) (NNP Union)) (NNP FP6) (NML (NML (NML (ADJP (NNP Hepatic) (CC and) (NNP Adipose)) (NN Tissue) (CC and) (NNS Functions)) (PP (IN in) (NP (DT the) (JJ Metabolic) (NN Syndrome)))) (-LRB- -LRB-) (NML (NNP Hepadip))) (-RRB- -RRB-) (JJ integrated) (NN program) (PRN (-LRB- -LRB-) (NP (NN http://www.hepadip.org)) (-RRB- -RRB-)) (PRN (-LRB- -LRB-) (NP (NN LSHM) (HYPH -) (NN CT) (HYPH -) (CD 2005) (HYPH –) (CD 018734)) (-RRB- -RRB-))) (: ;) (NP (NNP Diabetes) (NNP UK)) (: ;) (NP (NNP Medical) (NNP Research) (NNP Council)) (: ;) (NP (NNP Wellcome) (NNP Trust) (NML (NNP Integrative) (NNP Physiology)) (NN program)) (: ;) (NP (NP (NNP Academy)) (PP (IN of) (NP (NNP Finland))) (PRN (-LRB- -LRB-) (NP (NN grant) (NN number) (CD 111338)) (-RRB- -RRB-))) (: ;) (CC and) (NP (NP (NML (NNP Marie) (NNP Curie)) (NNP International) (NNP Reintegration) (NNP Grant)) (PP (IN from) (NP (DT the) (NNP European) (NNP Community)))))))) (. .)) )
